Polycyclic compound, preparation method therefor, and use thereof

By developing compound (I) as a VAV1 degrading agent, the problem of low efficiency and insufficient specificity of existing VAV1 protein degrading agents has been solved, achieving efficient and highly specific VAV1 protein degradation, which is suitable for the treatment of autoimmune diseases and tumor-related diseases.

WO2026237883A1PCT designated stage Publication Date: 2026-11-19SUZHOU MERNA THERAPEUTICS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/096165
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-09-30
Filing Date
2026-05-11
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing VAV1 protein degraders suffer from low degradation efficiency and insufficient specificity, failing to meet the actual needs of clinical treatment of autoimmune diseases and tumors.

Method used

A compound of formula (I) or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotope derivatives and pharmaceutically acceptable salts are provided as VAV1 degrading agents, which induce ubiquitination modification and are degraded by the proteasome by binding to the target protein VAV1 and E3 ubiquitin ligase.

Benefits of technology

It achieves efficient and highly specific degradation of VAV1 protein, reduces interference with normal cell function, and has long-lasting effects and resistance to drug resistance, making it suitable for the treatment of VAV1-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026096165_19112026_PF_FP_ABST
    Figure CN2026096165_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a polycyclic compound represented by formula (I), a preparation method therefor, a pharmaceutical composition comprising same, and pharmaceutical use thereof. The compound can be used for treating autoimmune diseases, inflammatory diseases, and tumors.
Need to check novelty before this filing date? Find Prior Art

Description

A polycyclic compound, its preparation method and application

[0001] This disclosure claims priority to Chinese Patent Application No. 2025106024510, filed on May 12, 2025, entitled "A Polycyclic Compound and Its Preparation Method and Application", and Chinese Patent Application No. 2025114193987, filed on September 30, 2025, the entire contents of which are incorporated herein by reference. Technical Field

[0002] This invention relates to the field of biomedicine, and in particular to a VAV1 degrading agent and its preparation method, a pharmaceutical composition comprising the same, and its pharmaceutical uses. Background Technology

[0003] The VAV protein family belongs to the Rho / Rac family of guanine nucleotide exchange factors and includes three members: VAV1, VAV2, and VAV3. VAV1 is primarily expressed on immune cells such as T cells, B cells, NK cells, and osteoclasts, and is a core positive regulator of T cell receptor (TCR) and B cell receptor (BCR) signaling. VAV1 activates Rho family GTPases, such as Rac1 and Cdc42, through its guanine nucleotide exchange factor (GEF) activity, regulating downstream signaling pathways, including the secretion of nuclear factor-activated T cells (NFAT), interferon-γ (IFNγ), and interleukin-2 (IL-2). It is crucial for the proliferation and activation of immune cells and the formation of cytokine storms, playing an indispensable role in maintaining normal immune function.

[0004] However, abnormal activation or overexpression of VAV1 can trigger pathological processes in various diseases. In the field of autoimmune diseases: In patients with systemic lupus erythematosus (SLE), VAV1 phosphorylation levels in T cells are significantly elevated, abnormally binding to SYK to enhance TCR signaling, promoting the activation of autoreactive T cells and the production of autoantibodies. Furthermore, specific NCF2 gene mutations exacerbate inflammatory responses by affecting the interaction between VAV1 and the NADPH oxidase complex. In patients with rheumatoid arthritis (RA), VAV1 gene polymorphisms (such as the rs2546133T allele) are associated with disease susceptibility and extra-articular manifestations; animal models show… Vav1-deficient mice showed significantly reduced antigen-induced arthritis symptoms, including synovial inflammation, cartilage destruction, and decreased secretion of pro-inflammatory factors (IL-6, TNF, IL-17A). VAV1 expression was downregulated in PBMCs of multiple sclerosis (MS) patients, and specific gene haplotypes (rs2546133-rs2617822CA) were associated with increased disease risk. Vav1-deficient mice exhibited significantly enhanced resistance to experimental autoimmune encephalomyelitis (EAE), suggesting its crucial role in central nervous system inflammation. Furthermore, VAV1 expression was upregulated in the intestinal mucosa of patients with inflammatory bowel disease (IBD), closely related to abnormal macrophage activation and activation of pro-inflammatory signaling pathways. In tumor immunology, high VAV1 expression in some T-cell lymphomas can enhance tumor cell survival and invasion by promoting Rac1-mediated actin remodeling and cell migration. These studies collectively demonstrate that abnormal regulation of VAV1 is an important pathological mechanism in various diseases, providing a strong basis for the development of targeted degradation agents.

[0005] Currently, the traditional treatment strategy for VAV1-related diseases mainly involves using immunosuppressants to inhibit VAV1 enzyme activity or block its downstream signaling pathways. However, these immunosuppressants have significant drawbacks; they have poor selectivity and, while inhibiting VAV1-related activity, can interfere with the function of normal cells, causing significant side effects.

[0006] With the continuous development of biomedical technology, protein degraders, especially molecular glue degraders, have gradually become a research hotspot. Molecular glue degraders function through a bifunctional mechanism, simultaneously binding to target proteins (such as VAV1) and E3 ubiquitin ligases (such as cereblon), inducing ubiquitination of the target protein, which is then degraded via the proteasome pathway. Compared with traditional immunosuppressants, molecular glue degraders have many advantages: First, they are highly selective, accurately identifying and eliminating pathogenic VAV1 proteins, avoiding unnecessary interference with normal cell function; second, they have long-lasting effects, continuously reducing the level of the target protein VAV1 after a single dose; and third, they can overcome drug resistance problems, targeting protein conformations or mutants that are difficult for traditional inhibitors to work with.

[0007] Despite the promising application prospects of molecular adhesive degraders, the development of molecular adhesive degraders targeting VAV1 is still in the exploratory stage. Existing studies have attempted to develop VAV1-targeting degraders, but these generally suffer from low degradation efficiency and insufficient specificity, failing to meet the actual needs of clinical treatment. Therefore, developing highly efficient and specific protein degraders targeting VAV1, especially novel molecular adhesive degraders capable of precisely regulating the VAV1 degradation process, is of paramount importance for the treatment of autoimmune diseases and related diseases such as tumors.

[0008] In view of this, the present invention is proposed. Summary of the Invention

[0009] The problem the invention aims to solve

[0010] To address the aforementioned problems, the present invention provides a compound of formula (I) as a VAV1 degrading agent, which can be used to treat diseases.

[0011] Solution for solving the problem

[0012] This invention provides a compound of formula (I) or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives, and pharmaceutically acceptable salts thereof.

[0013] in,

[0014] X 1 X 2 X 3 X 4 X 5 Each is independently selected from C(R) s 2. NR s , C(=O), S, O, SO and SO2;

[0015] Each time it appears, R s Each is independently selected from hydrogen, deuterium, and C. 1-6 Alkyl, C 1-6 Halogenated alkyl groups and C 1-6 Alkoxy;

[0016] X 6 Selected from C, N, and S;

[0017] R 1 Selected from non-existent, hydrogen, deuterium, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl groups and C 1-6 Alkoxy;

[0018] Ring A is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 heteroaryl groups;

[0019] Each time it appears, R A Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NRc C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. u Replaced;

[0020] Ring B is selected from bond, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 heteroaryl groups;

[0021] Each time it appears, R B Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a-C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. B-1 Replaced;

[0022] Or, each time it occurs, two Rs B And the atoms bonded to them together form C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16Aryl and 5-16 membered heteroaryl, said C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 The aryl and 5-16 heteroaryl groups are each independently bounded by one or more R groups. B-1 Replaced;

[0023] Each time it appears, R B-1 Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d-OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. u Replaced;

[0024] L 1 Selected from key, -(C=O)-, -S-, -S(=O)-, -S(=O)2-, -S(O)(NR)-, -SC 1-4 alkylene-, -C 1-4 Alkylenes -S-, -O-, -OC 1-4 alkylene-, -C 1-4 Alkylenes -O-, -NR'-, -NR'(C=O)-, -NR'-C 1-4 alkylene-, -C 1-4 Alkylene-NR'-, -C 1-4 Alkylene -C(=O)-, -C(=O)-C 1-4 Alkylene-, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1a Replaced; at the same time, the -SC 1-4 alkylene-, -C 1-4 Alkylene-S-, -OC 1-4 alkylene-, -C 1-4 Alkylene-O-, -NR'-C 1-4 alkylene-, -C 1-4 Alkylene-NR'-, -C 1-4Alkylene -C(=O)-, -C(=O)-C 1-4 Alkylene-, C 1-6 Alkylene, C 2-6 imide and C 2-6 One or more methylene, vinylene, or ethynylene groups in the ethynyl group are each independently separated by -Cy x -, -O-, -C(O)-, -C(S)-, -CR2-, -CF2, -CRF-, -CR(OR)-, -NR-, -C(NR)-, -S-, -S(O), -S(O)2, -S(O)(NR)- and -CR=CR- substitutions;

[0025] Each time -Cy appears x - Each is independently selected from C 6-16 Aryl, 5-16 heteroaryl, C 3-12 cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. u replace;

[0026] Each time it appears, R is independently selected from hydrogen, C, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 membered heteroaryl, said C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 heteroaryl groups are affected by one or more R groups. u replace;

[0027] Alternatively, two R atoms and the atoms bonded to them together form C. 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 membered heteroaryl, said C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 heteroaryl groups are affected by one or more R groups. u replace;

[0028] Each time L appears 1a Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, P(=O)R c R d -S(=O)(=NR) c )R b -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c Rd The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1b Replaced;

[0029] Or, each time it appears, two or more L 1a Together with the atoms bonded to them, they form C. 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1b Replaced;

[0030] Each time L appears 1b Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2ORb -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1c Replaced;

[0031] Each time L appears 1c Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)Ra -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1d Replaced;

[0032] Each time L appears 1d Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d ;

[0033] L 2 Selected from bonds, hydrogen, C 1-6 Alkyl, -C(=O)NR c R d C 6-16Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein -C(=O)NR c R d C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2a Replaced;

[0034] Each time L appears 2a Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2Ra -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2b Replaced;

[0035] Or, each time it appears, two or more L 2a Together with the atoms bonded to them, they form C. 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2b Replaced;

[0036] Each time L appears 2b Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a-S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2c Replaced;

[0037] Each time L appears 2c Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2d Replaced;

[0038] Each time L appears 2d Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR cR d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d ;

[0039] Each time it appears, R' is independently selected from hydrogen, deuterium, and C. 1-6 alkyl;

[0040] Each time it appears, R u Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -C 1-6 Alkyl-(6-10)aryl, -C 1-6 Alkyl-(5-14 quinary)heteroaryl, -C 1-6 Alkyl-C 3-12 cycloalkyl, -C 1-6 Alkyl-(3-12-membered) heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)Ra -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. x replace;

[0041] Or, each time it occurs, two or more R u And the atoms bonded to them form C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl groups and 3-12 membered heterocyclic groups are separated by one or more R groups x replace;

[0042] Each time it appears, R x Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a-C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. y replace;

[0043] Each time it appears, R a Each is independently selected from hydrogen and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. y replace;

[0044] Each time it appears, R b Each is independently selected from hydrogen and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. y replace;

[0045] Each time it appears, R c R d Each is independently selected from hydrogen and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. y replace;

[0046] Or, each time it appears, R c and R d And the atoms attached to them form (3-12) heterocyclic groups or (5-12) heteroaryl groups, said heterocyclic groups and heteroaryl groups being bonded by one or more R y replace;

[0047] Each time it appears, R y Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. z replace;

[0048] Each time it appears, R z Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups;

[0049] m is selected from 0, 1, 2, 3, 4, 5, and 6;

[0050] n is selected from 0, 1, 2, 3, 4, 5, and 6.

[0051] The effects of the invention

[0052] This invention provides a compound of formula (I) as a VAV1 degrading agent. This compound specifically induces the ubiquitination and degradation of VAV1 protein through a molecular gel degradation mechanism, and can be used to treat autoimmune diseases, inflammatory diseases, and tumors associated with abnormal VAV1 expression or dysfunction. The compound provided by this invention exhibits excellent inhibitory activity against abnormally activated immune cells (T cells and B cells) and cancer cell lines (pancreatic cancer and breast cancer), while also possessing excellent pharmacodynamics, in vitro / in vivo pharmacokinetic properties, and safety, showing high potential for clinical application. Detailed Implementation

[0053] To make the technical solution and beneficial effects of the present invention more apparent and understandable, a detailed description is provided below by listing specific embodiments. Unless otherwise defined, the technical and scientific terms used herein have the same meanings as those in the technical field to which this application pertains.

[0054] This invention provides a compound of formula (I) or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives, and pharmaceutically acceptable salts thereof.

[0055] in,

[0056] X 1 X 2 X 3 X 4 X 5 Each is independently selected from C(R) s 2. NR s , C(=O), S, O, SO and SO2;

[0057] Each time it appears, R s Each is independently selected from hydrogen, deuterium, and C. 1-6 Alkyl, C 1-6 Halogenated alkyl groups and C 1-6 Alkoxy;

[0058] X 6 Selected from C, N, and S;

[0059] R 1 Selected from non-existent, hydrogen, deuterium, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl groups and C 1-6 Alkoxy;

[0060] Ring A is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 heteroaryl groups;

[0061] Each time it appears, RA Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c Rd The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. u Replaced;

[0062] Ring B is selected from bond, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 heteroaryl groups;

[0063] Each time it appears, R B Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c Rd -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. B-1 Replaced;

[0064] Or, each time it occurs, two Rs B And the atoms bonded to them together form C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 membered heteroaryl, said C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 The aryl and 5-16 heteroaryl groups are each independently bounded by one or more R groups. B-1 Replaced;

[0065] Each time it appears, R B-1 Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a-C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. u Replaced;

[0066] L 1Selected from key, -(C=O)-, -S-, -S(=O)-, -S(=O)2-, -S(O)(NR)-, -SC 1-4 alkylene-, -C 1-4 Alkylenes -S-, -O-, -OC 1-4 alkylene-, -C 1-4 Alkylenes -O-, -NR'-, -NR'(C=O)-, -NR'-C 1-4 alkylene-, -C 1-4 Alkylene-NR'-, -C 1-4 Alkylene -C(=O)-, -C(=O)-C 1-4 Alkylene-, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1a Replaced; at the same time, the -SC 1-4 alkylene-, -C 1-4 Alkylene-S-, -OC 1-4 alkylene-, -C 1-4 Alkylene-O-, -NR'-C 1-4 alkylene-, -C 1-4 Alkylene-NR'-, -C 1-4 Alkylene -C(=O)-, -C(=O)-C 1-4 Alkylene-, C 1-6 Alkylene, C 2-6 imide and C 2-6 One or more methylene, vinylene, or ethynylene groups in the ethynyl group are each independently separated by -Cy x -, -O-, -C(O)-, -C(S)-, -CR2-, -CF2, -CRF-, -CR(OR)-, -NR-, -C(NR)-, -S-, -S(O), -S(O)2, -S(O)(NR)- and -CR=CR- substitutions;

[0067] Each time -Cy appears x - Each is independently selected from C 6-16 Aryl, 5-16 heteroaryl, C 3-12 cycloalkyl and 3-12 membered heterocyclic groups, wherein the C6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. u replace;

[0068] Each time it appears, R is independently selected from hydrogen, C, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 membered heteroaryl, said C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 heteroaryl groups are affected by one or more R groups. u replace;

[0069] Alternatively, two R atoms and the atoms bonded to them together form C. 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 membered heteroaryl, said C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 heteroaryl groups are affected by one or more R groups. u replace;

[0070] Each time L appears 1a Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, P(=O)R c R d -S(=O)(=NR) c )R b -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)Ra -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1b Replaced;

[0071] Or, each time it appears, two or more L 1a Together with the atoms bonded to them, they form C. 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 6-16 Aryl, 5-16 heteroaryl, C3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1b Replaced;

[0072] Each time L appears 1b Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR cR d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1c Replaced;

[0073] Each time L appears 1c Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR cC(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1d Replaced;

[0074] Each time L appears 1d Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NRc S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d ;

[0075] L 2 Selected from bonds, hydrogen, C 1-6 Alkyl, -C(=O)NR c R d C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein -C(=O)NR c R d C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2a Replaced;

[0076] Each time L appears 2a Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2b Replaced;

[0077] Or, each time it appears, two or more L 2a Together with the atoms bonded to them, they form C. 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2b Replaced;

[0078] Each time L appears 2b Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)Ra -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2c Replaced;

[0079] Each time L appears 2c Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR cS(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2d Replaced;

[0080] Each time L appears 2d Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a-OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d ;

[0081] Each time it appears, R' is independently selected from hydrogen, deuterium, and C. 1-6 alkyl;

[0082] Each time it appears, R u Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -C 1-6 Alkyl-(6-10)aryl, -C 1-6 Alkyl-(5-14 quinary)heteroaryl, -C 1-6 Alkyl-C 3-12 cycloalkyl, -C 1-6 Alkyl-(3-12-membered) heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. x replace;

[0083] Or, each time it occurs, two or more R u And the atoms bonded to them form C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl groups and 3-12 membered heterocyclic groups are separated by one or more R groups x replace;

[0084] Each time it appears, R x Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NRc R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. y replace;

[0085] Each time it appears, R a Each is independently selected from hydrogen and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. y replace;

[0086] Each time it appears, R b Each is independently selected from hydrogen and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. y replace;

[0087] Each time it appears, R c R d Each is independently selected from hydrogen and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. y replace;

[0088] Or, each time it appears, R c and R d And the atoms attached to them form (3-12) heterocyclic groups or (5-12) heteroaryl groups, said heterocyclic groups and heteroaryl groups being bonded by one or more R y replace;

[0089] Each time it appears, R y Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the amino group, C1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. z replace;

[0090] Each time it appears, R z Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups;

[0091] m is selected from 0, 1, 2, 3, 4, 5, and 6;

[0092] n is selected from 0, 1, 2, 3, 4, 5, and 6.

[0093] In some implementations, the X 1 and X 3 Each is independently selected from C (=O), S, O, SO and SO2.

[0094] In some implementations, the X 1 and X 3 Each is independently selected from C (=O).

[0095] In some implementations, the X 2 Selected from NR s , C(=O), S, O, SO and SO2.

[0096] In some implementations, the X 2 Selected from NR s .

[0097] In some implementations, the X 2 Selected from NH.

[0098] In some implementations, the X 4 and X 5 Each is independently selected from C(R) s )2, C(=O), S, O, SO and SO2.

[0099] In some implementations, the X4 and X 5 Each is independently selected from C(R) s )2.

[0100] In some implementations, the X 4 and X 5 Each is independently selected from CH2.

[0101] In some implementations, the X 6 Selected from C.

[0102] In some implementations, the R 1 Selected from non-existent, H, D, halogen, amino, hydroxyl and C 1-6 alkyl.

[0103] In some implementations, the R 1 Selected from non-existent, H, D, halogen, hydroxyl and amino.

[0104] In some implementations, the R 1 Selected from non-existent, H, D and halogens.

[0105] In some implementations, the R 1 Selected from non-existent and H.

[0106] In some embodiments, the compound has a structure as shown in formula (II):

[0107] in,

[0108] Ring A is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 heteroaryl groups;

[0109] Each time it appears, R A Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)ORb -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. u Replaced;

[0110] Ring B is selected from bond, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 heteroaryl groups;

[0111] Each time it appears, R B Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NRc R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. B-1 Replaced;

[0112] Or, each time it occurs, two Rs B And the atoms bonded to them together form C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 membered heteroaryl, said C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 The aryl and 5-16 heteroaryl groups are each independently bounded by one or more R groups. B-1 Replaced;

[0113] Each time it appears, R B-1 Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2ORb -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. u Replaced;

[0114] L 1 Selected from key, -(C=O)-, -S-, -S(=O)-, -S(=O)2-, -S(O)(NR)-, -SC 1-4 alkylene-, -C 1-4 Alkylenes -S-, -O-, -OC 1-4 alkylene-, -C 1-4 Alkylenes -O-, -NR'-, -NR'(C=O)-, -NR'-C 1-4 alkylene-, -C 1-4 Alkylene-NR'-, -C 1-4 Alkylene -C(=O)-, -C(=O)-C 1-4 Alkylene-, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 6-16 Aryl, 5-16 heteroaryl, C3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1a Replaced; at the same time, the -SC 1-4 alkylene-, -C 1-4 Alkylene-S-, -OC 1-4 alkylene-, -C 1-4 Alkylene-O-, -NR'-C 1-4 alkylene-, -C 1-4 Alkylene-NR'-, -C 1-4 Alkylene -C(=O)-, -C(=O)-C 1-4 Alkylene-, C 1-6 Alkylene, C 2-6 imide and C 2-6 One or more methylene, vinylene, or ethynylene groups in the ethynyl group are each independently separated by -Cy x -, -O-, -C(O)-, -C(S)-, -CR2-, -CF2, -CRF-, -CR(OR)-, -NR-, -C(NR)-, -S-, -S(O), -S(O)2, -S(O)(NR)- and -CR=CR- substitutions;

[0115] Each time -Cy appears x - Each is independently selected from C 6-16 Aryl, 5-16 heteroaryl, C 3-12 cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. u replace;

[0116] Each time it appears, R is independently selected from hydrogen, C, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 membered heteroaryl, said C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 heteroaryl groups are affected by one or more R groups.u replace;

[0117] Alternatively, two R atoms and the atoms bonded to them together form C. 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 membered heteroaryl, said C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 heteroaryl groups are affected by one or more R groups. u replace;

[0118] Each time L appears 1a Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, P(=O)R c R d -S(=O)(=NR) c )R b -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NRc C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1b Replaced;

[0119] Or, each time it appears, two or more L 1a Together with the atoms bonded to them, they form C. 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1b Replaced;

[0120] Each time L appears 1b Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a-OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1c Replaced;

[0121] Each time L appears 1c Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1d Replaced;

[0122] Each time L appears 1d Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b-OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d ;

[0123] L 2 Selected from bonds, hydrogen, C 1-6 Alkyl, -C(=O)NR c R d C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein -C(=O)NR c R d C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2a Replaced;

[0124] Each time L appears 2a Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR cS(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2b Replaced;

[0125] Or, each time it appears, two or more L 2a Together with the atoms bonded to them, they form C. 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2b Replaced;

[0126] Each time L appears 2b Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2c Replaced;

[0127] Each time L appears 2c Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c Rd -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2d Replaced;

[0128] Each time L appears 2d Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c Rd -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d ;

[0129] Each time it appears, R' is independently selected from hydrogen, deuterium, and C. 1-6 alkyl;

[0130] Each time it appears, R u Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -C 1-6 Alkyl-(6-10)aryl, -C 1-6 Alkyl-(5-14 quinary)heteroaryl, -C 1-6 Alkyl-C 3-12 cycloalkyl, -C 1-6 Alkyl-(3-12-membered) heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NRc R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. x replace;

[0131] Or, each time it occurs, two or more R u And the atoms bonded to them form C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl groups and 3-12 membered heterocyclic groups are separated by one or more R groups x replace;

[0132] Each time it appears, R x Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R dThe amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. y replace;

[0133] Each time it appears, R a Each is independently selected from hydrogen and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. y replace;

[0134] Each time it appears, R b Each is independently selected from hydrogen and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. y replace;

[0135] Each time it appears, R c R d Each is independently selected from hydrogen and C. 1-6 Alkyl, C1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. y replace;

[0136] Or, each time it appears, R c and R d And the atoms attached to them form (3-12) heterocyclic groups or (5-12) heteroaryl groups, said heterocyclic groups and heteroaryl groups being bonded by one or more R y replace;

[0137] Each time it appears, R y Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. z replace;

[0138] Each time it appears, R z Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups;

[0139] m is selected from 0, 1, 2, 3, 4, 5, and 6;

[0140] n is selected from 0, 1, 2, 3, 4, 5, and 6.

[0141] In some embodiments, ring A is selected from C. 6-16 Aryl and 5-16 heteroaryl compounds.

[0142] In some embodiments, ring A is selected from C. 6-14 Aryl and 6-10 heteroaryl compounds.

[0143] In some embodiments, ring A is selected from...

[0144] In some implementations, each time R occurs, A Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups.

[0145] In some implementations, each time R occurs, A Each is independently selected from hydrogen, oxo group, halogen, and C. 1-6 Halogenated alkoxy groups.

[0146] In some implementations, each time R occurs, A Each is independently selected from hydrogen, oxo group, halogen, and C. 1-3 Halogenated alkoxy groups.

[0147] In some implementations, each time R occurs, A Each is independently selected from hydrogen, oxo group, Cl and difluoromethoxy group.

[0148] In some embodiments, ring B is selected from key, C 3-8 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 heteroaryl compounds.

[0149] In some embodiments, ring B is selected from key, C5-8 cycloalkyl, C 6-10 Aryl, 5-10-membered heteroaryl and 5-10-membered heterocyclic group, wherein the 5-10-membered heteroaryl and 5-10-membered heterocyclic group contain 1-4 heteroatoms, wherein the heteroatoms are selected from N, O and S.

[0150] In some embodiments, ring B is selected from key,

[0151] In some implementations, each time R occurs, B Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. B-1 What it replaced.

[0152] In some implementations, each time R occurs, B Each is independently selected from hydrogen, oxo group, amino group, and C. 1-6 Alkyl groups, wherein the amino group and C 1-6 Alkyl groups are each independently bound by one or more R B-1 What it replaced.

[0153] In some implementations, each time R occurs, B Each is independently selected from hydrogen, oxo group, amino group, and C. 1-3 Alkyl groups, wherein the amino group and C 1-3 Alkyl groups are each independently bound by one or more R B-1 What it replaced.

[0154] In some implementations, each time R occurs, BEach group is independently selected from hydrogen, oxo, amino, and methyl, wherein each amino and methyl group is independently converted by one or more R groups. B-1 What it replaced.

[0155] In some implementations, each time R occurs, B-1 Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups.

[0156] In some implementations, each time R occurs, B-1 Each group is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl and amino groups.

[0157] In some implementations, each time R occurs, B-1 Each is independently selected from hydrogen.

[0158] In some implementations, the L 1 Selected from key, -(C=O)-, -S-, -S(=O)-, -S(=O)2-, -S(O)(NR)-, -S-, -SC 1-4 alkylene-, -C 1-4 Alkylenes -S-, -O-, -OC 1-4 alkylene-, -C 1-4 Alkylenes -O-, -NR'-, -NR'(C=O)-, -NR'-C 1-4 alkylene-, -C 1-4 Alkylene-NR'-, -C 1-4 Alkylene -C(=O)-, -C(=O)-C 1-4 Alkylene-, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1a What it replaced.

[0159] In some implementations, the L 1 Selected from key, -O-, -OC 1-4 Alkylene-, -NR'-, -C 1-6 alkylene-NH- and C 1-6 Alkylene, the C 1-6 Each alkylene group is independently bounded by one or more L 1a What it replaced.

[0160] In some implementations, the L 1 Selected from key, -O-, -OC 1-3 Alkylene-, -NR'-, -C 1-3 alkylene-NH- and C 1-3 Alkylene, the C 1-3 Each alkylene group is independently bounded by one or more L 1a What it replaced.

[0161] In some implementations, the L 1 Selected from the group consisting of -O-, -O-CH2-, -NH-, -CH2-NH-, methylene, ethylene, and propylene, wherein each of the methylene, ethylene, and propylene groups is independently bound by one or more L- groups. 1a What it replaced.

[0162] In some implementations, each time L occurs, 1a Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -NR c R d -SR b -S(=O)R a -S(=O)2R a -P(=O)R c R d -OS(=O)2R a -NR c C(=O)R a -NR c C(=O)OR b -S(=O)(=NR) c)R b and -OC(=O)NR c R d .

[0163] In some implementations, each time L occurs, 1a Each is independently selected from hydrogen, hydroxyl, amino, oxo group, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, -NR c R d -SR b -S(=O)R a -S(=O)2R a -P(=O)R c R d -OS(=O)2R a -NR c C(=O)R a -NR c C(=O)OR b -S(=O)(=NR) c )R b and -OC(=O)NR c R d .

[0164] In some implementations, each time L occurs, 1a Each is independently selected from hydrogen, hydroxyl, amino, oxo group, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, -NR c R d -SR b -S(=O)R a -S(=O)2R a -P(=O)R c R d -OS(=O)2R a -NR c C(=O)R a -NR c C(=O)OR b -S(=O)(=NR) c )R b and -OC(=O)NR c R d .

[0165] In some implementations, each time L occurs, 1aEach is independently selected from hydrogen, hydroxyl, amino, oxo, methyl, trifluoromethyl, methoxy, N(CH3)2, NH(CH3), SH, SCH3, S(O)CH3, S(=O)2CH3, S(=O)2OCH3, P(=O)(CH3)2, P(=O)(OH)2, P(=O)(OCH3)2, -OS(=O)2CH3, -NHC(=O)CH3, -N(CH3)C(=O)CH3, -NHC(=O)OCH3, -S(=O)(=NH)CH3, -S(=O)(=NCH3)CH3 and -OC(=O)NH(CH3).

[0166] In some implementations, the L 2 Selected from bonds, hydrogen, C 1-6 Alkyl, -C(=O)NR c R d C 6-14 Aryl, C 3-8 Cycloalkyl, 5-12-membered heteroaryl and 3-12-membered heterocyclic groups, wherein -C(=O)NR c R d C 6-14 Aryl, C 3-8 Cycloalkyl, 5-12-membered heteroaryl, and 3-12-membered heterocyclic groups are each independently bound by one or more L... 2a What it replaced.

[0167] In some implementations, the L 2 Selected from bonds, hydrogen, C 1-6 Alkyl, -C(=O)NR c R d C 6-10 Aryl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic and 5-7 membered heteroaryl, wherein -C(=O)NR c R d C 6-10 Aryl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic and 5-7 membered heteroaryl groups are bound by one or more L 2a What it replaced.

[0168] In some implementations, the L 2 Selected from bonds, hydrogen, C 1-3 Alkyl, -C(=O)NR c R d C 6-10 Aryl, C 3-8 Cycloalkyl, 4-7-membered heterocyclic and 5-7-membered heteroaryl groups, wherein the 4-7-membered heterocyclic and 5-7-membered heteroaryl groups contain 1-4 heteroatoms selected from N, O and S, and the C 6-10 Aryl, C3-8 Cycloalkyl, 4-7 membered heterocyclic and 5-7 membered heteroaryl groups are bound by one or more L 2a What it replaced.

[0169] In some implementations, the L 2 Selected from the following groups: bond, hydrogen, methyl, -C(=O)NH2, -C(=O)N(H)CH3, -C(=O)N(H)CH2CH3, -C(=O)N(CH3)2, -C(=O)N(CH3)CH2CH3, -C(=O)N(CH2CH3)2, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyridinyl, furanyl, thiophene, pyrrole, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, 1, 2,4-Thiadiazolyl, 1,2,3-Triazolyl, 1,2,4-Triazolyl, Pyridazinyl, Pyrazinyl, 2,3-Dihydro-1H-pyrazolyl, Oxalbidinyl, Tetrahydrofuranyl, Tetrahydropyranyl, Thiobutyl, Tetrahydrothiophenyl, Tetrahydrothiaranyl, Isothiazolyl, 1,3-Thiohexacyclic butyl, 1,2-Thiazinyl, 1,3-Thiazinyl, Thiazolyl, 1,3-Dazathidinyl, Imidazolyl, Pyrazolyl, Pyrrolidinyl, Piperidinyl, 1,3-Oxazinyl, 1,2-Dihydropyridinyl, Morpholinyl, Pyrimidinyl, Piperazinyl, Acetidinyl, Oxazolyl, Hexahydropyrimidinyl, Oxazolyl, Imidazolyl and The cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyridyl, furanyl, thiophene, pyrrolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, pyrazinyl, pyrazinyl, and 2,3-dihydro-1H-pyrazole are mentioned. alkyl, oxadiazinyl, tetrahydrofuranyl, tetrahydropyranyl, thiobutyl, tetrahydrothiophenyl, tetrahydrothiaranyl, isothiazolyl, 1,3-thiazolebutyl, 1,2-thiazinyl, 1,3-thiazinyl, thiazolyl, 1,3-diazhidinyl, imidazolyl, pyrazolyl, pyrrolidinyl, piperidinyl, 1,3-oxazinyl, 1,2-dihydropyridinyl, morpholinyl, pyrimidinyl, piperazinyl, acridinel, oxazolyl, hexahydropyrimidinyl, oxazolyl, imidazolyl and by one or more L 2a What it replaced.

[0170] In some implementations, each time L occurs, 2a Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the amino group, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2b What it replaced.

[0171] In some implementations, each time L occurs, 2a Each is independently selected from hydrogen, cyano, hydroxyl, amino, halogen, oxo group, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy groups, 4-5 membered heterocyclic groups and C 3-5 cycloalkyl, said amino, C 1-3 Alkyl, C 1-3 Alkoxy groups, 4-5 membered heterocyclic groups and C 3-5 Each cycloalkyl group is independently bound by one or more L 2b What it replaced.

[0172] In some implementations, each time L occurs, 2a Each is independently selected from hydrogen, cyano, hydroxyl, amino, halogen, oxo group, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy groups, 4-5 membered heterocyclic groups and C 3-5 Cycloalkyl groups, wherein the 4-5 membered heterocyclic group contains 1-4 heteroatoms selected from N, O, and S, and the amino group, C 1-3 Alkyl, C 1-3 Alkoxy groups, 4-5 membered heterocyclic groups and C 3-5 Each cycloalkyl group is independently bound by one or more L 2b What it replaced.

[0173] In some implementations, each time L occurs, 2aEach group is independently selected from hydrogen, F, cyano, hydroxyl, amino, oxo, methyl, trifluoroethyl, difluoroethyl, trifluoromethyl, difluoromethyl, methoxy, oxadiazine, and cyclopropyl, wherein each amino, methyl, methoxy, oxadiazine, and cyclopropyl group is independently separated by one or more L groups. 2b What it replaced.

[0174] In some implementations, each time it occurs, two or more L 2a Together with the atoms bonded to them, they form 5-16 membered heteroaryl groups, C 6-10 Aryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2b What it replaced.

[0175] In some implementations, each time it occurs, two or more L 2a Together with the atoms bonded to them, they form C. 3-5 cycloalkyl, C 6-10 Aryl, 4-6 membered heterocyclic and 5-7 membered heteroaryl, wherein C 6-10 Aryl, C 3-5 Cycloalkyl, 4-6 membered heterocyclic and 5-7 membered heteroaryl groups are each independently bound by one or more L groups. 2b What it replaced.

[0176] In some implementations, each time it occurs, two or more L 2a Together with the atoms bonded to them, they form C. 3-5 cycloalkyl, C 6-10 aryl, 4-6 membered heterocyclic and 5-7 membered heteroaryl, wherein the 4-6 membered heterocyclic and 5-7 membered heteroaryl contain 1-4 heteroatoms selected from N, O and S, and the C 6-10 Aryl, C 3-5 Cycloalkyl, 4-6 membered heterocyclic and 5-7 membered heteroaryl groups are each independently bound by one or more L groups. 2b What it replaced.

[0177] In some implementations, each time it occurs, two or more L 2a Together with the atoms bonded to them, they form cyclopropyl, cyclobutyl, cyclopentyl, pyrrolyl, oxadiazyl, tetrahydrofuranyl, pyrazolyl, imidazolyl, pyrazolyl, phenyl, furanyl, thiophenyl, pyrrolyl, oxadiazyl, and pyridyl groups, each of which is independently bound by one or more L... 2bWhat it replaced.

[0178] In some implementations, each time L occurs, 2b Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups.

[0179] In some implementations, each time L occurs, 2b Each is independently selected from hydrogen, oxo group, C 1-6 Alkoxy and C 1-6 alkyl.

[0180] In some implementations, each time L occurs, 2b Each is independently selected from hydrogen, oxo group, C 1-3 Alkoxy and C 1-3 alkyl.

[0181] In some implementations, each time L occurs, 2b Each is independently selected from hydrogen, oxo, methoxy, and methyl.

[0182] In some embodiments, -L1-L2 are selected from bonds, methyl, amino, etc. -CH2CF3、

[0183] In some embodiments, R' is independently selected from hydrogen, deuterium, and C. 1-3 alkyl.

[0184] In some embodiments, R' is independently selected from hydrogen, deuterium, methyl, ethyl, n-propyl, and isopropyl.

[0185] In some implementations, R a Each is independently selected from hydrogen and C.1-6 alkyl.

[0186] In some implementations, R a Each is independently selected from hydrogen and C. 1-3 alkyl.

[0187] In some implementations, R a Each is independently selected from hydrogen, methyl, ethyl, n-propyl, and isopropyl.

[0188] In some implementations, R b Each is independently selected from hydrogen and C. 1-6 alkyl.

[0189] In some implementations, R b Each is independently selected from hydrogen and C. 1-3 alkyl.

[0190] In some implementations, R b Each is independently selected from hydrogen, methyl, ethyl, n-propyl, and isopropyl.

[0191] In some implementations, R c Each is independently selected from hydrogen and C. 1-6 alkyl.

[0192] In some implementations, R c Each is independently selected from hydrogen and C. 1-3 alkyl.

[0193] In some implementations, R c Each is independently selected from hydrogen, methyl, ethyl, n-propyl, and isopropyl.

[0194] In some implementations, R d Each is independently selected from hydrogen and C. 1-6 alkyl.

[0195] In some implementations, R d Each is independently selected from hydrogen and C. 1-3 alkyl.

[0196] In some implementations, R d Each is independently selected from hydrogen, methyl, ethyl, n-propyl, and isopropyl.

[0197] On the other hand, the present invention also provides a compound or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotope derivatives, and pharmaceutically acceptable salts, characterized in that the compound is selected from:

[0198] This invention provides a compound or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotope derivatives, and pharmaceutically acceptable salts thereof, characterized in that the compound is selected from:

[0199] On the other hand, the present invention also provides a pharmaceutical composition comprising the aforementioned compound or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotope derivatives and pharmaceutically acceptable salts, and one or more pharmaceutically acceptable carriers, diluents or excipients.

[0200] In some embodiments, the unit dose of the pharmaceutical composition is 0.001 mg to 1000 mg.

[0201] In some embodiments, the pharmaceutical composition contains 0.01% to 99.99% of the aforementioned compound based on the total weight of the composition. In some embodiments, the pharmaceutical composition contains 0.1% to 99.9% of the aforementioned compound. In some embodiments, the pharmaceutical composition contains 0.5% to 99.5% of the aforementioned compound. In some embodiments, the pharmaceutical composition contains 1% to 99% of the aforementioned compound. In some embodiments, the pharmaceutical composition contains 2% to 98% of the aforementioned compound.

[0202] In some embodiments, the pharmaceutical composition contains 0.01% to 99.99% pharmaceutically acceptable carriers, diluents, or excipients based on the total weight of the composition. In some embodiments, the pharmaceutical composition contains 0.1% to 99.9% pharmaceutically acceptable carriers, diluents, or excipients. In some embodiments, the pharmaceutical composition contains 0.5% to 99.5% pharmaceutically acceptable carriers, diluents, or excipients. In some embodiments, the pharmaceutical composition contains 1% to 99% pharmaceutically acceptable carriers, diluents, or excipients. In some embodiments, the pharmaceutical composition contains 2% to 98% pharmaceutically acceptable carriers, diluents, or excipients.

[0203] All compounds involved in this invention, as well as mixtures and compositions comprising the compounds disclosed herein, can be administered to a living organism via any route of administration. Routes of administration may include oral administration, intravenous injection, intramuscular injection, subcutaneous injection, rectal administration, vaginal administration, sublingual administration, nasal inhalation, oral inhalation, eye drops, or local or systemic transdermal administration.

[0204] All compounds involved in this invention, as well as mixtures and compositions containing compounds disclosed herein, can be formulated into single doses containing the active compounds of this invention, as well as carriers, excipients, etc. The dosage forms can be tablets, capsules, injections, granules, powders, suppositories, pills, creams, pastes, gels, powders, oral solutions, inhalers, suspensions, dry suspensions, patches, lotions, etc. These dosage forms may contain commonly used pharmaceutical ingredients, such as diluents, absorbents, wetting agents, binders, disintegrants, colorants, pH adjusters, antioxidants, antibacterial agents, isotonic adjusters, anti-adhesives, etc.

[0205] Suitable formulations for the aforementioned dosage forms are available from publicly available sources, such as Remington: The Science and Practice of Pharmacy, 21st Edition, Lippincott Williams & Wilkins, 2006, and Rowe, Raymond C. Handbook of Pharmaceutical Excipients, Chicago, Pharmaceutical Press, 2005. Therefore, those skilled in the art can readily prepare them.

[0206] Depending on the nature and severity of the disease suffered by different individuals, the patient's age, sex, weight, route of administration, and other factors, different dosages can be selected. The dosage of the compound disclosed herein can be from 0.01 to 500 mg / kg per day, preferably 1-100 mg / kg per day, and can be administered once or multiple times.

[0207] On the other hand, the present invention also provides the compounds described herein or their stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotope derivatives and pharmaceutically acceptable salts, or the aforementioned pharmaceutical compositions, for use in the prevention and / or treatment of symptoms, diseases or conditions related to abnormal expression or dysfunction of VAV1.

[0208] In some embodiments, the conditions, diseases, or illnesses associated with abnormal VAV1 expression or dysfunction include autoimmune diseases, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, tumors, rhinitis, conjunctivitis, allergic contact dermatitis, inflammatory diseases, inflammatory bowel disease, Crohn's disease, ulcerative colitis, internal asthma, inflammatory lung injury, inflammatory liver injury, eczematous dermatitis, lipoid dermatitis, inflammatory eye disease, keratitis, myocarditis, hepatitis, pleurisy, type I or II diabetes, anemia, uveitis, psoriasis, ulcerative colitis, atherosclerosis, myocarditis, pulmonary fibrosis, systemic sclerosis, host diseases, myasthenia gravis, allergic diseases, Sjogren's syndrome, autoimmune liver disease, chronic inflammatory demyelinating polyneuropathy, and yellowing of the skin. Macular degeneration, amyloidosis, inflammatory eye diseases, chronic transplant-host disease, pulmonary hypertension or vasculitis, asthma, thyroiditis, atopic dermatitis, osteoarthritis, irritant contact dermatitis, inflammatory eye diseases, graft-versus-host disease, chronic transplant rejection, acute transplant rejection, transplant vascular disease, transplant atherosclerosis, transplant coronary artery disease, B-cell lymphoma, B-cell leukemia, T-cell leukemia, acute myeloid leukemia, axial spondyloarthritis, cancer, malignant tumors, hematologic malignancies, lymphoma, lymphocytosis, T-cell lymphoma, intestinal T-cell lymphoma, lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, lens keratinocyte lymphoma, kidney disease, lupus nephritis, inflammatory glomerular injury.

[0209] On the other hand, the present invention also provides the use of the compounds described herein or their stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotope derivatives and pharmaceutically acceptable salts, or the aforementioned pharmaceutical compositions, for the prevention and / or treatment of symptoms, diseases or conditions related to abnormal expression or dysfunction of VAV1.

[0210] In some embodiments, the conditions, diseases, or illnesses associated with abnormal VAV1 expression or dysfunction include autoimmune diseases, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, tumors, rhinitis, conjunctivitis, allergic contact dermatitis, inflammatory diseases, inflammatory bowel disease, Crohn's disease, ulcerative colitis, internal asthma, inflammatory lung injury, inflammatory liver injury, eczematous dermatitis, lipoid dermatitis, inflammatory eye disease, keratitis, myocarditis, hepatitis, pleurisy, type I or II diabetes, anemia, uveitis, psoriasis, ulcerative colitis, atherosclerosis, myocarditis, pulmonary fibrosis, systemic sclerosis, host diseases, myasthenia gravis, allergic diseases, Sjogren's syndrome, autoimmune liver disease, chronic inflammatory demyelinating polyneuropathy, and yellowing of the skin. Macular degeneration, amyloidosis, inflammatory eye diseases, chronic transplant-host disease, pulmonary hypertension or vasculitis, asthma, thyroiditis, atopic dermatitis, osteoarthritis, irritant contact dermatitis, inflammatory eye diseases, graft-versus-host disease, chronic transplant rejection, acute transplant rejection, transplant vascular disease, transplant atherosclerosis, transplant coronary artery disease, B-cell lymphoma, B-cell leukemia, T-cell leukemia, acute myeloid leukemia, axial spondyloarthritis, cancer, malignant tumors, hematologic malignancies, lymphoma, lymphocytosis, T-cell lymphoma, intestinal T-cell lymphoma, lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, lens keratinocyte lymphoma, kidney disease, lupus nephritis, inflammatory glomerular injury.

[0211] On the other hand, the present invention also provides the use of the compounds described herein or their stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotope derivatives and pharmaceutically acceptable salts, or the aforementioned pharmaceutical compositions, in the manufacture of medicaments for the prevention and / or treatment of conditions, diseases or illnesses associated with abnormal expression or dysfunction of VAV1.

[0212] In some embodiments, the conditions, diseases, or illnesses associated with abnormal VAV1 expression or dysfunction include autoimmune diseases, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, tumors, rhinitis, conjunctivitis, allergic contact dermatitis, inflammatory diseases, inflammatory bowel disease, Crohn's disease, ulcerative colitis, internal asthma, inflammatory lung injury, inflammatory liver injury, eczematous dermatitis, lipoid dermatitis, inflammatory eye disease, keratitis, myocarditis, hepatitis, pleurisy, type I or II diabetes, anemia, uveitis, psoriasis, ulcerative colitis, atherosclerosis, myocarditis, pulmonary fibrosis, systemic sclerosis, host diseases, myasthenia gravis, allergic diseases, Sjogren's syndrome, autoimmune liver disease, chronic inflammatory demyelinating polyneuropathy, and yellowing of the skin. Macular degeneration, amyloidosis, inflammatory eye diseases, chronic transplant-host disease, pulmonary hypertension or vasculitis, asthma, thyroiditis, atopic dermatitis, osteoarthritis, irritant contact dermatitis, inflammatory eye diseases, graft-versus-host disease, chronic transplant rejection, acute transplant rejection, transplant vascular disease, transplant atherosclerosis, transplant coronary artery disease, B-cell lymphoma, B-cell leukemia, T-cell leukemia, acute myeloid leukemia, axial spondyloarthritis, cancer, malignant tumors, hematologic malignancies, lymphoma, lymphocytosis, T-cell lymphoma, intestinal T-cell lymphoma, lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, lens keratinocyte lymphoma, kidney disease, lupus nephritis, inflammatory glomerular injury.

[0213] On the other hand, the present invention also provides a method for preventing and / or treating symptoms, diseases or conditions related to abnormal expression or dysfunction of VAV1, comprising administering to a subject in need a therapeutically effective amount of the compound of the present invention or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotope derivatives and pharmaceutically acceptable salts, or a therapeutically effective amount of the aforementioned pharmaceutical composition.

[0214] In some embodiments, the conditions, diseases, or illnesses associated with abnormal VAV1 expression or dysfunction include autoimmune diseases, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, tumors, rhinitis, conjunctivitis, allergic contact dermatitis, inflammatory diseases, inflammatory bowel disease, Crohn's disease, ulcerative colitis, internal asthma, inflammatory lung injury, inflammatory liver injury, eczematous dermatitis, lipoid dermatitis, inflammatory eye disease, keratitis, myocarditis, hepatitis, pleurisy, type I or II diabetes, anemia, uveitis, psoriasis, ulcerative colitis, atherosclerosis, myocarditis, pulmonary fibrosis, systemic sclerosis, host diseases, myasthenia gravis, allergic diseases, Sjogren's syndrome, autoimmune liver disease, chronic inflammatory demyelinating polyneuropathy, and yellowing of the skin. Macular degeneration, amyloidosis, inflammatory eye diseases, chronic transplant-host disease, pulmonary hypertension or vasculitis, asthma, thyroiditis, atopic dermatitis, osteoarthritis, irritant contact dermatitis, inflammatory eye diseases, graft-versus-host disease, chronic transplant rejection, acute transplant rejection, transplant vascular disease, transplant atherosclerosis, transplant coronary artery disease, B-cell lymphoma, B-cell leukemia, T-cell leukemia, acute myeloid leukemia, axial spondyloarthritis, cancer, malignant tumors, hematologic malignancies, lymphoma, lymphocytosis, T-cell lymphoma, intestinal T-cell lymphoma, lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, lens keratinocyte lymphoma, kidney disease, lupus nephritis, inflammatory glomerular injury.

[0215] Terminology Explanation

[0216] Unless otherwise stated, the terms used in the specification and claims have the following meanings.

[0217] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight-chain or branched group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12) carbon atoms, and more preferably an alkyl group containing 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-Dimethylpentyl, 2,4-Dimethylpentyl, 2,2-Dimethylpentyl, 3,3-Dimethylpentyl, 2-Ethylpentyl, 3-Ethylpentyl, n-Octyl, 2,3-Dimethylhexyl, 2,4-Dimethylhexyl, 2,5-Dimethylhexyl, 2,2-Dimethylhexyl, 3,3-Dimethylhexyl, 4,4-Dimethylhexyl, 2-Ethylhexyl, 3-Ethylhexyl, 4-Ethylhexyl, 2-Methyl-2-Ethylpentyl, 2-Methyl-3-Ethylpentyl, n-Nonyl, 2-Methyl-2-Ethylhexyl, 2-Methyl-3-Ethylhexyl, 2,2-Diethylpentyl, n-Decyl, 3,3-Diethylhexyl, 2,2-Diethylhexyl, and their various branched isomers, etc. More preferably, lower alkyl groups containing 1 to 6 carbon atoms are used. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, etc. Alkyl groups can be substituted or unsubstituted, and when substituted, they can be substituted at any usable connection point. The substituents are preferably independently selected independently from one or more substituents chosen from the following: D atom, halogen, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.

[0218] The term "alkylene" refers to a saturated straight-chain or branched aliphatic hydrocarbon group, which is a residue derived from a parent alkane by removing two hydrogen atoms from the same carbon atom or two different carbon atoms. It is a straight-chain or branched group containing 1 to 20 carbon atoms, preferably containing 1 to 12 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) carbon atoms, more preferably alkylene containing 1 to 6 carbon atoms. Non-limiting examples of alkylene include, but are not limited to, methylene (-CH2-), 1,1-ethylene (-CH(CH3)-), 1,2-ethylene (-CH2CH2)-, 1,1-propylene (-CH(CH2CH3)-), 1,2-propylene (-CH2CH(CH3)-), 1,3-propylene (-CH2CH2CH2-), 1,4-butylene (-CH2CH2CH2CH2-), etc. The alkylene group can be substituted or unsubstituted, and when substituted, it can be substituted at any usable connection point. The substituent is preferably independently selected independently from one or more substituents selected from alkenyl, alkynyl, alkoxy, haloalkoxy, cycloalkyloxy, heterocyclic alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkyloxy, heterocyclic alkoxy, cycloalkylthio, heterocyclic alkoxy, and oxo.

[0219] The term "alkenyl" refers to an alkyl compound containing at least one carbon-carbon double bond in its molecule, wherein the definition of alkyl is as described above. Alkenyl groups can be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, independently selected from alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl substituents.

[0220] The term "alkynyl" refers to an alkyl compound containing at least one carbon-carbon triple bond in its molecule, wherein the definition of alkyl is as described above. The alkynyl group can be substituted or unsubstituted; when substituted, the substituent is preferably one or more of the following groups, independently selected from alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl substituents.

[0221] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, wherein the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 8 (e.g., 3, 4, 5, 6, 7, and 8) carbon atoms, and more preferably 3 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cyclohepttrienyl, cyclooctyl, etc.; polycyclic cycloalkyl groups include spirocyclic, fused-ring, and bridged-ring cycloalkyl groups.

[0222] The term "spirocycloalkyl" refers to a 5- to 20-membered polycyclic group that shares a single carbon atom (called a spiro atom) between its rings, and may contain one or more double bonds. Preferably, it is 6- to 14-membered, more preferably 7- to 10-membered (e.g., 7, 8, 9, or 10-membered). Spirocycloalkyl groups are classified as monospirocycloalkyl, bispirocycloalkyl, or polyspirocycloalkyl groups based on the number of shared spiro atoms between the rings, with monospirocycloalkyl and bispirocycloalkyl groups being preferred. More preferably, it is a 3 / 5-membered, 3 / 6-membered, 4 / 4-membered, 4 / 5-membered, 4 / 6-membered, 5 / 5-membered, or 5 / 6-membered monospirocycloalkyl group. Non-limiting examples of spirocycloalkyl groups include:

[0223] The term "fused cycloalkyl" refers to a 5- to 20-membered polycyclic aromatic hydrocarbon group in which each ring in the system shares an adjacent pair of carbon atoms with other rings in the system, wherein one or more rings may contain one or more double bonds. Preferably, it is 6 to 14-membered, more preferably 7 to 10-membered (e.g., 7, 8, 9, or 10-membered). Depending on the number of constituent rings, it can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic fused cycloalkyl, preferably bicyclic or tricyclic, more preferably 3 / 4-membered, 3 / 5-membered, 3 / 6-membered, 4 / 4-membered, 4 / 5-membered, 4 / 6-membered, 5 / 4-membered, 5 / 5-membered, 5 / 6-membered, 6 / 3-membered, 6 / 4-membered, 6 / 5-membered, and 6 / 6-membered bicyclic alkyl groups. Non-limiting examples of fused cycloalkyl groups include:

[0224] The term "bridged cycloalkyl" refers to a 5- to 20-membered polycyclic carbon group in which any two rings share two non-directly bonded carbon atoms, and may contain one or more double bonds. Preferably, it is 6- to 14-membered, more preferably 7- to 10-membered (e.g., 7, 8, 9, or 10-membered). Depending on the number of rings, it can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic bridged cycloalkyl, preferably bicyclic, tricyclic, or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of bridged cycloalkyl groups include:

[0225] The cycloalkyl ring comprises a cycloalkyl group (including monocyclic, spirocyclic, fused, and bridged rings) fused to an aryl, heteroaryl, or heterocyclic alkyl ring as described above, wherein the ring attached to the parent structure is a cycloalkyl group. Non-limiting examples include... etc.; preferred

[0226] The cycloalkyl group can be substituted or unsubstituted, and when substituted, it can be substituted at any usable connection point. The substituent is preferably selected independently from one or more substituents selected from halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl and heteroaryl.

[0227] The term "alkoxy" refers to -O-(alkyl) and -O-(cycloalkyl), where alkyl and cycloalkyl are defined as described above. Non-limiting examples of alkoxy groups include methoxy, ethoxy, propoxy, and butoxy. Alkoxy groups can be optionally substituted or unsubstituted, and when substituted, they are preferably one or more of the following groups, independently selected from D atoms, halogens, alkoxy groups, haloalkyl groups, haloalkoxy groups, cycloalkyloxy groups, heterocyclic oxy groups, hydroxyl groups, hydroxyalkyl groups, cyano groups, amino groups, nitro groups, cycloalkyl groups, heterocyclic groups, aryl groups, and heteroaryl groups.

[0228] The term "heterocyclic group" refers to a saturated or partially unsaturated monocyclic or polycyclic non-aromatic cyclic substituent comprising 3 to 20 ring atoms, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the sulfur may optionally be oxidized (i.e., forming sulfoxide or sulfone), but excluding the -OO-, -OS-, or -SS- ring moiety, and the remaining ring atoms are carbon. Preferably, it comprises 3 to 12 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) ring atoms, wherein 1 to 4 (e.g., 1, 2, 3, and 4) are heteroatoms; more preferably, it comprises 3 to 8 ring atoms (e.g., 3, 4, 5, 6, 7, and 8), wherein 1 to 3 (e.g., 1, 2, and 3) are heteroatoms; even more preferably, it comprises 3 to 6 ring atoms, wherein 1 to 3 are heteroatoms; most preferably, it comprises 5 or 6 ring atoms, wherein 1 to 3 are heteroatoms. Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, tetrahydropyranyl, 1,2,3,6-tetrahydropyridyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, and homopiperazinyl. Polycyclic heterocyclic groups include spirocyclic, fused-ring, and bridged-ring heterocyclic groups.

[0229] The term "spiroheterocyclic group" refers to a 5- to 20-membered non-aromatic polycyclic heterocyclic group in which one or more ring atoms share a single atom (called a spiro atom) between the rings, wherein the one or more ring atoms are heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the sulfur may optionally be oxidized (i.e., forming a sulfoxide or sulfone), and the remaining ring atoms are carbon. It may contain one or more double bonds. Preferably, it is 6 to 14-membered, more preferably 7 to 10-membered (e.g., 7, 8, 9, or 10-membered). Spiroheterocyclic groups are classified into monospirocyclic, bispirocyclic, or multispirocyclic groups according to the number of shared spiro atoms between the rings, with monospirocyclic and bispirocyclic groups being preferred. More preferably, it is a 3 / 5-membered, 3 / 6-membered, 4 / 4-membered, 4 / 5-membered, 4 / 6-membered, 5 / 5-membered, or 5 / 6-membered monospirocyclic group. Non-limiting examples of spirocyclic groups include:

[0230] The term "fused heterocyclic group" refers to a 5- to 20-membered non-aromatic polycyclic heterocyclic group in which each ring in the system shares an adjacent pair of atoms with other rings in the system. One or more rings may contain one or more double bonds, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the sulfur may optionally be oxidized (i.e., forming sulfoxide or sulfone), and the remaining ring atoms are carbon. Preferably, it is 6- to 14-membered, more preferably 7- to 10-membered (e.g., 7, 8, 9, or 10-membered). Depending on the number of constituent rings, it can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic fused heterocyclic groups, preferably bicyclic or tricyclic, more preferably 3-membered / 4-membered, 3-membered / 5-membered, 3-membered / 6-membered, 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 4-membered, 5-membered / 5-membered, 5-membered / 6-membered, 6-membered / 3-membered, 6-membered / 4-membered, 6-membered / 5-membered, and 6-membered / 6-membered bicyclic fused heterocyclic groups. Non-limiting examples of fused heterocyclic groups include:

[0231] The term "bridged heterocyclic group" refers to a 5- to 14-membered, non-aromatic polycyclic heterocyclic group in which any two rings share two non-directly bonded atoms. It may contain one or more double bonds, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the sulfur may optionally be oxidized (i.e., forming sulfoxide or sulfone), and the remaining ring atoms are carbon. Preferably, it is 6- to 14-membered, more preferably 7- to 10-membered (e.g., 7, 8, 9, or 10-membered). Depending on the number of rings, it can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic, or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of bridged heterocyclic groups include:

[0232] The heterocyclic ring comprises a heterocyclic group (including monocyclic, spirocyclic, fused heterocyclic, and bridged heterocyclic rings) fused to an aryl, heteroaryl, or cycloalkyl ring as described above, wherein the ring connected to the parent structure is a heterocyclic group, and non-limiting examples include:

[0233] wait.

[0234] The heterocyclic group can be substituted or unsubstituted. When substituted, it can be substituted at any usable connection point. The substituent is preferably selected independently from one or more substituents selected from halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.

[0235] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (fused polycyclic) group having a conjugated π-electron system, preferably 6- to 10-membered, such as phenyl and naphthyl. The aryl ring comprises an aryl ring fused to a heteroaryl, heterocyclic, or cycloalkyl ring as described above, wherein the ring attached to the parent structure is an aryl ring, and non-limiting examples include:

[0236] The aryl group can be substituted or unsubstituted, and when substituted, it can be substituted at any usable connection point. The substituent is preferably selected independently from one or more substituents selected from halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl and heteroaryl.

[0237] The term "heteroaryl" refers to a heteroaryl system comprising 1 to 4 (e.g., 1, 2, 3, and 4) heteroatoms and 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur, and nitrogen. The heteroaryl group is preferably 5 to 10-membered (e.g., 5, 6, 7, 8, 9, or 10-membered), more preferably 5- or 6-membered, such as furanyl, thiophene, pyridinyl, pyrroleyl, N-alkylpyrroleyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, etc. The heteroaryl ring comprises a heteroaryl group fused to an aryl, heterocyclic, or cycloalkyl ring as described above, wherein the ring connected to the parent structure is a heteroaryl ring, and non-limiting examples include:

[0238] The heteroaryl group can be substituted or unsubstituted. When substituted, it can be substituted at any usable connection point. The substituent is preferably selected independently from one or more substituents selected from halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl and heteroaryl.

[0239] The aforementioned cycloalkyl, heterocyclic, aryl, and heteroaryl groups include residues derived from removing one hydrogen atom from a parent ring atom, or residues derived from removing two hydrogen atoms from the same or two different ring atoms of the parent, namely "divalent cycloalkyl", "divalent heterocyclic", "aryl", and "heteroaryl".

[0240] The term “cycloalkyloxy” refers to cycloalkyl-O-, where the cycloalkyl group is as defined above.

[0241] The term “heterocyclic oxy group” refers to the heterocyclic group -O-, where the heterocyclic group is as defined above.

[0242] The term "aryloxy group" refers to aryl-O-, where the aryl group is as defined above.

[0243] The term "halogenated alkyl" refers to an alkyl group that has been substituted with one or more halogens, wherein the alkyl group is as defined above.

[0244] The term "haloalkoxy" refers to an alkoxy group that is substituted by one or more halogens, wherein the alkoxy group is as defined above.

[0245] The term "halogen" refers to fluorine, chlorine, bromine, or iodine.

[0246] The term "hydroxyl group" refers to -OH.

[0247] The terms "thio" or "mercapto" refer to -SH.

[0248] The term "amino" refers to -NH2.

[0249] The term "cyano" refers to -CN.

[0250] The term "nitro" refers to -NO2.

[0251] The term "oxo" or "oxo" refers to "=O".

[0252] The term "carbonyl" refers to C=O.

[0253] In the chemical structure of the compound described in this invention, the bond... This indicates that the configuration is not specified; that is, if chiral isomers exist in the chemical structure, the bond... It can be Or simultaneously include Two configurations. Bond It can be It is a cis configuration. Although all the above structural formulas are shown in certain isomer forms for simplicity, the present invention can include all isomers, such as tautomers, rotatimers, geometric isomers, diastereomers, racemates, and enantiomers. In the chemical structure of the compounds described in this disclosure, the bond... No configuration was specified, i.e., key The configuration can be E-type or Z-type, or it can contain both E-type and Z-type configurations.

[0254] "Optional" or "optionally" means that the event or environment described below may but does not have to occur, and the description includes the possibility or absence of the event or environment. For example, "optionally alkyl-substituted heterocyclic group" means that the alkyl group may but does not have to be present, and the description includes cases where the heterocyclic group is substituted with an alkyl group and cases where the heterocyclic group is not substituted with an alkyl group.

[0255] "Substituted" refers to one or more hydrogen atoms in a group, preferably 1 to 5, more preferably 1 to 3 hydrogen atoms, which are independently substituted by the corresponding number of substituents. Those skilled in the art can determine possible or impossible substitutions without much effort (through experimentation or theory). For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom having an unsaturated bond (such as an alkene).

[0256] The term "pharmaceutical composition" refers to a mixture containing one or more of the compounds described herein or their physiologically / pharmacologically acceptable salts or prodrugs, along with other chemical components, such as physiologically / pharmacologically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to a living organism, thereby promoting the absorption of the active ingredient and the exertion of its biological activity.

[0257] The term "carrier" refers to a system that does not cause significant irritation to an organism and does not eliminate the biological activity and properties of the given compound, and can alter the way a drug enters the body and its distribution in the body, control the rate of drug release, and deliver the drug to the target organ. Non-limiting examples include microcapsules and microspheres, nanoparticles, liposomes, etc.

[0258] The term "isotope derivative" refers to compounds whose structure differs only in the presence of one or more isotope-enriched atoms. For example, compounds having the structure disclosed herein, using "deuterium" or "tritium" instead of hydrogen, or using... 18 F-fluorine labeling ( 18 F isotopes) can be used instead of fluorine, or... 11 C-, 13 C-, or 14 C-enriched carbon ( 11 C-, 13 C-, or 14 C-carbon labeling; 11 C-, 13 C-, or 14Compounds in which carbon atoms are replaced by C-isotopes are within the scope of this disclosure. Such compounds can be used as analytical tools or probes in, for example, biological assays, or as in vivo diagnostic imaging tracers for diseases, or as tracers for pharmacodynamic, pharmacokinetic, or receptor studies. The various deuterated forms of compounds disclosed herein refer to compounds in which each available hydrogen atom bonded to a carbon atom can be independently replaced by a deuterium atom. Those skilled in the art can synthesize deuterated forms of compounds by referring to relevant literature. Commercially available deuteration starting materials can be used in the preparation of deuterated forms of compounds, or they can be synthesized using conventional techniques with deuteration reagents, including but not limited to deuterated boranes, trideuterated borane tetrahydrofuran solutions, deuterated lithium aluminum hydride, deuterated iodoethane, and deuterated iodomethane. Deuterated compounds generally retain activity comparable to undeuterated compounds, and better metabolic stability can be achieved when deuterated at certain specific sites, resulting in certain therapeutic advantages.

[0259] The term "solvent" refers to the physical combination of a compound of this disclosure with one or more, preferably one to three, solvent molecules, whether organic or inorganic. This physical combination includes hydrogen bonds. In some cases, such as when one or more, preferably one to three, solvent molecules are incorporated into the lattice of a crystalline solid, the solvate will be separated. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Solvation methods are well known in the art.

[0260] The term "prodrug" refers to a compound that can be converted in the body to produce an active drug substance under physiological conditions, such as through hydrolysis in the blood.

[0261] The term "hydrate" refers to a substance formed by the combination of a compound of this application or its pharmaceutically acceptable salt with water through non-covalent intermolecular forces. Common hydrates include (but are not limited to) hemihydrates, monohydrates, dihydrates, and trihydrates.

[0262] The term "pharmaceutically acceptable" means that these compounds, materials, compositions, and / or dosage forms are suitable for contact with patient tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, within reasonable medical judgment, have a reasonable benefit / risk ratio, and are effective for their intended use.

[0263] The terms "pharmaceutically acceptable salt" or "medicinally acceptable salt" refer to salts of the compounds disclosed herein that are safe and effective in mammalian use and possess the intended biological activity. Salts can be prepared either during the final isolation and purification of the compound or by reacting suitable groups with suitable bases or acids. Bases commonly used to form pharmaceutically acceptable salts include inorganic bases as well as organic bases. Acids commonly used to form pharmaceutically acceptable salts include inorganic acids as well as organic acids.

[0264] The term "isomer" means any geometric isomer, tautomer, zwitterion, stereoisomer, enantiomer, or diastereomer of a compound. A compound may include one or more chiral centers and / or double bonds, and thus exist as a stereoisomer, such as a double-bonded isomer (i.e., a geometric E / Z isomer) or a diastereomer (e.g., an enantiomer (i.e., (+) or (-)) or a cis / trans isomer). This disclosure covers any and all isomers of the compounds described herein, including stereoisomerically pure forms (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure) and mixtures of enantiomers and stereoisomers, such as racemates. Mixtures of enantiomers and stereoisomers of compounds, and the ways in which they are resolved into their constituent enantiomers or stereoisomers, are well known.

[0265] The term "stereoisomer" refers to compounds that have the same chemical structure but whose atoms or groups are arranged differently in space. Stereoisomers include enantiomers, diastereomers, conformational isomers (rotational isomers), geometric (cis / trans) isomers, and hindered isomers, etc.

[0266] The term "tautomer" refers to structural isomers with different energies that can interconvert via low energy barriers. For example, proton tautomers (also known as proton transfer tautomers) include interconversions via proton transfer, such as keto-enol and imine-enamine isomerization, lactam-lactamimide isomerization, pyrazolyl isomerization, and so on.

[0267] As used herein, the singular forms of “a,” “an,” and “the” include plural references, and vice versa, unless the context clearly indicates otherwise.

[0268] When the term "about" is applied to parameters such as pH, concentration, temperature, etc., it indicates that the parameter can vary by ±10%, and sometimes more preferably within ±5%. As those skilled in the art will understand, when a parameter is not critical, figures are usually given for illustrative purposes only and not as limitations.

[0269] The terms involved in this invention have been defined above. Those skilled in the art can also understand the above terms in conjunction with the prior art. The following is a further description based on the content of this invention and the definition of the terms.

[0270] The following examples are for illustrative purposes only and are not intended to limit the scope of the invention. Experimental methods not specifically described in the following examples are generally performed under conventional conditions or as recommended by the manufacturer. Unless otherwise stated, parts and percentages are by weight and weight percentages. In the preparation process, each reaction is carried out in an inert solvent at room temperature to reflux temperature. The reaction time is typically from 0.25 hours to 48 hours.

[0271] The synthetic processes disclosed herein can accommodate a wide range of functional groups, thus allowing the use of a variety of substituted starting materials. These processes generally provide the desired final compound at or near the end of the process, although in some cases it may be necessary to further convert the compound into its pharmaceutically acceptable salt.

[0272] The compounds disclosed herein can be prepared in a variety of ways using commercially available starting materials, compounds known in the literature, or readily prepared intermediates, by employing standard synthetic methods and procedures known to those skilled in the art or obvious to those skilled in the art based on the teachings herein. Standard synthetic methods and procedures for preparing organic molecules, as well as functional group transformations and manipulations, are available from relevant scientific literature or from standard textbooks in the field. While not limited to any one or more sources, classic textbooks incorporated herein by reference include, such as Smith, MB, March, J., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th Edition, John.

[0273] In the reaction schemes described herein, a variety of stereoisomers can be produced. When a specific stereoisomer is not indicated, this should be understood to mean all possible stereoisomers that can be produced by the reaction. Those skilled in the art will recognize that the reaction can be optimized to preferentially obtain one isomer, or new schemes can be designed to produce a single isomer. If a mixture is produced, the isomers can be separated using techniques such as preparative thin-layer chromatography, preparative HPLC, preparative chiral HPLC, or preparative SFC.

[0274] In the embodiments of this disclosure, the LC-MS instrument used is a Waters ACQUITY Arc or equivalent. The mass spectrometry (MS) uses an ESI source and indicates only the molecular weight M of the parent molecule, typically reporting [M+H]. +Furthermore, NMR spectra were obtained using a Varian 400MHz NMR spectrometer or equivalent equipment, typically with CDCl3 and DMSO-d6 as solvents, and chemical shifts were reported in ppm. The various peaks are described as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet). Coupling constants are expressed in Hz.

[0275] Some embodiments were synthesized using method A:

[0276] Compound A and compound B are coupled to yield the final product;

[0277] Among them, X 1 X 2 X 3 X 4 X 5 X 6 R 1 Ring A, R A Ring B, R B L 1 L 2 m and n are as defined in the text of this application.

[0278] Some embodiments were synthesized using method B:

[0279] first step:

[0280] Compound A reacts with pinacol diboronic acid ester to give compound B.

[0281] Step Two:

[0282] Compound B was coupled with compound C to give the final product;

[0283] Among them, X 1 X 2 X 3 X 4 X 5 X 6 R 1 Ring A, R A Ring B, R B L 1 L 2 m and n are as defined in the text of this application.

[0284] The method of the present invention will be described below through specific embodiments. It should be understood that these embodiments are used to illustrate the basic principles, main features and advantages of the present invention, and the present invention is not limited to the scope of the following embodiments. The implementation conditions used in the embodiments can be further adjusted according to specific requirements, and the implementation conditions not specified are usually the conditions in conventional experiments.

[0285] The following is a list of abbreviations used in the experimental section:

[0286] AcOK Potassium Acetate

[0287] Boc2O ditert-butyl dicarbonate

[0288] B2pin2 pinacol diboronate

[0289] CH3I iodomethane

[0290] CO and carbon monoxide

[0291] DCM dichloromethane

[0292] DIEA N,N-Diisopropylethylamine

[0293] DMF N,N-dimethylformamide

[0294] DMP (dimethyl phthalate)

[0295] DMSO (dimethyl sulfoxide)

[0296] EtOAc (ethyl acetate)

[0297] EtOH (ethanol)

[0298] h hours

[0299] HCl hydrochloric acid

[0300] H2O water

[0301] K2CO3 (potassium carbonate)

[0302] KHMDS bis(trimethylsilyl)aminopotassium

[0303] KOH (potassium hydroxide)

[0304] K3PO4 Potassium phosphate

[0305] m-CPBA (m-chloroperoxybenzoic acid)

[0306] M moles per liter

[0307] MeCN Acetonitrile

[0308] MeOH (methanol)

[0309] Min minutes

[0310] Sodium hydride (NaH)

[0311] n-BuLi n-Butyllithium

[0312] NH3 ammonia

[0313] NMP N-methylpyrrolidone

[0314] Pd(amphos)Cl2 bis[di-tert-butyl-(4-dimethylaminophenyl)phosphine]palladium(II) dichloride

[0315] Pd2(dba)3 Tris(dibenzylacetone)palladium

[0316] Pd(dppf)Cl2 1,1'-bis(diphenylphosphino)ferrocene palladium(II) chloride

[0317] Pd(OAc)2 Palladium acetate

[0318] PE petroleum ether

[0319] PhMe Toluene

[0320] PPh3 triphenylphosphine

[0321] rt room temperature

[0322] SnCl2 (Stadium chloride)

[0323] TFA (trifluoroacetic acid)

[0324] THF Tetrahydrofuran

[0325] Ti(OEt)4 tetraethyl titanate

[0326] TLC (Thin Layer Chromatography)

[0327] TMSCN Trimethylcyanosilane

[0328] Xantphos 4,5-bisdiphenylphosphine-9,9-dimethyloxanthracene

[0329] Xphos Pd G2 Chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II)

[0330] Zinc iodide (ZnI2)

[0331] Example 1: Preparation of intermediate 3-(3-bromo-2-chlorophenyl)piperidine-2,6-dione (INT1)

[0332] first step:

[0333] 1-Bromo-2-chloro-3-toluene (50.00 g, 0.2433 mol), N-bromosuccinimide (64.95 g, 0.3649 mol), and benzoyl peroxide (29.47 g, 0.121 mol) were added to carbon tetrachloride (500 mL) under nitrogen protection. The system was heated to 80 °C and stirred for 2 hours. After cooling to room temperature, the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EtOAc, 0-50%) to obtain 1-bromo-3-(bromomethyl)-2-chlorobenzene (INT1-1, 57.00 g, yield 82.37%, yellow oil).

[0334] Step Two:

[0335] Trimethylcyanosilane (31.61 g, 0.32 mol) and tetrabutylammonium fluoride (83.31 g, 0.32 mol) were added to a solution of INT1-1 (57.00 g, 0.20 mol) in acetonitrile (570 mL). The reaction mixture was stirred at 25 °C for 16 hours under a nitrogen atmosphere. The mixture was concentrated under reduced pressure, and the residue was diluted with water (300 mL), extracted with ethyl acetate (300 mL x 3), washed with saturated brine (300 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EtOAc, 0-30%) to give 2-(3-bromo-2-chlorophenyl)acetonitrile (INT1-2, 22.58 g, yield 48.88%, white solid).

[0336] Step 3:

[0337] Sodium methoxide (1.05 g, 0.10 mmol) and tert-butyl acrylate (12.51 g, 0.10 mmol) were added to a solution of tetrahydrofuran (200 mL) containing INT1-2 (22.5 g, 0.10 mol). The reaction mixture was stirred at 20 °C for 2 hours. The mixture was concentrated under reduced pressure to give crude tert-butyl 4-(3-bromo-2-chlorophenyl)-4-cyanobutyrate (INT1-3, 12.00 g, yield 34.27%, yellow oil).

[0338] Step 4:

[0339] INT1-3 (12.0 g, 33.46 mmol) was mixed in glacial acetic acid (120 mL), and sulfuric acid (28.27 g, 288.30 mmol) was added. The reaction mixture was stirred at 90 °C for 3 hours. The mixture was poured into water (500 mL) and filtered. The filter cake was washed with water and dried to give 3-(3-bromo-2-chlorophenyl)piperidine-2,6-dione (INT1, 6.00 g, yield 32.33%, white solid), [M+H] + =302.

[0340] Example 2: Preparation of intermediate 3-(3-bromo-2-(difluoromethoxy)phenyl)piperidine-2,6-dione (INT2)

[0341] first step:

[0342] At 25°C, 2-bromo-6-ethylphenol (2.0 g, 9.95 mmol) was added to a solution of KOH (11.16 g, 198.95 mmol), water (18 mL), and acetonitrile (18 mL). Then, 1-[[bromo(difluoro)methyl]-ethoxy-phosphoryl]oxyethane (5.31 g, 19.90 mmol) was added at -28°C. The mixture was stirred at -28°C for 0.3 h, and then at 25°C for 3.5 h. The mixture was diluted with water (20 mL). It was then extracted with dichloromethane (20 mL x 3). The organic layer was washed with brine (30 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (PE / EtOAc, 0-5%) to obtain 1-bromo-2-(difluoromethoxy)-3-methylbenzene (INT2-1, 4.0 g, yield 74.7%, colorless oil).

[0343] Step Two:

[0344] INT2-1 (4.0 g, 16.9 mmol) was dissolved in carbon tetrachloride (40 mL), and NBS (4.5 g, 25.4 mmol) and AIBN (1.1 g, 6.8 mmol) were added. The mixture was stirred at 80 °C for 12 h. After cooling to room temperature, the mixture was diluted with water (100 mL), extracted with ethyl acetate (100 mL * 2), and the organic phase was washed with saturated brine (100 mL). The mixture was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EtOAc, 0-5%) to give 2-(3-bromo-2-(difluoromethoxy)phenyl)acetonitrile (INT2-2, 3.1 g, yield 55.03%, colorless oil).

[0345] Step 3:

[0346] Trimethylsilane cyanide (1.26 g, 12.7 mmol) was added to an acetonitrile (30 mL) solution of INT2-2 (3.1 g, 9.9 mmol). TBAF (13 mL, 1 M THF solution, 13 mmol) was added to the mixture at 0 °C, and the mixture was stirred at 25 °C for 20 hours. The mixture was diluted with water (50 mL), extracted with ethyl acetate (50 mL x 2), washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EtOAc, 0-10%) to give 2-(3-bromo-2-(difluoromethoxy)phenyl)acetonitrile (INT2-3, 1.5 g, yield 53.06%, colorless oil).

[0347] Step 4:

[0348] At room temperature, INT2-3 (1.2 g, 4 mmol) and tert-butyl 2-enoate (0.71 g, 5 mmol) were dissolved in toluene (15 mL), and potassium carbonate (1.1 g, 8 mmol) and BTEAC (110 mg, 0.4 mmol) were added. The mixture was stirred at 75 °C for 5 h. After cooling to room temperature, the mixture was diluted with water (20 mL), extracted with ethyl acetate (30 mL * 2), and the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EtOAc, 0-80%) to give tert-butyl 4-(3-bromo-2-(difluoromethoxy)phenyl)-4-cyanobutyrate (INT2-4, 1.2 g, yield 60.87%, colorless oil).

[0349] Step 5:

[0350] At room temperature, sulfuric acid (1.5 g, 15 mmol) was added to a solution of 1.2 g (3 mmol) of acetic acid (15 mL), and the mixture was stirred at 90 °C for 3 hours. The mixture was cooled to room temperature, poured into an ice-water mixture (45 mL), stirred for 10 minutes to form a precipitate, filtered, and the filter cake was washed with 10 mL of water. The filter cake was collected and dried to give 3-(3-bromo-2-(difluoromethoxy)phenyl)piperidine-2,6-dione (INT2, 300 mg, yield 26%, white solid), [M+H]. + =334.

[0351] Example 3: Preparation of intermediate 3-(2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborane-2-yl)phenyl)piperidine-2,6-dione (INT3)

[0352] INT1 (4.0 g, 13.2 mmol), [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride dichloromethane complex (0.55 g, 0.6 mmol), bis(boron) (5.03 g, 19.7 mmol), and potassium acetate (2.59 g, 26.4 mmol) were mixed in a 1,4-dioxane (10 mL) solution under nitrogen protection and stirred at 85 °C for 3 hours. After cooling to room temperature, the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EtOAc, 0-50%) to obtain 3-(2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborane-2-yl)phenyl)piperidin-2,6-dione (INT3, 2.0 g, yield 43.27%, yellow solid), [M+H). + =350.

[0353] Example 4: Preparation of 3-(2-(difluoromethoxy)-4'-(2-oxopyridin-1(2H)-yl)-[1,1'-biphenyl]-3-yl)piperidine-2,6-dione (compound 1)

[0354] 1-(4-methylphenyl)pyridin-2-one (180 mg, 0.6 mmol), INT2 (200 mg, 0.6 mmol), and potassium phosphate (380 mg, 1.8 mmol) were dissolved in dioxane (10 mL), and Pd(dppf)Cl2 (44 mg, 0.06 mmol) was added. The mixture was heated to 100 °C and stirred for 15 h under nitrogen protection. The mixture was then cooled to room temperature. It was diluted with water (10 mL), extracted with ethyl acetate (10 mL x 3), washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EtOAc, 0–80%) to give 3-(2-(difluoromethoxy)-4'-(2-oxopyridin-1(2H)-yl)-[1,1'-biphenyl]-3-yl)piperidin-2,6-dione (compound 1, 40 mg, yield 15.12%, white solid), [M+H). + =425.

[0355] 1 H NMR (400MHz, DMSO) δ10.95(s,1H),7.68(dd,J=6.9,1.6Hz,1H),7.62(d,J=8.5Hz,1H),7.59-7.49(m,2H),7.48-7.34(m,2H),6.78-6.29(m,3H),4.25 (dd,J=12.6,4.9Hz,2H),2.80(ddd,J=18.0,13.1,5.3Hz,1H),2.57(dd,J=17.0,3.3Hz,1H),2.33(ddd,J=16.2,12.9,8.7Hz,1H), 2.11-1.95(m,1H).

[0356] Example 5: Preparation of 3-(2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborane-2-yl)phenyl)piperidine-2,6-dione (compound 2)

[0357] first step:

[0358] 2-(di-tert-butylphosphino)-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl(2-amino-1,1'-biphenyl-2-yl)palladium(II) (200.53 mg, 0.234 mmol), 3-bromo-1-methylpyrazole (754.83 mg, 4.69 mmol), tert-butyl {6-amino-2-azaspiro[3.3]heptane-2-yl}carboxylate (500 mg, 2.344 mmol) and cesium carbonate (2.29 g, 7.03 mmol) were added to 1,4-dioxane (10 mL), and the mixture was stirred at 100 °C for 16 hours under nitrogen protection. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (PE / EtOAc, 0-50%) to obtain 6-((1-methyl-1H-pyrazol-3-yl)amino)-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (compound 2-1, 300 mg, yield 43.56%, yellow oil).

[0359] Step Two:

[0360] To a solution of compound 2-1 (300 mg, 1.022 mmol) in dichloromethane (6 mL), trifluoroacetic acid (2 mL) was added, and the mixture was stirred at room temperature for 3 hours. The dichloromethane and trifluoroacetic acid were removed by concentration under reduced pressure. The residue was diluted with water (3 mL), the pH was adjusted to 10 with saturated sodium carbonate solution, and the mixture was extracted with ethyl acetate (30 mL * 3). The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give N-(1-methyl-1H-pyrazol-3-yl)-2-azaspiro[3.3]heptane-6-amine (compound 2-2, 0.11 g, yield 55.76%, yellow solid).

[0361] Step 3:

[0362] Methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (110.58 mg, 0.13 mmol), compound 2-2 (250 mg, 1.30 mmol), INT1 (393.41 mg, 1.30 mmol), and cesium carbonate (508.40 mg, 1.56 mmol) were added to a 1,4-dioxane (10 mL) solution. The mixture was stirred at 100 °C for 16 hours under nitrogen protection. The mixture was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(6-(((1-methyl-1H-pyrazol-3-yl)amino)-2-azaspiro[3.3]heptane-2-yl)phenyl)piperidin-2,6-dione (compound 2, 27 mg, yield 5.02%, yellow solid), [M+H + =414.

[0363] 1 HNMR (400MHz, DMSO) δ10.87(d,J=4.8Hz,1H),8.55(d,J=5.6Hz,0.5H),8.07(d,J=3.2Hz,0.5H),7.53( s,1H),7.13-7.06(m,1H),6.72(t,J=7.6Hz,1H),6.56-8.50(m,1H),5.82(d,J=3.2Hz,1H),5.65(s,0.5 H),5.44(s,0.5H),4.38(s,1H),4.16-4.11(m,2H),3.85(s,1.5H),3.69(s,1.5H),3.50(s,1H),2.85- 2.65(m,2H),2.61-5.55(s,2H),2.36-2.15(m,2H),2.00-1.95(m,2H),1.83-1.80(m,2H),1.45(s,1H).

[0364] Example 6: Preparation of 3-(2-chloro-3-(6-(6-methoxypyridin-2-yl)-2,6-diazaspiro[3.3]heptane-2-yl)phenyl)piperidine-2,6-dione (compound 3)

[0365] first step:

[0366] Tris(dibenzylacetone)dipalladium (229.77 mg, 0.25 mmol), 4,5-bis(diphenylphosphine-9,9-dimethyloxanthracene) (29.036 mg, 0.50 mmol), tert-butyl 2,6-diazaspiro[3.3]heptane-2-yl}carboxylate (500 mg, 2.51 mmol), 2-bromo-6-methoxypyridine (518.96 mg, 2.76 mmol), and cesium carbonate (2.45 g, 7.52 mmol) were added to a solution of N,N-dimethylformamide (10 mL), and the system was stirred at 100 °C for 16 hours under nitrogen protection. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (PE / EtOAc, 0-50%) to obtain tert-butyl 6-(6-methoxypyridin-2-yl)-2,6-diazaspiro[3.3]heptane-2-carboxylic acid (compound 3-1, 320 mg, yield 41.55%, yellow oil).

[0367] Step Two:

[0368] Compound 3-1 (320 mg, 1.04 mmol) was dissolved in dichloromethane (6 mL), and trifluoroacetic acid (2 mL) was added. The mixture was stirred at room temperature for 3 hours. The dichloromethane and trifluoroacetic acid were removed by concentration under reduced pressure. The residue was diluted with water (3 mL), the pH was adjusted to 10 with saturated sodium carbonate solution, and the mixture was extracted with ethyl acetate (30 mL * 3). The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 2-(6-methoxypyridin-2-yl)-2,6-diazaspiro[3.3]heptane (compound 3-2, 0.15 g, yield 69.74%, yellow solid).

[0369] Step 3:

[0370] Methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (62.15 mg, 0.07 mmol), compound 3-2 (150 mg, 0.73 mmol), INT1 (221.11 mg, 0.73 mmol), and cesium carbonate (285.73 mg, 0.88 mmol) were added to a 5 mL solution of 1,4-dioxane. The mixture was stirred at 100 °C for 16 hours under nitrogen protection. The mixture was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(6-(6-methoxypyridin-2-yl)-2,6-diazaspiro[3.3]heptane-2-yl)phenyl)piperidin-2,6-dione (compound 3, 10.67 mg, yield 3.42%, yellow solid), [M+H + :427.

[0371] 1 HNMR (400MHz, DMSO) δ10.87(s,1H),7.43(t,J=8.0Hz,3H),7.15(t,J=7.6Hz,3H),6.72(d,J=7.2Hz,2H),6.57(d,J=8.4Hz,2H),6.04 (d,J=8.0Hz,2H),5.92(d,J=8.0Hz,2H),4.17(s,5H),4.09(s,4H),3.77(s,3H),2.74-2.67(m,2H),2.26-2.23(m,1H),1.98(s,1H).

[0372] Example 7: Preparation of 3-(2-chloro-3-(6-(2-oxopyridin-1(2H)-yl)-2-azaspiro[3.3]heptane-2-yl)phenyl)piperidin-2,6-dione (compound 4)

[0373] first step:

[0374] Under ice bath conditions, triphenylphosphine (36.8 g, 0.1401 mol) was added in portions to a solution of 10 g (0.0467 mol) of 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (46.5 g, 0.1401 mol) in dichloromethane (200 mL). The mixture was stirred at 25 °C for 6 hours. The mixture was quenched with water, and the organic phase was washed with saturated brine (300 mL). The solution was dried over anhydrous sodium sulfate and concentrated under reduced pressure. Crude 6-bromo-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (compound 4-1, 10 g, yellow oil) was obtained and used directly in the next step.

[0375] Step Two:

[0376] Potassium carbonate (7.48 g, 0.05415 mol) was added to a solution of compound 4-1 (10 g, 0.0361 mol) and pyridin-2(1H)-one (4.12 g, 0.4332 mol) in N,N-dimethylformamide (200 mL). The mixture was stirred at 25 °C for 16 hours. The mixture was quenched with water (200 mL), extracted with ethyl acetate (100 mL x 3), washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EtOAc, 0-40%) to give tert-butyl 6-(2-oxopyridin-1(2H)-yl)-2-azaspiro[3.3]heptane-2-carboxylic acid (compound 4-2, 1.00 g, yield 9.54%, off-white solid).

[0377] Step 3:

[0378] Trifluoroacetic acid (7.75 g, 0.068 mol) was added to a solution of compound 4-2 (1.00 g, 0.004 mol) in dichloromethane (20 mL). The mixture was stirred at 25 °C for 4 hours. The trifluoroacetic acid was removed by concentration under reduced pressure, diluted with dichloromethane (20 mL), and the pH was adjusted to 8 with sodium bicarbonate aqueous solution. Extraction was performed with ethyl acetate (10 mL * 3). Concentration under reduced pressure yielded crude 1-(2-azaspiro[3.3]heptane-6-yl)pyridin-2(1H)-one (compound 4-3, 0.1 g, colorless oil), which was used directly in the next step.

[0379] Step 4:

[0380] Under nitrogen protection, a solution of compound 4-3 (40 mg, 0.2103 mmol), INT1 (70 mg, 0.2313 mmol), and cesium carbonate (206 mg, 0.6309 mmol) in dioxane (10 mL) was mixed with 18 mg of methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (18 mg, 0.02103 mmol). The mixture was stirred at 100 °C for 16 hours under nitrogen protection. The mixture was cooled to room temperature, filtered to remove the solid, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography (HPLC) to obtain 3-(2-chloro-3-(6-(2-oxopyridin-1(2H)-yl)-2-azaspiro[3.3]heptane-2-yl)phenyl)piperidin-2,6-dione (compound 4, 7.8 mg, yield 8.75%, white solid), [M+H). + :412.

[0381] 1 H NMR(400MHz, DMSO-d6)δ10.83(s,1H),8.14(dd,J=5.0,1.3Hz,1H),7.76-7.62(m,1H),7.14(t ,J=7.9Hz,1H),7.07-6.88(m,1H),6.79(d,J=8.3Hz,1H),6.69(dd,J=7.6,1.2Hz,1H),6.53(dd ,J=8.2,1.2Hz,1H),5.10(p,J=7.1Hz,1H),4.17(dd,J=11.8,5.1Hz,1H),4.12-4.02(m,2H),4 .02-3.89(m,2H),2.81-2.60(m,3H),2.49-2.44(m,1H),2.36-2.15(m,3H),2.02-1.88(m,1H).

[0382] Example 8: Preparation of 3-(2-chloro-3-(3-(((1-methyl-1H-pyrazol-3-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 5)

[0383] first step:

[0384] To a solution of 6-bromobenzo[d]thiazol-2(3H)-one (500 mg, 2.17 mmol) and potassium carbonate (600 mg, 4.34 mmol) in N,N-dimethylformamide (5 mL), 3-(chloromethyl)-1-methylpyrazole (312 mg, 2.39 mmol) was added. Under nitrogen protection, the mixture was stirred at 80 °C for 3 hours. The reaction solution was diluted with ethyl acetate (100 mL), filtered, and the organic phase was washed three times with saturated sodium chloride, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EtOAc, 0-50%) to give 6-bromo-3-((1-methyl-1H-pyrazole-3-yl)methyl)benzo[d]thiazol-2(3H)-one (compound 5-1, 230 mg, yield 32.6%, white solid).

[0385] Step Two:

[0386] Compound 5-1 (50 mg, 0.15 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborane-2-yl)-1,3,2-dioxaborane (47 mg, 0.18 mmol) were added to a solution of 1,4-dioxane (5 mL). The mixture was stirred at 25 °C under nitrogen protection, and potassium acetate (30 mg, 0.31 mmol) and Pd(dppf)Cl2 (11 mg, 0.02 mmol) were added. The mixture was stirred at 100 °C for 3 hours. After cooling to room temperature, the mixture was diluted with water (10 mL), extracted with ethyl acetate (10 mL x 3), washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EtOAc, 0-30%) to give 3-((1-methyl-1H-pyrazol-3-yl)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)benzo[d]thiazol-2(3H)-one (compound 5-2, 40 mg, yield 64.27%, white solid).

[0387] Step 3:

[0388] Compound 5-2 (50 mg, 0.13 mmol), INT1 (49 mg, 0.16 mmol), and potassium phosphate (100 mg, 0.48 mmol) were dissolved in dioxane (10 mL). Under nitrogen protection, the mixture was stirred at 25 °C, and Pd(dppf)Cl2 (10 mg, 0.01 mmol) was added. The mixture was then heated to 100 °C and stirred for 15 hours. After cooling to room temperature, the mixture was diluted with water (10 mL), extracted with ethyl acetate (10 mL x 3), washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EtOAc, 0-80%) to give 3-(2-chloro-3-(3-(((1-methyl-1H-pyrazol-3-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 5, 30 mg, yield 45.29%, white solid), [M+H). + :467.

[0389] 1 H NMR (400MHz, DMSO) δ10.94(s,1H),7.73(s,1H),7.63(d,J=1.8Hz,1H),7.36(ddd,J=19.6,13.6,5.2Hz,5H),6.19(d,J=2.0Hz,1H ),5.11(s,2H),4.34(dd,J=12.1,4.9Hz,1H),3.78(s,3H),2.89-2.70(m,1H),2.59-2.53(m,1H),2.32(s,1H),2.16-1.95(m,1H).

[0390] Example 9: Preparation of 3-(2-chloro-3-(1-((1-methyl-1H-pyrazol-3-yl)methyl)-2,2-dioxo-1,3-dihydrobenzo[c]isothiazo-5-yl)phenyl)piperidine-2,6-dione (compound 6)

[0391] first step:

[0392] A solution of bromine (338 mg, 2.11 mmol) in acetic acid (2 mL) was added dropwise to a solution of 1,3-dihydro-2,1-benzisothiazole 2,2-dioxide (340 mg, 2.01 mmol) in acetic acid (8 mL). The mixture was stirred at 25 °C for 3 hours. The solution was concentrated under reduced pressure, and the residue was recrystallized from petroleum ether-ethyl acetate (1:2) to give 5-bromo-1,3-dihydrobenzo[C]isothiazolium 2,2-dioxide (compound 6-1, 300 mg, yield 60.1%, yellow solid).

[0393] Step Two:

[0394] Potassium carbonate (334 mg, 2.42 mmol) was added to a solution of compound 6-1 (300 mg, 1.21 mmol) and 3-(chloromethyl)-1-methyl-1H-pyrazole (166 mg, 1.27 mmol) in N,N-dimethylformamide (5 mL), and the mixture was stirred at 25°C for 4 hours. The reaction mixture was slowly poured into water (10 mL), filtered, the filter cake was washed with water, and dried to give 5-bromo-1-((1-methyl-1H-pyrazole-3-yl)methyl)-1,3-dihydrobenzo[c]isothiazolium 2,2-dioxide (compound 6-2, 80 mg, yield 17.40%, yellow solid).

[0395] Step 3:

[0396] [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (17 mg, 0.023 mmol), compound 6-2 (80 mg, 0.23 mmol), INT3 (98 mg, 0.28 mmol), and potassium phosphate (149 mg, 0.70 mmol) were added to a mixed solution of 1,4-dioxane (5 mL) and water (0.5 mL). The mixture was stirred at 100 °C for 5 hours under nitrogen protection. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (DCM / EtOAc, 0-30%) to give 3-(2-chloro-3-(1-((1-methyl-1H-pyrazol-3-yl)methyl)-2,2-dioxo-1,3-dihydrobenzo[c]isothiazolyl)phenyl)piperidin-2,6-dione (compound 6, 29.42 mg, yield 25.45%, white solid), [M+H] + :484.

[0397] 1 H NMR (400MHz, DMSO) δ10.92(s,1H),7.64(d,J=2.1Hz,1H),7.40-7.30(m,4H),7.27(dd,J=7.2,2.1Hz,1H),6.98(d,J=8.3Hz,1H),6.22(d,J=2.2Hz,1H ),4.75(s,2H),4.69(s,2H),4.33(dd,J=12.2,4.9Hz,1H),3.82(s,3H),2. 87-2.72(m,1H),2.58-2.54(m,1H),2.38-2.28(m,1H),2.07-1.98(m,1H).

[0398] Example 10: Preparation of 3-(2-chloro-3-(1-((1-methyl-1H-pyrazol-3-yl)methyl)-2,2-dioxo-3,4-dihydro-1H-benzo[c][1,2]thiazin-6-yl)phenyl)piperidine-2,6-dione (compound 7)

[0399] first step:

[0400] O-methylhydroxylamine hydrochloride (4.5 g, 54 mmol) was suspended in acetonitrile (40 mL). The mixture was cooled in an ice bath, and an aqueous solution of sodium hydroxide (2.2 g, 54 mmol) was added dropwise over 10 minutes (15 mL). After stirring at 0 °C for 25 minutes, a dry dropping funnel was replaced, and an anhydrous acetonitrile solution of 2-phenylethylsulfonyl chloride (5 g, 24 mmol) (20 mL) was added dropwise over 15 minutes. The mixture was stirred in an ice bath for 20 minutes and then at 25 °C for 22 hours. After evaporating to remove the organic solvent, water (80 mL) was added, and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was dried to give N-methoxy-2-phenylethane-1-sulfonamide (compound 7-1, 5.2 g, yield 85.96%, colorless solid).

[0401] Step Two:

[0402] Iodobenzene (463 mg, 2.27 mmol) and m-chloroperoxybenzoic acid (5.75 g, 24.99 mmol, 75%) were added to a 2,2,2-trifluoroethanol (50 mL) solution of compound 7-1 (4.87 g, 22.62 mmol), and the mixture was stirred at 25 °C for 4 hours. The mixture was then stirred with an aqueous solution of sodium sulfite (25 g, 20 mmol) (50 mL) at 25 °C for 25 minutes. The mixture was then extracted with ethyl acetate (40 mL x 3), and the organic phase was washed with saturated sodium bicarbonate solution (50 mL) and saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM / EtOAc, 0-10%) to give 1-methoxy-3,4-dihydro-1H-benzo[c][1,2]thiazine 2,2-dioxide (compound 7-2, 3.0 g, yield 62.19%, pale yellow solid).

[0403] Step 3:

[0404] N-bromosuccinimide (1.88 g, 10.55 mmol) was added to a solution of compound 7-2 (1.5 g, 7.03 mmol) in N,N-dimethylformamide (15 mL) at room temperature. The mixture was stirred at 25 °C for 3 hours. It was then diluted with ethyl acetate (50 mL), washed with saturated sodium sulfite solution (50 mL) and saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM / EtOAc, 0-10%) to give 6-bromo-1-methoxy-3,4-dihydro-1H-benzo[c][1,2]thiazine 2,2-dioxide (compound 7-3, 1.68 g, yield 81.80%, pale yellow solid).

[0405] Step 4:

[0406] To a solution of compound 7-3 (500 mg, 1.71 mmol) in tetrahydrofuran (10 mL), samarium iodide (25.7 mL, 2.57 mmol, 0.1 M tetrahydrofuran solution) was added, and the mixture was refluxed and stirred for 16 hours under nitrogen protection. The mixture was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (DCM / EtOAc, 0-10%) to give 6-bromo-3,4-dihydro-1H-benzo[c][1,2]thiazine 2,2-dioxide (compound 7-4, 380 mg, yield 84.78%, pale yellow solid).

[0407] Step 5:

[0408] To a solution of compound 7-4 (190 mg, 0.72 mmol) in N,N-dimethylformamide (5 mL), 3-(chloromethyl)-1-methyl-1H-pyrazole (104 mg, 0.80 mmol) and potassium carbonate (199 mg, 1.44 mmol) were added. The mixture was stirred at 25 °C for 16 hours. The mixture was diluted with ethyl acetate (20 mL), the organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM / EtOAc, 0 to -20%) to give 6-bromo-1-((1-methyl-1H-pyrazole-3-yl)methyl)-3,4-dihydro-1H-benzo[c][1,2]thiazine 2,2-dioxide (compound 7-5, 150 mg, yield 58.48%, pale yellow solid).

[0409] Step 6:

[0410] To a solution of compound 7-5 (70 mg, 0.196 mmol) in 1,4-dioxane (4 mL) and water (0.1 mL), INT3 (77 mg, 0.22 mmol), potassium phosphate (126 mg, 0.594 mmol), and 1,1-bis(diphenylphosphine)dimerferropalladium dichloride (14 mg, 0.019 mmol) were added. The mixture was stirred at 100 °C for 16 hours. After cooling to room temperature, the residue was diluted with water (10 mL), extracted with ethyl acetate (10 mL x 3), washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM / EtOAc, 0-40%) to give 3-(2-chloro-3-(1-((1-methyl-1H-pyrazol-3-yl)methyl)-2,2-dioxo-3,4-dihydro-1H-benzo[c][1,2]thiazin-6-yl)phenyl)piperidin-2,6-dione (compound 7, 24 mg, yield 24.54%, pale yellow solid), [M+H) + :499.

[0411] 1 H NMR (400MHz, DMSO) δ10.92(s,1H),7.61(d,J=2.1Hz,1H),7.40-7.32(m,2H),7.30-7.23(m,4H),6.13(d,J=2.1Hz,1H),4.90(s,2H),4.33(dd,J=12.2 ,5.0Hz,1H),3.80(s,3H),3.56(t,J=6.9Hz,2H),3.38(t,J=6.8Hz,2H),2. 84-2.73(m,1H),2.58-2.52(m,1H),2.40-2.25(m,1H),2.08-1.97(m,1H).

[0412] Example 11: Preparation of 3-(2-chloro-3-(3-(((1-methyl-1H-pyrazol-3-yl)methyl)-2-oxo-2,3-dihydrothiazo[4,5-b]pyridin-6-yl)phenyl)piperidin-2,6-dione (compound 8)

[0413] first step:

[0414] 3,5-Dibromopyridin-2-amine (3.0 g, 11.95 mmol) and potassium ethyl xanthate (3.8 g, 23.90 mmol) were added to anhydrous N,N-dimethylformamide (30 mL) solution under nitrogen protection, and the mixture was stirred at 130 °C for 16 hours. After cooling to room temperature, 1 M hydrochloric acid (approximately 20 mL) was slowly added, resulting in the precipitation of a yellow solid. The mixture was stirred at 25 °C for approximately 1 hour, and then filtered to collect the solid, yielding crude 6-bromothiazo[4,5-b]pyridin-2(3H)-thione (compound 8-1, 2.0 g, yield 54.17%, yellow solid).

[0415] Step Two:

[0416] To a 10 mL aqueous solution of compound 8-1 (2.0 g, 8.10 mmol), 2 M potassium hydroxide solution (8 mL, 16.19 mmol) and 30% hydrogen peroxide (1.8 g, 16.19 mmol) were added. The mixture was stirred at 25 °C for 1 hour, followed by the addition of sodium cyanoborohydride (297.9 mg, 4.74 mmol). The reaction mixture was stirred at 25 °C for 16 hours. 1 M hydrochloric acid (approximately 10 mL) was slowly added, resulting in the precipitation of a yellow solid. The mixture was stirred at 25 °C for approximately 1 hour, and then the solid was collected by filtration to give 6-bromothiazo[4,5-b]pyridin-2(3H)-one (compound 8-2, 1.1 g, yield 46.91%, yellow solid).

[0417] Step 3:

[0418] Potassium carbonate (1.08 g, 7.79 mmol) was added to a solution of compound 8-2 (600 mg, 2.60 mmol) and 3-(chloromethyl)-1-methyl-1H-pyrazole (407 mg, 3.12 mmol) in N,N-dimethylformamide (10 mL) at room temperature. Under nitrogen protection, the mixture was stirred at 80 °C for 16 hours, cooled to room temperature, diluted with water (30 mL), extracted with ethyl acetate (30 mL x 3), washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EtOAc, 0-10%) to give 6-bromo-3-((1-methyl-1H-pyrazole-3-yl)methyl)thiazo[4,5-b]pyridin-2(3H)-one (compound 8-3, 170 mg, yield 16.08%, yellow solid).

[0419] Step 4:

[0420] Under nitrogen protection, [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (27 mg, 0.037 mmol), compound 8-3 (120 mg, 0.37 mmol), INT3 (129 mg, 0.37 mmol), and potassium phosphate (235 mg, 1.11 mmol) were added to a mixed solution of 1,4-dioxane (2 mL) and water (0.2 mL). The system was stirred at 80 °C for 16 hours. After cooling to room temperature, the solution was diluted with water (30 mL), extracted with ethyl acetate (30 mL x 3), washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM / EtOAc, 0-100%) to give 3-(2-chloro-3-(3-((1-methyl-1H-pyrazol-3-yl)methyl)-2-oxo-2,3-dihydrothiazo[4,5-b]pyridin-6-yl)phenyl)piperidin-2,6-dione (compound 8, 27.35 mg, yield 14.81%, white solid), [M+H). + =468.

[0421] 1 H NMR (400MHz, DMSO) δ10.95(s,1H),8.34(d,J=2.0Hz,1H),8.26(d,J=2.0Hz,1H),7.60(d,J=2.1Hz,1H),7.47-7.40(m,3H),6.16(d,J=2.2Hz ,1H),5.15(s,2H),4.36(dd,J=12.2,5.0Hz,1H),3.76(s,3H),2.85-2.76(m,1H),2.58-2.56(m,1H),2.37-2.32(m,1H),2.08-2.01(m,1H).

[0422] Example 12: Preparation of 3-(2-chloro-3-(5-(((1-methyl-1H-pyrazol-3-yl)methyl)hexahydropyrrolo[3,4-c]pyrrolo-2(1H)-yl)phenyl)piperidin-2,6-dione (compound 9)

[0423] first step:

[0424] Potassium carbonate (976 mg, 7.06 mmol) and 3-(chloromethyl)-1-methyl-1H-pyrazole (309 mg, 2.36 mmol) were added to a solution of hexahydropyrrolo[3,4-c]pyrrolo-2(1H)-carboxylic acid tert-butyl ester (500 mg, 2.36 mmol) in N,N-dimethylformamide (10 mL). The mixture was stirred at 25 °C for 2 hours. The solution was then extracted with ethyl acetate (30 mL x 3) using 20 mL of water. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EtOAc, 0-50%) to give 5-((1-methyl-1H-pyrazole-3-yl)methyl)hexahydropyrrolo[3,4-c]pyrrolo-2(1H)-carboxylic acid tert-butyl ester (compound 9-1, 400 mg, yield 55.4%, yellow oil).

[0425] Step Two:

[0426] Compound 9-1 (260 mg, 0.85 mmol) was dissolved in 4 M ethyl acetate hydrochloride (5 mL), stirred at 25 °C for 1 hour, concentrated under reduced pressure, and the residue was purified by high performance liquid chromatography to obtain 2-((1-methyl-1H-pyrazol-3-yl)methyl)octahydropyrrolo[3,4-c]pyrrole (compound 9-2, 120 mg, yield 68.6%, white solid).

[0427] Step 3:

[0428] Compound 9-2 (100 mg, 0.48 mmol), INT1 (147 mg, 0.485 mmol), cesium carbonate (317 mg, 0.97 mmol), and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (41 mg, 0.048 mmol) were added to a 1,4-dioxane (5 mL) solution under nitrogen protection, and the system was stirred at 100 °C for 16 hours. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by high-performance liquid chromatography (HPLC) to give 3-(2-chloro-3-(5-(((1-methyl-1H-pyrazol-3-yl)methyl)hexahydropyrrolo[3,4-c]pyrrolo-2(1H)-yl)phenyl)piperidin-2,6-dione (compound 9, 3.8 mg, yield 1.8%, white solid), [M+H). + :427.

[0429] 1H NMR (400MHz, DMSO) δ10.90(s,1H),10.11(d,J=133.8Hz,1H),7.77(s,1H),7.26(t,J=7.8Hz,1H),7.09(d,J=7.6Hz,1H),7.02(d,J=7.3Hz,1H),6.40(s ,1H),4.42-4.20(m,3H),3.86(s,3H),3.80(s,1H),3.50(s,1H),3.28(s,4H ), 3.16-2.74 (m, 6H), 2.28 (dd, J = 22.1, 13.0Hz, 1H), 1.98 (d, J = 5.6Hz, 1H).

[0430] Example 13: Preparation of 3-(2-chloro-3-(3-((1-methoxycyclopropyl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 10)

[0431] first step:

[0432] A solution of 6-bromobenzo[d]thiazol-2(3H)-one (500 mg, 2.18 mmol) and (1-methoxycyclopropyl)methanol (270 mg, 2.62 mmol) in tetrahydrofuran (10 mL) was cooled to 0 °C, and triphenylphosphine (690 mg, 2.62 mmol) and diethyl azodicarbonate (460 mg, 2.62 mmol) were added. The mixture was stirred at room temperature for 3 hours. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to obtain 6-bromo-3-((1-methoxycyclopropyl)methyl)benzo[d]thiazol-2(3H)-one (compound 10⁻¹, 350 mg, yield 51.17%, white solid).

[0433] Step Two:

[0434] Compound 10-1 (50 mg, 0.174 mmol) and INT3 (60 mg, 0.174 mmol) were added to a mixed solution of N,N-dimethylformamide (2 mL) and water (0.5 mL), followed by potassium phosphate (60 mg, 0.348 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (12.3 mg, 0.017 mmol). The mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (30 mL * 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(3-((1-methoxycyclopropyl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidin-2,6-dione (compound 10, 34.5 mg, yield 47.39%, white solid), [M+H + :456.1.

[0435] 1 H NMR (400MHz, DMSO) δ10.93(s,1H),7.73(d,J=1.7Hz,1H),7.50(d,J=8.5Hz,1H),7.41-7.34(m,4H),4.35(d,J=7.2Hz,1 H),4.24(s,2H),3.28(s,3H),2.84-2.75(m,1H),2.59-2.53(m,1H),2.39-2.30(m,1H),2.08-2.02(m,1H),0.82(s,4H).

[0436] Example 14: Preparation of 3-(2-chloro-3-(3-(1-hydroxycyclopropyl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 11)

[0437] first step:

[0438] Imidazole (4.7 g, 68 mmol) was added to a solution of methyl 1-hydroxycyclopropane-1-carboxylate (2 g, 17 mmol) and tert-butyldiphenylchlorosilane (9.3 g, 34 mmol) in N,N-dimethylformamide (20 mL). The system was stirred at room temperature for 3 hours. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give methyl 1-((tert-butyldiphenylsilyl)oxy)cyclopropane-1-carboxylate (compound 11-1, 5 g, yield 83%, white solid).

[0439] Step Two:

[0440] A 10 mL solution of compound 11-1 (900 mg, 2.54 mmol) in toluene was cooled to -78 °C, and diisobutylaluminum hydride (6.3 mL, 6.3 mmol) was added. The mixture was stirred at -78 °C for 2 hours. Methanol (5 mL) was added to the mixture, and the mixture was stirred at room temperature for 15 minutes. The mixture was filtered, the filter cake was washed with dichloromethane, and concentrated under reduced pressure to give crude (1-((tert-butyldiphenylsilyl)oxy)cyclopropyl)methanol (compound 11-2, 800 mg, white solid), which was used directly in the next reaction.

[0441] Step 3:

[0442] A solution of compound 11-2 (280 mg, 0.87 mmol) and 6-bromo-3-((1-methoxycyclopropyl)methyl)benzo[d]thiazol-2(3H)-one (200 mg, 0.87 mmol) in tetrahydrofuran (10 mL) was cooled to 0 °C, and triphenylphosphine (342 mg, 1.3 mmol) and diethyl azodicarbonate (227 mg, 1.3 mmol) were added. The mixture was stirred at room temperature for 3 hours. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 6-bromo-3-((1-((tert-butyldiphenylsilyl)oxy)cyclopropyl)methyl)benzo[d]thiazol-2(3H)-one (compound 11-3, 300 mg, yield 64%, white solid).

[0443] Step 4:

[0444] Compound 11-3 (77 mg, 0.14 mmol) and INT3 (50 mg, 0.14 mmol) were added to a mixed solution of N,N-dimethylformamide (2 mL) and water (0.5 mL), followed by potassium phosphate (60 mg, 0.28 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (12 mg, 0.014 mmol). The mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (30 mL * 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to obtain 3-(3-((1-((tert-butyldiphenylsilyl)oxy)cyclopropyl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazo-6-yl)-2-chlorophenyl)piperidin-2,6-dione (compound 11-4, 80 mg, yield 82%, white solid).

[0445] Step 5:

[0446] To a solution of compound 11-4 (50 mg, 0.07 mmol) in tetrahydrofuran (5 mL), tetrabutylammonium fluoride (0.11 mL, 0.11 mmol) was added, and the mixture was stirred for 2 hours under nitrogen protection at room temperature. Extraction was performed with ethyl acetate (30 mL x 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(3-(1-hydroxycyclopropyl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidin-2,6-dione (compound 11, 9.8 mg, yield 32%, white solid), [M+H]. + :443.0.

[0447] 1 H NMR (400MHz, DMSO) δ10.92(s,1H),7.70(d,J=1.7Hz,1H),7.59(d,J=8.5Hz,1H),7.45-7.30(m,4H),4.35(dd,J=12.1,4.9Hz,1H),4.08( s,2H),2.87-2.72(m,1H),2.59-2.53(m,1H),2.41-2.25(m,1H),2.12-1.98(m,1H),0.76(dd,J=6.7,4.9Hz,2H),0.65(t,J=5.8Hz,2H).

[0448] Example 15: Preparation of 3-(2-chloro-3-(2-oxo-3-((tetrahydro-2H-pyran-4-yl)methyl)-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidine-2,6-dione (compound 12)

[0449] first step:

[0450] Potassium carbonate (540 mg, 3.93 mmol) and potassium iodide (21.6 mg, 0.13 mmol) were added to a 10 mL acetonitrile solution of 6-bromobenzo[d]thiazol-2(3H)-one (300 mg, 1.31 mmol) and 4-(bromomethyl)tetrahydro-2H-pyran (281 mg, 1.57 mmol). The mixture was stirred at 80 °C for 2 hours. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 6-bromo-3-((tetrahydro-2H-pyran-4-yl)methyl)benzo[d]thiazol-2(3H)-one (compound 12-1, 330 mg, yield 76.8%, white solid).

[0451] Step Two:

[0452] Compound 12-1 (65 mg, 0.198 mmol) and INT3 (60 mg, 0.174 mmol) were added to a mixed solution of N,N-dimethylformamide (2 mL) and water (0.5 mL), followed by potassium phosphate (60 mg, 0.348 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (12.3 mg, 0.017 mmol). The mixture was stirred at 80 °C for 3 hours under nitrogen protection. Extracted with ethyl acetate (30 mL x 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(2-oxo-3-((tetrahydro-2H-pyran-4-yl)methyl)-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 12, 6.1 mg, yield 7.44%, white solid), [M+H] + :471.1.

[0453] 1 H NMR (400MHz, DMSO) δ10.94(s,1H),7.74(d,J=1.7Hz,1H),7.52(d,J=8.4Hz, 1H),7.44-7.33(m,4H),4.35(dd,J=12.1,5.0Hz,1H),3.89(d,J=7.4Hz,2H), 3.84(d,J=8.0Hz,2H),3.24(t,J=11.0Hz,2H),2.84-2.75(m,2H),2.57(s,1 H), 2.10-1.97 (m, 2H), 1.54 (d, J = 12.2Hz, 2H), 1.33 (dt, J = 12.0, 7.9Hz, 2H).

[0454] Example 16: Preparation of 3-(2-chloro-3-(3-methyl-2-oxo-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidine-2,6-dione (compound 13)

[0455] first step:

[0456] Potassium carbonate (897.84 mg, 6.525 mmol) was added to a solution of 6-bromobenzo[d]thiazol-2(3H)-one (300 mg, 1.3050 mmol) and methyl iodide (370 mg, 2.61 mmol) in dimethyl sulfoxide (20 mL), and the mixture was stirred at 30 °C for 12 hours. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 6-bromo-3-methylbenzo[d]thiazol-2(3H)-one (compound 13-1, 70 mg, yield 23.33%, white solid).

[0457] Step Two:

[0458] Compound 13-1 (50 mg, 0.2048 mmol) and INT3 (85.92 mg, 0.246 mmol) were added to a mixed solution of N,N-dimethylformamide (10 mL) and water (2.5 mL), followed by potassium phosphate (86.94 mg, 0.4096 mmol) and [dicyclohexyl[2',4',6'-tris(isopropyl)[1,1'-biphenyl]-2-yl]phosphine](methanesulfonic acid)[2'-(methylamino)[1,1'-biphenyl]-2-yl]palladium (17.62 mg, 0.02078 mmol). The mixture was stirred at 80 °C for 3 hours under nitrogen protection. The residue was concentrated under reduced pressure, and then purified by silica gel column chromatography (DCM / MeOH, 0–20%) to give 3-(2-chloro-3-(3-methyl-2-oxo-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 13, 2.3 mg, yield 2.44%, white solid), [M+H). + :387.0.

[0459] 1 H NMR(400MHz,MeOD)δ7.59(d,J=1.6Hz,1H),7.44-7.30(m,5H),4.39(dd,J=12.0,5.2Hz,1H),3.5 1(s,3H),2.74(ddd,J=21.2,14.6,9.2Hz,2H),2.42(qd,J=12.4,4.6Hz,1H),2.24-2.16(m,1H).

[0460] Example 17: Preparation of 3-(2-chloro-3-(2-oxo-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidine-2,6-dione (compound 14)

[0461] INT3 (80 mg, 0.2288 mmol) and 6-bromobenzo[d]thiazol-2(3H)-one (57.91 mg, 0.251 mmol) were added to a solution of N,N-dimethylformamide (8 mL) and water (2 mL), followed by potassium phosphate (72.85 mg, 0.3432 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (19.69 mg, 0.023 mmol). The system was stirred at 80 °C for 8 hours. The residue was concentrated under reduced pressure, and then purified by silica gel column chromatography (DCM / MeOH, 0–20%) to give 3-(2-chloro-3-(2-oxo-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 14, 13.3 mg, yield 15.60%, white solid), [M+H). + 372.9.

[0462] 1 H NMR (400MHz, DMSO) δ12.00(s,1H),10.92(s,1H),7.63(d,J=1.4Hz,1H),7.43-7.27(m,4H),7.19(d,J=8.2Hz,1H) ,4.34(dd,J=12.1,4.9Hz,1H),2.86-2.73(m,1H),2.56(s,1H),2.33(dd,J=12.5,4.1Hz,1H),2.11-1.96(m,1H).

[0463] Example 18: Preparation of 2-{6-[2-chloro-3-(2,6-dicarbonylpiperidin-3-yl)phenyl]-2-carbonyl-1,3-benzothiazolyl-3-yl}-N,N-dimethylacetamide (compound 15)

[0464] first step:

[0465] Potassium carbonate (901 mg, 6.52 mmol) and potassium iodide (36 mg, 0.22 mmol) were added to a 10 mL acetonitrile solution of 6-bromobenzo[d]thiazolyl-2(3H)-one (500 mg, 2.17 mmol) and 2-bromo-N,N-dimethylacetamide (469 mg, 2.83 mmol). The mixture was stirred at 80 °C for 12 h. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 2-(6-bromo-2-oxo-1,3-benzothiazolyl-3-yl)-N,N-dimethylacetamide (compound 15-1, 400 mg, yield 52.56%, white solid).

[0466] Step Two:

[0467] Compound 15-1 (65 mg, 0.21 mmol) and INT3 (60 mg, 0.17 mmol) were added to a mixed solution of N,N-dimethylformamide (2 mL) and water (0.5 mL), followed by potassium phosphate (72.85 mg, 0.34 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (14.77 mg, 0.017 mmol). The mixture was stirred at 80 °C for 3 hours under nitrogen protection. Extracted with ethyl acetate (10 mL * 3), the organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 2-{6-[2-chloro-3-(2,6-dicarbonylpiperidin-3-yl)phenyl]-2-carbonyl-1,3-benzothiazol-3-yl}-N,N-dimethylacetamide (compound 15, 24.6 mg, yield 33.28%, white solid), [M + H]. + :458.1.

[0468] 1 H NMR (400MHz, DMSO) δ10.94(s,1H),7.74(d,J=1.7Hz,1H),7.43-7.29(m,5H),4.93(s,2H),4.35(dd,J=12.2,5.0 Hz,1H),3.13(s,3H),2.87(s,3H),2.85-2.75(m,1H),2.59-2.52(m,1H),2.38-2.30(m,1H),2.08-2.01(m,1H).

[0469] Example 19: Preparation of 3-(2-chloro-3-(3-(2-methoxyethyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 16)

[0470] first step:

[0471] Potassium carbonate (540 mg, 3.93 mmol) and potassium iodide (21.6 mg, 0.13 mmol) were added to a solution of 6-bromobenzo[d]thiazol-2(3H)-one (300 mg, 1.31 mmol) and 1-bromo-2-methoxyethane (220 mg, 1.57 mmol) in acetonitrile (10 mL). The mixture was stirred at 80 °C for 2 hours. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 6-bromo-3-(2-methoxyethyl)benzo[d]thiazol-2(3H)-one (compound 16-1, 280 mg, yield 74.47%, white solid).

[0472] Step Two:

[0473] Compound 16-1 (50 mg, 0.174 mmol) and INT3 (60 mg, 0.174 mmol) were added to a mixed solution of N,N-dimethylformamide (2 mL) and water (0.5 mL), followed by potassium phosphate (60 mg, 0.348 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (12.3 mg, 0.017 mmol). The mixture was stirred at 80 °C for 8 hours under nitrogen protection. Extracted with ethyl acetate (30 mL * 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(3-(2-methoxyethyl)-2-oxo-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 16, 2.9 mg, yield 3.87%, white solid), [M+H). + :430.1.

[0474] 1 H NMR (400MHz, DMSO) δ10.93(s,1H),7.72(d,J=1.7Hz,1H),7.47(d,J=8.4Hz,6H),7.41-7.34(m,4H),4.35(dd,J=12.1,5.0Hz,1H),4.17 (t,J=5.3Hz,2H),3.65(t,J=5.3Hz,2H),3.25(s,3H),2.84-2.75(m,1H),2.56(d,J=3.9Hz,1H),2.36-2.31(m,1H),2.09-2.02(m,1H).

[0475] Example 20: Preparation of 3-(3-(2-(azacyclobutane-1-yl)-2-oxoethyl)-2-oxo-2,3-dihydrobenzo[d]thiazo-6-yl)-2-chlorophenyl)piperidine-2,6-dione (compound 17)

[0476] first step:

[0477] Potassium carbonate (639.91 mg, 4.56 mmol) and potassium iodide (25.25 mg, 0.15 mmol) were added to a 10 mL solution of 6-bromobenzo[d]thiazolyl-2(3H)-one (350 mg, 1.52 mmol) and 1-(acetidin-1-yl)-2-chloroethane-1-one (264.15 mg, 1.98 mmol). The mixture was stirred at 80 °C for 1 hour. After the reaction was completed as monitored by LCMS, the solution was concentrated under reduced pressure, diluted with ethyl acetate, washed successively with water and saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (PE / EtOAc, 61%) to obtain 3-(2-(azacyclobutan-1-yl)-2-oxoethyl)-6-bromobenzo[d]thiazol-2(3H)-one (compound 17-1, 360 mg, yield 70.88%, white solid).

[0478] Step Two:

[0479] Compound 17-1 (70 mg, 0.21 mmol), INT3 (89.74 mg, 0.25 mmol), potassium phosphate (90.81 mg, 0.42 mmol), and (SP-4-3)-[dicyclohexyl[2',4',6'-tris(isopropyl)[1,1'-biphenyl]-2-yl]phosphine](methanesulfonic acid)[2'-(methylamino)[1,1'-biphenyl]-2-yl]palladium (18.41 mg, 0.02 mmol) were dissolved in a solution of N,N-dimethylformamide and water (DMF / H2O = 4 / 1, 10 mL). The reaction mixture was stirred at 50 °C for 2 hours under nitrogen protection. The reaction solution was cooled to room temperature and the solvent was removed by rotary evaporation. The crude product was purified by high-performance liquid chromatography (HPLC) to obtain 3-(3-(2-(azacyclobutan-1-yl)-2-oxoethyl)-2-oxo-2,3-dihydrobenzo[d]thiazo-6-yl)-2-chlorophenyl)piperidin-2,6-dione (compound 17, 10 mg, yield 10.66%, white solid), [M+H). + :470.0.

[0480] 1H NMR (400MHz, DMSO) δ10.93 (s, 1H), 7.74 (d, J = 1.7Hz, 1H), 7.38 (m, 3H), 7.33 (m, 2H), 4.68 (s, 2H), 4.34 (m, 3H), 3.94 (d, J = 7.7Hz, 2H), 2.79 (m, 1H), 2.56 (d, J = 3.8Hz, 1H), 2.30 (td, J = 15.1, 8.2Hz, 3H), 2.04 (m, 1H).

[0481] Example 21: Preparation of 3-(2-chloro-3-(2-oxo-3-(2-one-2-(pyrrolidone-1-yl)ethyl)-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 18)

[0482] first step:

[0483] A solution of 6-bromobenzo[d]thiazol-2(3H)-one (300 mg, 1.30 mmol) and 2-chloro-1-(pyrrolidone-1-yl)ethane-1-one (230.95 mg, 1.56 mmol) in acetonitrile (10 mL) was mixed with potassium carbonate (539.81 mg, 3.91 mmol) and potassium iodide (21.64 mg, 0.13 mmol). The mixture was stirred at 80 °C for 12 hours. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 6-bromo-3-(2-carbonyl-2-(pyrrolidone-1-yl)ethyl)benzo[d]thiazol-2(3H)-one (compound 18-1, 350 mg, yield 75.52%, white solid).

[0484] Step Two:

[0485] In a mixed solution of N,N-dimethylformamide (4 mL) and water (1 mL) of compounds 18-1 (70 mg, 0.20 mmol) and INT3 (86.05 mg, 0.24 mmol), potassium phosphate (86.96 mg, 0.41 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (17.64 mg, 0.020 mmol) were added, and the mixture was stirred at 80 °C for 3 hours under nitrogen protection. Extracted with ethyl acetate (10 mL * 3), the organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(2-carbonyl-3-(2-carbonyl-2-(pyrrolidine-1-yl)ethyl)-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidin-2,6-dione (compound 19, 24.84 mg, yield 22.04%, white solid), [M+H] + :484.0.

[0486] 1 H NMR (400MHz, DMSO) δ10.93 (s, 1H), 7.74 (d, J = 1.6Hz, 1H), 7.42-7.30 (m, 5H), 4.84(s,2H),4.35(dd,J=12.2,5.0Hz,1H),3.62(t,J=6.8Hz,2H),3.33(t,J= 6.8Hz,2H),2.85-2.71(m,1H),2.56(d,J=3.6Hz,1H),2.34(d,J=12.8,4.1Hz ,1H),2.09-.201(m,1H),1.95(t,J=13.4,6.7Hz,2H),1.81(t,J=6.7Hz,2H).

[0487] Example 22: Preparation of 3-(2-chloro-3-(2-oxo-3-(2-(2-oxopyrrolidone-1-yl)ethyl)-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 19)

[0488] first step:

[0489] Potassium carbonate (901 mg, 6.5192 mmol) and potassium iodide (72.15 mg, 0.4346 mmol) were added to a 10 mL acetonitrile solution of 6-bromobenzo[d]thiazol-2(3H)-one (500 mg, 2.1731 mmol) and 1-(2-chloroethyl)pyrrolidone-2-one (481 mg, 3.2596 mmol). The mixture was stirred at 80 °C for 2 hours. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (DCM / MeOH, 0–20%) to give 6-bromo-3-(2-(2-oxopyrrolidone-1-yl)ethyl)benzo[d]thiazol-2(3H)-one (compound 19-1, 700 mg, yield 56.64%, white solid).

[0490] Step Two:

[0491] To a solution of compound 19-1 (300 mg, 0.88 mmol) and pinacol diboron ester (670 mg, 2.63 mmol) in 1,4-dioxane (10 mL), potassium acetate (259 mg, 2.64 mmol) and [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride dichloromethane complex (63 mg, 0.088 mmol) were added. The mixture was stirred at 90 °C for 10 hours under nitrogen protection. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (DCM / MeOH, 0–20%) to give 3-(2-(2-oxopyrrolidone-1-yl)ethyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborane-2-yl)benzo[d]thiazol-2(3H)-one (compound 19-2, 307 mg, yield 68.44%, white solid).

[0492] Step 3:

[0493] The mixture of N,N-dimethylformamide (10 mL) and water (2.5 mL) containing compounds 19-2 (120 mg, 0.309 mmol) and INT1 (112 mg, 0.3708 mmol) was mixed with potassium phosphate (131.54 mg, 0.618 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (26.59 mg, 0.0309 mmol). The mixture was stirred at 50 °C for 1 hour under nitrogen protection. The residue was concentrated under reduced pressure, and purified by silica gel column chromatography (DCM / MeOH, 0–20%) to give 3-(2-chloro-3-(2-oxo-3-(2-(2-oxopyrrolidone-1-yl)ethyl)-2,3-dihydrobenzo[d]thiazolyl)phenyl)piperidin-2,6-dione (compound 19, 54.15 mg, yield 45.13%, white solid), [M+H).+ :389.1.

[0494] 1 H NMR (400MHz, DMSO) δ10.92(s,1H),7.72(d,J=1.7Hz,1H),7.50-7.32(m,5H),4.35(dd,J=12.1,5.0Hz,1H),4.13(t,J=5.7Hz,2H),3.52(t,J= 5.6Hz,2H),3.41(t,J=6.9Hz,2H),2.94-2.72(m,1H),2.66-2.54(m,1H),2.37(dd,J=12.8,4.0Hz,1H),2.19-2.01(m,3H),1.96-1.79(m,2H).

[0495] Example 23: Preparation of 3-(2-chloro-3-(3-(((S)-3-methyl-2-oxooxazolidine-5-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 20)

[0496] first step:

[0497] Potassium carbonate (540 mg, 3.91 mmol) was added to a solution of 6-bromobenzo[d]thiazol-2(3H)-one (300 mg, 1.3 mmol) and (S)-5-(chloromethyl)oxazolidine-2-one (195 mg, 1.43 mmol) in N,N-dimethylformamide (15 mL). The system was stirred at 80 °C for 48 hours. The reaction solution was diluted with water (50 mL) and extracted with ethyl acetate (50 mL x 3). The organic phases were combined and washed with saturated brine (100 mL). The organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The residue was separated and purified by silica gel column chromatography (PE / EtOAc, 0-100%) to obtain (S)-5-((6-bromo-2-oxobenzo[d]thiazolyl-3(2H)-yl)methyl)oxazolidin-2-one (compound 20-1, 200 mg, yield 46.60%, yellow solid).

[0498] Step Two:

[0499] Iodimethane (862 mg, 6.07 mmol) was added to a solution of compound 20-1 (200 mg, 0.61 mmol) and potassium carbonate (839 mg, 6.07 mmol) in N,N-dimethylformamide (10 mL) under ice bath conditions. The mixture was stirred at room temperature for 72 hours. The reaction solution was diluted with water (50 mL) and extracted with ethyl acetate (50 mL x 3). The organic phases were combined and washed with saturated brine (100 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The residue was purified by silica gel column chromatography (PE / EtOAc, 0–100%) to give (S)-5-((6-bromo-2-oxobenzo[d]thiazolyl-3(2H)-yl)methyl)-3-methyloxazolidin-2-one (compound 20-2, 30 mg, yield 14.38%, yellow solid).

[0500] Step 3:

[0501] Under nitrogen protection, potassium phosphate (37 mg, 0.17 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (7.5 mg, 0.0087 mmol) were added to an N,N-dimethylformamide / water (4 mL / 1 mL) solution of compound 20-2 (30.0 mg, 0.087 mmol) and INT3 (30.5 mg, 0.087 mmol). The system was stirred at 50 °C for 1 hour. Dilute with water (50 mL), extract with ethyl acetate (50 mL * 3), concentrate the organic phase under reduced pressure, and purify the residue by high-performance liquid chromatography to obtain 3-(2-chloro-3-(3-(((S)-3-methyl-2-oxooxazolidine-5-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidin-2,6-dione (compound 20, 11.7 mg, yield 27.57%, white solid), [M+H] + :486.0.

[0502] 1 H NMR (400MHz, DMSO) δ10.94(s,1H),7.75(s,1H),7.56-7.54(m,1H),7.43-7.33(m,4H),4.87-4.83(m,1H),4.37-4.32(m,2H),4.23- 4.18(m,1H),3.72(t,J=8.8Hz,1H),3.40-3.36(m,1H),2.83-2.76(m,4H),2.56-2.52(m,1H),2.35-2.32(m,1H),2.06-2.02(m,1H).

[0503] Example 24: Preparation of 3-(2-chloro-3-(3-(((R)-3-methyl-2-oxooxazolidine-5-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 21)

[0504] first step:

[0505] Cesium carbonate (1.42 g, 4.35 mmol) and potassium iodide (541 mg, 3.26 mmol) were added to a solution of 6-bromobenzo[d]thiazol-2(3H)-one (500 mg, 2.17 mmol) and (R)-5-(chloromethyl)oxazolidine-2-one (442 mg, 3.26 mmol) in N,N-dimethylformamide (20 mL). The mixture was stirred at 80 °C for 48 hours. The solution was concentrated under reduced pressure, and the residue was diluted with water (50 mL) and extracted with ethyl acetate (50 mL x 3). The organic phases were combined and washed with saturated brine (50 mL). The organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The residue was purified by silica gel column chromatography (PE / EtOAc, 0–70%) to give (R)-5-((6-bromo-2-oxobenzo[d]thiazolyl-3(2H)-yl)methyl)oxazolidin-2-one (compound 21-1, 380 mg, yield 53.1%, yellow solid).

[0506] Step Two:

[0507] Iodimethane (492 mg, 3.46 mmol) was added to a solution of compound 21-1 (380 mg, 1.15 mmol) and potassium carbonate (479 mg, 3.46 mmol) in N,N-dimethylformamide (10 mL) under ice bath conditions. The mixture was stirred at room temperature for 72 hours. The mixture was concentrated under reduced pressure, and the residue was diluted with water (50 mL) and extracted with ethyl acetate (50 mL x 3). The organic phases were combined and washed with saturated brine (30 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. The residue was purified by silica gel column chromatography (PE / EtOAc, 0–70%) to give (R)-5-((6-bromo-2-oxobenzo[d]thiazolyl-3(2H)-yl)methyl)-3-methyloxazolidin-2-one (compound 21-2, 110 mg, yield 27.8%, yellow solid).

[0508] Step 3:

[0509] To a solution of compound 21-2 (60 mg, 0.17 mmol) and INT3 (58.9 mg, 0.17 mmol) in N,N-dimethylformamide / water (4 mL / 1 mL), potassium phosphate (72.9 mg, 0.34 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (14.8 mg, 0.017 mmol) were added. Under nitrogen protection, the mixture was stirred at 50 °C for 1 hour. The mixture was concentrated under reduced pressure, and the residue was diluted with water (20 mL) and extracted with ethyl acetate (30 mL x 3). The organic phases were combined and washed with saturated brine (30 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The residue was purified by high-performance liquid chromatography to yield 3-(2-chloro-3-(3-(((R)-3-methyl-2-oxooxazolidine-5-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidin-2,6-dione (compound 21, 25.5 mg, yield 30.0%, white solid), [M+H). + :486.0.

[0510] 1 H NMR (400MHz, DMSO-d6) δ10.94(s,1H),7.75(d,J=1.6Hz,1H),7.57-7.54(m,1H),7.41-7.34(m,4H),4.89-4.83(m,1H),4.38-4.32(m,2H),4.23- 4.19(m,1H),3.72(t,J=8.8Hz,1H),3.40-3.36(m,1H),2.84-2.79(m,1H ),2.76(s,3H),2.57-2.54(m,1H),2.36-2.32(m,1H),2.07-2.03(m,1H).

[0511] Example 25: Preparation of 3-(2-chloro-3-(3-((1-methylazacyclobutane-3-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidine-2,6-dione (compound 22)

[0512] first step:

[0513] To a solution of 6-bromobenzo[d]thiazolyl-2(3H)-one (200 mg, 0.87 mmol), tert-butyl 3-(bromomethyl)azacyclobutane-1-carboxylate (261.98 mg, 1.04 mmol) in acetonitrile (10 mL), potassium carbonate (359.89 mg, 2.61 mmol) and potassium iodide (28.86 mg, 0.17 mmol) were added. The mixture was stirred at 80 °C for 16 hours. The reaction mixture was filtered, the filtrate was collected and concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to obtain tert-butyl 3-((6-bromo-2-oxobenzo[d]thiazolyl-3(2H)-yl)methyl)azacyclobutane-1-carboxylate (compound 22-1, 300 mg, yield 77.59%, yellow solid).

[0514] Step Two:

[0515] Under ice bath conditions, trifluoroacetic acid (5 mL) was added to a solution of compound 22-1 (300 mg, 0.75 mmol) in dichloromethane (10 mL), and the mixture was stirred under ice bath conditions for 3 hours. Dichloromethane and trifluoroacetic acid were removed by concentration under reduced pressure to obtain crude 3-(azacyclobutane-3-ylmethyl)-6-bromobenzo[d]thiazol-2(3H)-one (compound 22-2, 250 mg, yellow oil), which was used directly in the next reaction.

[0516] Step 3:

[0517] Paraformaldehyde (26.81 mg, 1.67 mmol) was added to a methanol (10 mL) solution of compound 22-2 (250 mg, 0.84 mmol), and the mixture was stirred at room temperature for 1 hour. Sodium cyanoborohydride (157.53 mg, 2.51 mmol) was then added. The mixture was stirred at room temperature for 16 hours. The reaction was quenched with an aqueous solution of ammonium chloride (30 mL), extracted with ethyl acetate (30 mL x 3), concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 6-bromo-3-((1-methylazacyclobutane-3-yl)methyl)benzo[d]thiazol-2(3H)-one (compound 22-3, 130 mg, yield 44.70%, yellow solid).

[0518] Step 4:

[0519] Under nitrogen protection, potassium phosphate (24.28 mg, 0.11 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (7.38 mg, 0.008 mmol) were added to a solution of compound 22-3 (21.5 mg, 0.07 mmol) and INT3 (20 mg, 0.06 mmol) in N,N-dimethylformamide / water (5 mL / 1 mL) under nitrogen protection and stirred at 75 °C for 3 hours. Extracted with water (30 mL) and ethyl acetate (30 mL x 3), the organic phase was concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(3-((1-methylazacyclobutane-3-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 22, 5.07 mg, yield 19.23%, white solid), [M+H]. + :456.0.

[0520] 1 H NMR (400MHz, DMSO) δ10.93(s,1H),8.22(s,0.5H),7.73(d,J=1.7Hz,1H),7.46(d,J=8 .4Hz,1H),7.42-7.37(m,3H),7.34(dd,J=7.0,2.2Hz,1H),4.35(dd,J=12.2,5.0Hz,1 H),4.19(d,J=7.2Hz,2H),3.27(t,J=7.3Hz,3H),3.02(t,J=6.5Hz,2H),2.80(ddd,J= 17.4, 12.5, 5.3Hz, 2H), 2.34 (dd, J=12.3, 3.9Hz, 1H), 2.22 (s, 3H), 2.09-2.00 (m, 1H).

[0521] Example 26: Preparation of 3-(2-chloro-3-(3-(1-methylpiperidin-4-yl)-2-oxo-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 23)

[0522] first step:

[0523] Potassium carbonate (901 mg, 6.52 mmol) and potassium iodide (361 mg, 2.17 mmol) were added to a solution of 6-bromobenzo[d]thiazolyl-2(3H)-one (500 mg, 2.17 mmol) and 4-((methanesulfonyl)oxy)piperidine-1-carboxylic acid tert-butyl ester (1.82 g, 6.52 mmol) in N-methylpyrrolidone (10 mL). The mixture was stirred for 16 hours under nitrogen protection at 100 °C. Dilute with water (50 mL), extract with ethyl acetate (50 mL * 3), combine the organic phases, dry with anhydrous sodium sulfate, concentrate under reduced pressure, and purify the residue by silica gel column chromatography (PE / EtOAc, 0–20%) to obtain tert-butyl 4-(6-bromo-2-oxobenzo[d]thiazolyl-3(2H)-yl)piperidine-1-carboxylate (compound 23-1, 260 mg, yield 28.95%, pale yellow solid).

[0524] Step Two:

[0525] Trifluoroacetic acid (2 mL) was added to a solution of compound 23-1 (260 mg, 0.629 mmol) in dichloromethane (10 mL), and the mixture was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure, and the residue was diluted with water (50 mL). The pH was adjusted to 8.0 with saturated sodium bicarbonate solution, and the mixture was extracted with dichloromethane (50 mL * 3). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (DCM / MeOH, 0–10%) to give 6-bromo-3-(piperidin-4-yl)benzo[d]thiazolyl-2(3H)-one (compound 23-2, 150 mg, yield 76.13%, off-white solid).

[0526] Step 3:

[0527] Acetic acid (21 mg, 0.351 mmol) was added to a solution of compound 23-2 (150 mg, 0.351 mmol) and paraformaldehyde (53 mg, 1.76 mmol) in 1,2-dichloroethane (10 mL). The mixture was stirred at room temperature for 1 hour under nitrogen protection. The reaction mixture was cooled to 0 °C, and sodium triacetoxyborohydride (223 mg, 1.05 mmol) was added to the reaction mixture. The mixture was stirred at room temperature for another hour under nitrogen protection. The reaction was quenched with water (50 mL), extracted with ethyl acetate (50 mL x 3), and the organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–70%) to give 6-bromo-3-(1-methylpiperidin-4-yl)benzo[d]thiazol-2(3H)-one (compound 23-3, 40 mg, yield 34.82%, white solid).

[0528] Step 4:

[0529] To a solution of compounds 23-3 (10 mg, 30.56 μmol) and INT3 (10.7 mg, 30.56 μmol) in N,N-dimethylformamide / water (5 mL / 1 mL), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (2.63 mg, 3.1 μmol) and tripotassium phosphate (19.5 mg, 91.7 μmol) was added, and the mixture was stirred for 30 minutes at 80 °C under nitrogen protection. Dilute with water (50 mL), extract with ethyl acetate (50 mL * 3), combine the organic phases, dry to anhydrous sodium sulfate, concentrate under reduced pressure, and purify the residue by preparative high-performance liquid chromatography to obtain 3-(2-chloro-3-(3-(1-methylpiperidin-4-yl)-2-oxo-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 23, 2 mg, yield 13.93%, white solid), [M+H + :469.9.

[0530] 1 H NMR (400MHz, DMSO-d6) δ10.94(s,1H),8.24(s,1H),7.93(d,J=1.2Hz,1H),7.72(d,J=8.4Hz,1H),7.43-7.39(m,4H),5.19-5.13 (m,1H),4.35(dd,J=12.2,5.0Hz,1H),2.84-2.59(m,4H),2.41-2.22(m,4H),2.20(s,3H),2.11-2.05(m,2H),1.88-1.80(m,2H).

[0531] Example 27: Preparation of 3-(2-chloro-3-(2-oxo-3-(pyridin-2-yl)-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidine-2,6-dione (compound 24)

[0532] first step:

[0533] Potassium carbonate (1.26 g, 9.13 mmol) was added to a solution of 6-bromobenzo[d]thiazol-2(3H)-one (700 mg, 3.04 mmol) and 2-fluoro-5-nitropyridine (519 mg, 3.65 mmol) in N,N-dimethylformamide (10 mL). The mixture was stirred at 60 °C for 16 hours under nitrogen protection. The solution was diluted with water (50 mL), extracted with ethyl acetate (50 mL x 3), and the organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–20%) to give 6-bromo-3-(5-nitropyridine-2-yl)benzo[d]thiazol-2(3H)-one (compound 24-1, 1 g, yield 93.33%, brown solid).

[0534] Step Two:

[0535] Iron powder (127 mg, 2.27 mmol) and ammonium chloride (122 mg, 2.27 mmol) were added to an ethanol / water (10 mL / 2.5 mL) solution of compound 24-1 (200 mg, 0.568 mmol), and the mixture was stirred at 70 °C for 16 hours. The mixture was diluted with water (50 mL), extracted with ethyl acetate (50 mL * 3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–20%) to give 3-(5-aminopyridin-2-yl)-6-bromobenzo[d]thiazol-2(3H)-one (compound 24-2, 1 g, yield 73.78%, brown solid).

[0536] Step 3:

[0537] To a 10 mL ethanol solution of compound 24-2 (135 mg, 0.419 mmol), tert-butyl nitrite (216 mg, 2.10 mmol) was added, and the mixture was refluxed and stirred for 2 hours. The solution was diluted with water (50 mL), extracted with ethyl acetate (50 mL x 3), and the organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–30%) to give 6-bromo-3-(pyridin-2-yl)benzo[d]thiazolyl-2(3H)-one (compound 24-3, 60 mg, yield 46.62%, white solid).

[0538] Step 4:

[0539] To a solution of compounds 24-3 (60 mg, 0.195 mmol) and INT3 (68 mg, 0.195 mmol) in N,N-dimethylformamide / water (5 mL / 1 mL), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (17 mg, 0.020 mmol) and potassium phosphate (124 mg, 0.586 mmol) was added, and the mixture was stirred for 30 minutes at 80 °C under nitrogen protection. Dilute with water (50 mL), extract with ethyl acetate (50 mL * 3), combine the organic phases, dry to anhydrous sodium sulfate, concentrate under reduced pressure, and purify the residue by preparative high-performance liquid chromatography to obtain 3-(2-chloro-3-(2-oxo-3-(pyridin-2-yl)-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 24, 26.9 mg, yield 30.61%, white solid), [M+H + :450.0.

[0540] 1 H NMR (400MHz, DMSO-d6) δ10.92(s,1H),8.73(dd,J=4.8,1.2Hz,1H),8.15(td,J=7. 6,2.30Hz,1H),7.83(d,J=2.0Hz,1H),7.76(d,J=8.0Hz,1H),7.62(ddd,J=7.6,4. 8,0.8Hz,1H),7.42-7.32(m,4H),7.11(d,J=8.4Hz,1H),4.35(dd,J=12.0,4.8Hz, 1H),2.84-2.75(m,1H),2.69-2.56(m,1H),2.40-2.29(m,1H),2.08-2.01(m,1H).

[0541] Example 28: Preparation of 3-(2-chloro-3-(2-oxo-3-(2-(2-oxopyridin-1(2H)-yl)ethyl)-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidin-2,6-dione (compound 25)

[0542] first step:

[0543] To a solution of 6-bromobenzo[d]thiazol-2(3H)-one (500 mg, 2.17 mmol) in N,N-dimethylformamide (10 mL), dibromoethane (1224.72 mg, 6.51 mmol) and potassium carbonate (901.23 mg, 6.52 mmol) were added. The mixture was stirred at 60 °C for 16 hours. The solution was concentrated under reduced pressure, diluted with water (50 mL), and extracted with ethyl acetate (50 mL x 2). The organic phase was washed with saturated brine (100 mL). The residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 6-bromo-3-(2-bromoethyl)benzo[d]thiazol-2(3H)-one (compound 25-1, 400 mg, yield 49.16%, yellow oil).

[0544] Step Two:

[0545] To a solution of compound 25-1 (200 mg, 0.59 mmol) in dimethylformamide (10 mL), pyridine-2(1H)-one (84.65 mg, 0.89 mmol) and potassium carbonate (164.0 mg, 1.18 mmol) were added. The system was stirred at 60 °C for 16 hours. The mixture was concentrated under reduced pressure, diluted with water (50 mL), and extracted with ethyl acetate (50 mL x 2). The organic phase was washed with saturated brine (100 mL). The residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 6-bromo-3-(2-(2-oxopyridin-1(2H)-yl)ethyl)benzo[d]thiazolyl-2(3H)-one (compound 25-2, 80 mg, yield 34.55%, yellow oil).

[0546] Step 3:

[0547] To a solution of compound 25-2 (80 mg, 0.22 mmol) in N,N-dimethylformamide / water (4 mL / 1 mL), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (19.6 mg, 0.02 mmol) and potassium phosphate (96.71 mg, 0.21 mmol) were added. The mixture was stirred at 80 °C for 3 hours under nitrogen protection. The residue was concentrated under reduced pressure, and then purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(2-oxo-3-(2-(2-oxopyridin-1(2H)-yl)ethyl)-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 25, 27.29 mg, yield 23.53%, white solid), [M+H). + :494.0.

[0548] 1H NMR (400MHz, DMSO) δ10.89 (s, 1H), 8.08 (ddd, J = 5.0, 2.0, 0.7Hz, 1H), 7.67 (d, J = 1.8Hz, 1H), 7.6 3(ddd,J=8.5,7.1,2.0Hz,1H),7.48(d,J=8.4Hz,1H),7.38(d,J=7.7Hz,1H),7.36-7.27(m,4H),6 .92(ddd,J=7.1,5.0,0.9Hz,1H),6.66(d,J=8.3Hz,1H),4.57(t,J=5.3Hz,2H),4.40-4.34(m,2H ),4.33-4.27(m,1H)2.83-2.69(m,1H),2.65-2.48(m,1H),2.40-2.25(m,1H),2.06-1.94(m,1H).

[0549] Example 29: Preparation of 3-(2-chloro-3-(3-(((S)-3-methyl-2-oxooxazolidine-4-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 26)

[0550] first step:

[0551] Triphenylphosphine (513 mg, 1.96 mmol) and diisopropyl azodicarbonate (395 mg, 1.96 mmol) were added to a tetrahydrofuran (20 mL) solution of 6-bromo-3H-1,3-benzothiazol-2-one (300 mg, 1.3 mmol) and (S)-4-(hydroxymethyl)oxazolidine-2-one (198.5 mg, 1.7 mmol) (20 mL). The reaction mixture was stirred at 25 °C for 12 hours under nitrogen protection. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–80%) to give (S)-4-((6-bromo-2-oxobenzo[d]thiazol-3(2H)-yl)methyl)oxazolidine-2-one (compound 26-1, 400 mg, yield 93.2%, colorless oil).

[0552] Step Two:

[0553] Iodimethane (3.45 g, 24.3 mmol) was added to a solution of compound 26-1 (380 mg, 1.22 mmol) and potassium carbonate (1.68 g, 12.2 mmol) in N,N-dimethylformamide (20 mL). The system was stirred at 50 °C for 24 hours. The mixture was diluted with water (60 mL) and filtered. The filter cake was purified by silica gel column chromatography (PE / EtOAc, 0–60%) to give (S)-4-((6-bromo-2-oxobenzo[d]thiazolyl-3(2H)-yl)methyl)-3-methyloxazolidin-2-one (compound 26-2, 320 mg, yield 80.8%, white oil).

[0554] Step 3:

[0555] Potassium phosphate (74 mg, 0.35 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (30 mg, 0.035 mmol) were added to a mixed solution of N,N-dimethylformamide / water (6 mL / 1.5 mL) of compounds 26-2 (60 mg, 0.17 mmol) and INT3 (61 mg, 0.17 mmol) (6 mL / 1.5 mL). The mixture was stirred at 50 °C for 1 hour under nitrogen protection. The reaction solution was cooled and filtered. The filtrate was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(3-(((S)-3-methyl-2-oxooxazolidine-4-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl)phenyl)piperidin-2,6-dione (compound 26, 31.2 mg, yield 29.46%, white solid), [M+H). + :486.0.

[0556] 1 H NMR (400MHz, DMSO-d6) δ10.94(s,1H),7.78(d,J=1.6Hz,1H),7.58(d,J=8.5Hz,1H),7.47-7.33(m,4H),4.41-4.27(m,3H),4.20(t, J=8.0Hz,2H),4.09(dd,J=8.8,4.7Hz,1H),2.86-2.74(m,4H),2.55(dd,J=12.7,5.0Hz,1H),2.40-2.28(m,1H),2.09-2.01(m,1H).

[0557] Example 30: Preparation of 3-(2-chloro-3-(3-(((R)-3-methyl-2-oxooxazolidine-4-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 27)

[0558] first step:

[0559] Triphenylphosphine (513 mg, 1.96 mmol) and diisopropyl azodicarbonate (395 mg, 1.96 mmol) were added to a tetrahydrofuran (20 mL) solution of 6-bromo-3H-1,3-benzothiazol-2-one (300 mg, 1.3 mmol) and (R)-4-(hydroxymethyl)oxazolidine-2-one (198.5 mg, 1.7 mmol) (20 mL). The reaction mixture was stirred at 25 °C for 12 hours under nitrogen protection. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–90%) to give (R)-4-((6-bromo-2-oxobenzo[d]thiazol-3(2H)-yl)methyl)oxazolidine-2-one (compound 27-1, 400 mg, yield 93.2%, colorless oil).

[0560] Step Two:

[0561] Iodimethane (3.45 g, 24.3 mmol) was added to a solution of compound 27-1 (380 mg, 1.22 mmol) and potassium carbonate (1.68 g, 12.2 mmol) in N,N-dimethylformamide (20 mL). The system was stirred at 50 °C for 24 hours. The mixture was diluted with water (60 mL) and filtered. The filter cake was purified by silica gel column chromatography (PE / EtOAc, 0–90%) to give (R)-4-((6-bromo-2-oxobenzo[d]thiazolyl-3(2H)-yl)methyl)-3-methyloxazolidin-2-one (compound 27-2, 320 mg, yield 80.8%, white oil).

[0562] Step 3:

[0563] Potassium phosphate (74 mg, 0.35 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (30 mg, 0.035 mmol) were added to a mixed solution of N,N-dimethylformamide / water (6 mL / 1.5 mL) of compounds 27-2 (60 mg, 0.17 mmol) and INT3 (61 mg, 0.17 mmol). The mixture was stirred at 50 °C for 1 hour under nitrogen protection. The reaction solution was cooled and filtered. The filtrate was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(3-(((R)-3-methyl-2-oxooxazolidine-4-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl)phenyl)piperidin-2,6-dione (compound 27, 6.5 mg, yield 7.46%, white solid), [M+H).+ :485.9.

[0564] 1 H NMR (400MHz, DMSO) δ10.93(s,1H),7.78(d,J=1.7Hz,1H),7.58(d,J=8.5Hz,1H),7.46-7.33(m,4H),4.41-4.27(m,3H),4.20(t,J=8 .0Hz,2H),4.09(dd,J=8.7,4.7Hz,1H),2.85-2.75(m,4H),2.57(d,J=3.6Hz,1H),2.34(dd,J=12.3,2.9Hz,1H),2.10-2.00(m,1H).

[0565] Example 31: Preparation of 3-(2-chloro-3-(2-oxo-3-(pyrimidin-2-yl)-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 28)

[0566] first step:

[0567] Potassium carbonate (1621.87 mg, 11.73 mmol) and potassium iodide (64.88 mg, 0.39 mmol) were added to a solution of 6-bromobenzo[d]thiazol-2(3H)-one (900 mg, 3.91 mmol) and 2-chloropyrimidine (1133.02 mg, 11.73 mmol) in acetonitrile (10 mL). The mixture was stirred at 80 °C for 12 h. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 6-bromo-3-(pyrimidin-2-yl)benzo[d]thiazol-2(3H)-one (compound 28-1, yield 8.7%, 170 mg, white solid).

[0568] Step Two:

[0569] Potassium phosphate (144.68 mg, 0.682 mmol) and methanesulfonic acid (2-dimethylformamide / water (2 mL / 0.5 mL)) (2-dimethylformamide / water (2 mL / 0.5 mL)) were added to a mixed solution of compound 28-1 (70 mg, 0.227 mmol) and INT3 (79.43 mg, 0.227 mmol). The mixture was stirred at 80 °C for 8 hours under nitrogen protection. Extracted with ethyl acetate (10 mL * 3), the organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(2-oxo-3-(pyrimidin-2-yl)-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 28, 6.5 mg, yield 6.07%, white solid), [M + H). + :451.0.

[0570] 1H NMR (400MHz, DMSO) δ10.94(s,1H),9.13(d,J=4.9Hz,2H),7.85(d,J=1.8Hz,1H),7.78(t,J=4.9Hz,1H),7.41(dd,J=7.1,4.7Hz,2H),7.36( ddd,J=8.4,5.4,2.2Hz,2H),7.21(d,J=8.5Hz,1H),4.35(dd,J=12.2,5.0Hz,1H),2.85-2.75(m,1H),2.41-2.26(m,2H),2.08-1.99(m,1H).

[0571] Example 32: Preparation of 3-(3-(2-(1H-pyrazol-1-yl)ethyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)-2-chlorophenyl)piperidine-2,6-dione (compound 29)

[0572] first step:

[0573] At 0 °C, triphenylphosphine (690 mg, 2.62 mmol) and diethyl azodicarbonate (460 mg, 2.62 mmol) were added to a tetrahydrofuran (10 mL) solution of 6-bromobenzo[d]thiazol-2(3H)-one (500 mg, 2.18 mmol) and 2-(1H-pyrazol-1-yl)ethanol-1-ol (240 mg, 2.17 mmol). The mixture was stirred at room temperature for 3 hours. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 3-(2-(1H-pyrazol-1-yl)ethyl)-6-bromobenzo[d]thiazol-2(3H)-one (compound 29-1, 350 mg, yield 51.17%, white solid).

[0574] Step Two:

[0575] Potassium phosphate (60 mg, 0.286 mmol) and methanesulfonic acid (2-dimethylformamide (2 mL) and water (0.5 mL) were added to a mixed solution of compound 29-1 (50 mg, 0.143 mmol) and INT3 (50 mg, 0.143 mmol). The mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (30 mL x 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(3-(2-(1H-pyrazol-1-yl)ethyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)-2-chlorophenyl)piperidin-2,6-dione (compound 29, 26.0 mg, yield 40%, white solid). [M+H] + :466.9.

[0576] 1 H NMR (400MHz, DMSO) δ10.92(s,1H),7.70(d,J=1.8Hz,2H),7.47–7.26(m,5H),7.12(d,J=8.5Hz,1H),6.16(t,J=2.0Hz,1H),4.47 (t,J=5.8Hz,2H),4.37–4.28(m,3H),2.90–2.72(m,1H),2.56(d,J=3.8Hz,1H),2.34(tt,J=12.4,6.4Hz,1H),2.12–1.92(m,1H).

[0577] Example 33: Preparation of 3-(2-chloro-3-(2-oxo-3-(pyrimidin-2-ylmethyl)-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 30)

[0578] first step:

[0579] Triphenylphosphine (1429.18 mg, 5.44896 mmol) and diethyl azodicarbonate (948.99 mg, 5.44896 mmol) were added to a tetrahydrofuran (10 mL) solution of pyrimidin-2-ylmethanol (500 mg, 4.5408 mmol) and 6-bromobenzo[d]thiazol-2(3H)-one (1253.71 mg, 5.4486 mmol). The mixture was stirred at 30 °C for 3 hours. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (DCM / MeOH, 0–20%) to give 6-bromo-3-(pyrimidin-2-ylmethyl)benzo[d]thiazol-2(3H)-one (compound 30-1, 4.0 g, yield 27.34%, white solid).

[0580] Step Two:

[0581] To a mixed solution of compound 30-1 (200 mg, 0.6208 mmol) and INT3 (260.45 mg, 0.744 mmol) in N,N-dimethylformamide (10 mL) and water (2.5 mL), potassium phosphate (263.54 mg, 1.2416 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (53.42 mg, 0.06208 mmol) were added, and the mixture was stirred at 50 °C for 1 hour under nitrogen protection. The residue was concentrated under reduced pressure, and then purified by silica gel column chromatography (DCM / MeOH, 0–5%) to give 3-(2-chloro-3-(2-oxo-3-(pyrimidin-2-ylmethyl)-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 30, 18 mg, yield 6.07%, white solid), [M+H). + :464.9.

[0582] 1H NMR (400MHz, DMSO) δ10.92(s,1H),8.80(d,J=4.9Hz,2H),7.77(d,J=1.7Hz,1H),7.37(dddd,J=30.9,23.4,15.7,6.7Hz,6H),5.43 (s,2H),4.34(dd,J=12.2,5.0Hz,1H),3.02–2.72(m,1H),2.56(s,1H),2.35(dd,J=13.6,5.3Hz,1H),2.05(dd,J=9.1,4.1Hz,1H).

[0583] Example 34: Preparation of 3-(3-(3-(2-(azacyclobutane-1-yl)ethyl)-2-oxo-2,3-dihydrobenzo[d]thiazo-6-yl)-2-chlorophenyl)piperidine-2,6-dione (compound 31)

[0584] first step:

[0585] To a tetrahydrofuran (15 mL) solution of 6-bromobenzo[d]thiazol-2(3H)-one (300 mg, 1.30 mmol) and 2-(azacyclobutan-1-yl)ethyl-1-ol (131.89 mg, 1.30 mmol), triphenylphosphine (513 mg, 1.96 mmol) and diethyl azodicarbonate (395.49 mg, 1.96 mmol) were added, and the mixture was stirred at room temperature for 3 hours. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 3-(2-(azacyclobutan-1-yl)ethyl)-6-bromobenzo[d]thiazol-2(3H)-one (compound 31-1, 400 mg, yield 58.77%, white solid).

[0586] Step Two:

[0587] To a mixed solution of compound 31-1 (50 mg, 0.1287 mmol) and INT3 (55.80 mg, 0.1596 mmol) in N,N-dimethylformamide (4 mL) and water (1 mL), potassium phosphate (67.76 mg, 0.3192 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (13.73 mg, 0.0159 mmol) were added. The mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (30 mL * 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(3-(3-(2-(azacyclobutan-1-yl)ethyl)-2-oxo-2,3-dihydrobenzo[d]thiazo-6-yl)-2-chlorophenyl)piperidin-2,6-dione (compound 31, 13.29 mg, yield 18.23%, white solid), [M+H] + :456.0.

[0588] 1 H NMR (400MHz, DMSO) δ10.94(s,1H),9.74(s,1H),7.80(d,J=1.7Hz,1H),7.52(d ,J=8.4Hz,1H),7.45–7.39(m,3H),7.32(dd,J=7.0,2.2Hz,1H),4.35(dd,J=12 .3,5.0Hz,1H),4.23(d,J=5.2Hz,2H),4.12(s,4H),3.56(s,2H),2.77(dd,J=1 2.4, 5.0Hz, 2H), 2.57 (d, J = 4.0Hz, 1H). 2.40–2.32 (m, 2H), 2.08–2.02 (m, 1H).

[0589] Example 35: Preparation of 3-(2-chloro-3-(3-(2-hydroxyethyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 32)

[0590] first step:

[0591] To a tetrahydrofuran (15 mL) solution of 6-bromobenzo[d]thiazol-2(3H)-one (300 mg, 1.30 mmol) and 2-((tert-butyldimethylsilyl)oxy)ethyl-1-ol (229.91 mg, 1.30 mmol), triphenylphosphine (513 mg, 1.96 mmol) and diethyl azodicarbonate (395.49 mg, 1.96 mmol) were added, and the mixture was stirred at room temperature for 3 hours. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 6-bromo-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)benzo[d]thiazol-2(3H)-one (compound 32-1, 380 mg, yield 67.53%, white solid).

[0592] Step Two:

[0593] To a mixed solution of compound 32-1 (50 mg, 0.1287 mmol) and INT3 (45 mg, 0.1287 mmol) in N,N-dimethylformamide (4 mL) and water (1 mL), potassium phosphate (54.64 mg, 0.2574 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (11.07 mg, 0.0128 mmol) were added, and the mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (30 mL * 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(3-(3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)-2-chlorophenyl)piperidin-2,6-dione (compound 32-2, 50 mg, yield 65.81%, white solid).

[0594] Step 3:

[0595] Triethylamine trihydrofluoride (36.42 mg, 0.2259 mmol) was added to a solution of compound 32-2 (40 mg, 0.0753 mmol) in dichloromethane (3 mL), and the mixture was stirred at 25 °C for 3 hours. Extraction was performed with ethyl acetate (30 mL x 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(3-(2-hydroxyethyl)-2-oxo-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 32, 5.55 mg, yield 17.53%, white solid), [M+H). +:417.0.

[0596] 1 H NMR (400MHz, DMSO) δ10.92(s,1H),7.93(s,1H),7.72(d,J=8.3Hz,1H),7.42–7.35(m,4H),5.11–5.01(m,1H),4.61–4.55(m,2H),4.35 (dd,J=12.1,4.9Hz,1H),3.79(dd,J=9.6,5.2Hz,2H),2.83–2.74(m,1H),2.57(d,J=3.5Hz,1H),2.39–2.30(m,1H),2.11–2.04(m,1H).

[0597] Example 36: Preparation of 3-(2-chloro-3-(2-oxo-3-(2,2,2-trifluoroethyl)-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidine-2,6-dione (compound 33)

[0598] first step:

[0599] To a solution of 6-bromobenzo[d]thiazol-2(3H)-one (300 mg, 1.3039 mmol) and 2,2,2-trifluoroethyl trifluoromethanesulfonate (364.74 mg, 1.5647 mmol) in acetonitrile (5 mL), potassium carbonate (540.64 mg, 3.9117 mmol) and potassium iodide (21.63 mg, 0.1304 mmol) were added, and the mixture was stirred at 80 °C for 1 hour. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to obtain 6-bromo-3-(2,2,2-trifluoroethyl)benzo[d]thiazol-2(3H)-one (compound 33-1, 350 mg, yield 85.73%, white solid).

[0600] Step Two:

[0601] To a mixed solution of compound 33-1 (50 mg, 0.1597 mmol) and INT3 (55.83 mg, 0.1597 mmol) in N,N-dimethylformamide (2 mL) and water (0.5 mL), potassium phosphate (101.7 mg, 0.4791 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (13.74 mg, 0.016 mmol) were added, and the mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (10 mL * 3), the organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(2-oxo-3-(2,2,2-trifluoroethyl)-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 33, 24.8 mg, yield 33.88%, white solid), [M+H + :455.0.

[0602] 1 H NMR (400MHz, DMSO) δ10.93(s,1H),7.80(d,J=1.7Hz,1H),7.60(d,J=8.5Hz,1H),7.46–7.34(m,4H),4.98(d,J=9.2Hz ,2H),4.35(dd,J=12.2,5.0Hz,1H),2.85–2.74(m,1H),2.59–2.53(m,1H),2.34(qd,J=12.9,4.2Hz,1H),2.07(s,1H).

[0603] Example 37: Preparation of 3-(2-chloro-3-(2-oxo-3-(pyridazin-3-ylmethyl)-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 34)

[0604] first step:

[0605] At 0 °C, triphenylphosphine (690 mg, 2.62 mmol) and diethyl azodicarbonate (460 mg, 2.62 mmol) were added to a tetrahydrofuran (10 mL) solution of 6-bromobenzo[d]thiazol-2(3H)-one (500 mg, 2.18 mmol) and pyridazin-3-ylmethanol (240 mg, 2.17 mmol). The mixture was stirred at room temperature for 3 hours. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 6-bromo-3-(pyridazin-3-ylmethyl)benzo[d]thiazol-2(3H)-one (compound 34-1, 350 mg, yield 51.17%, white solid).

[0606] Step Two:

[0607] To a mixed solution of compound 34-1 (50 mg, 0.143 mmol) and INT3 (50 mg, 0.143 mmol) in N,N-dimethylformamide (2 mL) and water (0.5 mL), potassium phosphate (60 mg, 0.286 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (12.3 mg, 0.014 mmol) were added, and the mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (30 mL * 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(2-oxo-3-(pyridazin-3-ylmethyl)-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 34, 26.4 mg, yield 40%, white solid), [M+H + :464.9.

[0608] 1 H NMR (400MHz, DMSO) δ10.92(s,1H),9.19(t,J=3.3Hz,1H),7.76(dd,J=17.7,2.3Hz,3H),7.44–7.29(m,5H),5.54(s,2H), 4.34(dd,J=12.2,5.0Hz,1H),2.87–2.72(m,1H),2.56(d,J=3.6Hz,1H),2.34(tt,J=12.8,6.4Hz,1H),2.13–1.98(m,1H).

[0609] Example 38: Preparation of 2-(6-(2-chloro-3-(2,6-dioxopiperidin-3-yl)phenyl)-2-oxobenzo[d]thiazolyl-3(2H)-yl)-N-methylacetamide (compound 35)

[0610] first step:

[0611] Potassium carbonate (540 mg, 3.93 mmol) and potassium iodide (21.6 mg, 0.13 mmol) were added to a 10 mL acetonitrile solution of 6-bromobenzo[d]thiazol-2(3H)-one (300 mg, 1.31 mmol) and 2-chloro-N-methylacetamide (210 mg, 1.96 mmol). The mixture was stirred at 80 °C for 2 hours. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 2-(6-bromo-2-oxobenzo[d]thiazol-3(2H)-yl)-N-methylacetamide (compound 35-1, 280 mg, yield 71.25%, white solid).

[0612] Step Two:

[0613] To a mixed solution of compound 35-1 (50 mg, 0.174 mmol) and INT3 (60 mg, 0.174 mmol) in N,N-dimethylformamide (2 mL) and water (0.5 mL), potassium phosphate (60 mg, 0.348 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (12.3 mg, 0.017 mmol) were added, and the mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (30 mL * 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 2-(6-(2-chloro-3-(2,6-dioxopiridin-3-yl)phenyl)-2-oxobenzo[d]thiazolyl-3(2H)-yl)-N-methylacetamide (compound 35, 31.3 mg, yield 42.41%, white solid), [M+H). + :444.0.

[0614] 1H NMR (400MHz, DMSO) δ10.92(s,1H),8.25(d,J=4.6Hz,1H),7.74(d,J=1.7Hz,1H),7.36(ddd,J=13.0,6.4,4.2Hz,4H),7.25(d,J=8.4Hz,1H),4.6 1(s,2H),4.35(dd,J=12.2,5.0Hz,1H),2.83–2.75(m,1H),2.64(d,J=4.6Hz,3H),2.56(d,J=3.5Hz,1H),2.39–2.31(m,1H),2.08–1.99(m,1H).

[0615] Example 39: Preparation of 3-(6-(2-chloro-3-(2,6-dioxopiperidin-3-yl)phenyl)-2-oxobenzo[d]thiazolyl-3(2H)-yl)-N,N-dimethylpropionamide (compound 36)

[0616] first step:

[0617] Potassium carbonate (540 mg, 3.93 mmol) and potassium iodide (21.6 mg, 0.13 mmol) were added to a solution of 6-bromobenzo[d]thiazol-2(3H)-one (300 mg, 1.31 mmol) and 3-chloro-N,N-dimethylpropionamide (265 mg, 1.96 mmol) in acetonitrile (10 mL). The mixture was stirred at 80 °C for 2 hours. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 3-(6-bromo-2-oxobenzo[d]thiazol-3(2H)-yl)-N,N-dimethylpropionamide (compound 36-1, 100 mg, yield 23.26%, white solid).

[0618] Step Two:

[0619] To a mixed solution of compound 36-1 (50 mg, 0.152 mmol) and INT3 (60 mg, 0.174 mmol) in N,N-dimethylformamide (2 mL) and water (0.5 mL), potassium phosphate (60 mg, 0.348 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (12.3 mg, 0.017 mmol) were added, and the mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (30 mL * 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(6-(2-chloro-3-(2,6-dioxopiridin-3-yl)phenyl)-2-oxobenzo[d]thiazolyl-3(2H)-yl)-N,N-dimethylpropionamide (compound 36, 18.3 mg, yield 25.49%, white solid), [M+H). + :472.0.

[0620] 1 H NMR (400MHz, DMSO) δ10.92(s,1H),7.73(d,J=1.7Hz,1H),7.49(d,J=8.4Hz,1H),7.41–7.37(m,3H),7.33(dd,J=7.0,2.1Hz,1H),4.35(dd,J=12.2,5.1Hz ,1H),4.20–4.15(m,2H),2.93(s,3H),2.82(s,3H),2.77(dd,J=14.1,6.9Hz, 3H), 2.56 (d, J = 3.7Hz, 1H), 2.36 (dd, J = 12.8, 8.7Hz, 1H), 2.07–2.02 (m, 1H).

[0621] Example 40: Preparation of 3-(2-chloro-3-(3-(((1s,3s)-3-hydroxycyclobutyl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 37)

[0622] first step:

[0623] Triphenylphosphine (411 mg, 1.57 mmol) was added to a tetrahydrofuran (10 mL) solution of 6-bromobenzo[d]thiazolyl-2(3H)-one (300 mg, 1.31 mmol) and ((1s, 3s)-3-((tert-butyldimethylsilyl)oxy)cyclobutyl)methanol (340 mg, 1.57 mmol). The mixture was stirred for 10 minutes under nitrogen protection at 0 °C, and then diethyl azodicarbonate (273 mg, 1.57 mmol) was added. The mixture was stirred at room temperature for 3 hours. Add water (10 mL), extract with ethyl acetate (10 mL * 3), concentrate under reduced pressure, and separate and purify the residue by silica gel column chromatography (PE / EtOAc, 0–50%) to obtain 6-bromo-3-(((1s,3s)-3-((tert-butyldimethylsilyl)oxy)cyclobutyl)methyl)benzo[d]thiazol-2(3H)-one (compound 37-1, 330 mg, yield 58.7%, white solid).

[0624] Step Two:

[0625] Potassium phosphate (98 mg, 0.46 mmol), INT3 (80 mg, 0.23 mmol), and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (20 mg, 0.023 mmol) were added to a mixed solution of compound 37-1 (100 mg, 0.23 mmol) in N,N-dimethylformamide (4 mL) and water (1 mL). The mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (30 mL * 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(3-(3-(((1s,3s)-3-((tert-butyldimethylsilyl)oxy)cyclobutyl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)-2-chlorophenyl)piperidine-2,6-dione (compound 37-2, 85 mg, yield 64.7%, yellow oil).

[0626] Step 3:

[0627] Tetrabutylammonium fluoride (1 M, 0.5 mL) was added to a tetrahydrofuran (4 mL) solution of compound 37-2 (85 mg, 0.15 mmol) and stirred at room temperature for 0.5 hours. Extraction was performed with ethyl acetate (30 mL x 3), the organic phase was washed with saturated brine (30 mL x 2), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(3-(((1s,3s)-3-hydroxycyclobutyl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidin-2,6-dione (compound 37, 23.3 mg, yield 34%, white solid), [M+H]. + :456.9.

[0628] 1 H NMR (400MHz, DMSO) δ10.94(s,1H),7.73(d,J=1.6Hz,1H),7.45–7.32(m,5H),4.35(dd,J=12.2,5.0Hz,1H),4.01(d,J=6.5Hz,2H),3.87(d,J=7.0Hz,1H ),2.84–2.75(m,1H),2.56(d,J=3.6Hz,1H),2.34(dd,J=12.4,3.8Hz,1H),2 .29–2.20(m,2H),2.18–2.09(m,1H),2.08–2.00(m,1H),1.71–1.58(m,2H).

[0629] Example 41: Preparation of 3-(2-chloro-3-(3-(((1r,3r)-3-hydroxycyclobutyl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 38)

[0630] first step:

[0631] To a solution of ((1r,3r)-3-((tert-butyldimethylsilyl)oxy)cyclobutyl)methanol (300 mg, 1.39 mmol) and triethylamine (421 mg, 4.16 mmol) in dichloromethane (20 mL), p-toluenesulfonyl chloride (292 mg, 1.53 mmol) was added, and the mixture was stirred at 50 °C for 4 hours. Water (10 mL) was added, and the mixture was extracted with ethyl acetate (10 mL x 3). The extract was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to obtain ((1r,3r)-3-((tert-butyldimethylsilyl)oxy)cyclobutyl)methyl 4-methylbenzenesulfonate (compound 38-1, 170 mg, yield 33%, yellow oil).

[0632] Step Two:

[0633] Potassium carbonate (190 mg, 1.37 mmol) and potassium iodide (15 mg, 0.09 mmol) were added to a 10 mL solution of compound 38-1 (170 mg, 0.46 mmol). The mixture was stirred at 80 °C for 5 hours. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–30%) to give 6-bromo-3-(((1r,3r)-3-((tert-butyldimethylsilyl)oxy)cyclobutyl)methyl)benzo[d]thiazol-2(3H)-one (compound 38-2, 130 mg, yield 65.2%, yellow oil).

[0634] Step 3:

[0635] Potassium phosphate (127 mg, 0.60 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (26 mg, 0.03 mmol) were added to a mixed solution of N,N-dimethylformamide (20 mL) and water (4 mL) of compound 38-2 (130 mg, 0.30 mmol) and INT3 (105 mg, 0.30 mmol). The mixture was stirred at 50 °C for 1 hour. The residue was concentrated under reduced pressure and purified by silica gel column chromatography (PE / EtOAc, 0–40%) to obtain 3-(3-(3-(((1r,3r)-3-((tert-butyldimethylsilyl)oxy)cyclobutyl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazo-6-yl)-2-chlorophenyl)piperidine-2,6-dione (compound 38-2, 120 mg, 70% yield, yellow oil).

[0636] Step 4:

[0637] Tetrabutylammonium fluoride (1 M, 0.5 mL) was added to a tetrahydrofuran (4 mL) solution of compound 38-3 (120 mg, 0.21 mmol) and stirred at room temperature for 0.5 hours. Extraction was performed with ethyl acetate (30 mL x 3), the organic phase was washed with saturated brine (30 mL x 2), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(3-(((1r,3r)-3-hydroxycyclobutyl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 38, 26.2 mg, yield 27.3%, white solid), [M+H]. + :456.9.

[0638] 1H NMR (400MHz, DMSO) δ10.93(s,1H),7.73(d,J=1.7Hz,1H),7.49–7.31(m,5H),5.05(d,J=6.1Hz,1H),4.35(dd,J=12.2,5.2Hz,2H),4.06(d, J=8.2Hz,2H),2.85–2.74(m,1H),2.68–2.55(m,2H),2.34(dd,J=12.4,4.0Hz,1H),2.06(ddt,J=12.8,8.7,4.4Hz,3H),1.96–1.86(m,2H).

[0639] Example 42: Preparation of 3-(2-chloro-3-(2-oxo-3-(((S)-2-oxopyrrolidone-3-yl)methyl)-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 39)

[0640] first step:

[0641] Triphenylphosphine (855 mg, 3.26 mmol) and diisopropyl azodicarbonate (659 mg, 3.26 mmol) were added to a tetrahydrofuran (20 mL) solution of 6-bromo-3H-1,3-benzothiazol-2-one (500 mg, 2.17 mmol) and 3-(hydroxymethyl)pyrrolidone-2-one (300 mg, 2.61 mmol). The mixture was stirred at 25 °C for 16 hours under nitrogen protection. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–75%) to obtain 1.2 g of crude product (a mixture of the product and triphenylphosphine oxide). The crude product was separated and purified by chiral preparative chromatography. The first peak obtained was (S)-6-bromo-3-((2-oxopyrrolidone-3-yl)methyl)benzo[d]thiazol-2(3H)-one (compound 39-1, 270 mg, yield: 38%, white solid). The second peak obtained was (R)-6-bromo-3-((2-oxopyrrolidone-3-yl)methyl)benzo[d]thiazol-2(3H)-one (compound 39-2, 220 mg, yield: 31%, white solid).

[0642] Step Two:

[0643] To a mixed solution of compound 39-1 (60 mg, 0.1834 mmol) and INT3 (64.12 mg, 0.1834 mmol) in N,N-dimethylformamide (4 mL) and water (1 mL), potassium phosphate (116.79 mg, 0.5502 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (15.78 mg, 0.0183 mmol) were added, and the mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (30 mL x 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(2-oxo-3-(((S)-2-oxopyrrolidone-3-yl)methyl)-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 39, 33.13 mg, yield 38.28%, white solid), [M+H] + :470.1.

[0644] 1 H NMR (400MHz, DMSO) δ10.94(s,1H),7.83(s,1H),7.75(d,J=1.6Hz,1H),7.48(d,J=8.5Hz,1H),7 .43–7.36(m,3H),7.36–7.32(m,1H),4.35(dd,J=12.1,4.9Hz,1H),4.21(dd,J=14.4,5.5Hz,1H) ,4.13–4.07(m,1H),3.25–3.19(m,1H),3.15(t,J=8.0Hz,1H),2.83–2.76(m,2H),2.56(d,J=3.5 Hz,1H),2.34(dt,J=12.7,8.9Hz,2H),2.15–2.10(m,1H),2.08–2.03(m,1H),1.90–1.83(m,1H).

[0645] Example 43: Preparation of 3-(2-chloro-3-(2-oxo-3-(((R)-2-oxopyrrolidone-3-yl)methyl)-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 40)

[0646] To a mixed solution of compound 39-2 (60 mg, 0.1834 mmol) and INT3 (64.12 mg, 0.1834 mmol) in N,N-dimethylformamide (4 mL) and water (1 mL), potassium phosphate (116.79 mg, 0.5502 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (15.78 mg, 0.0183 mmol) were added, and the mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (30 mL x 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(2-oxo-3-(((R)-2-oxopyrrolidone-3-yl)methyl)-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 40, 33.82 mg, yield 39.26%, white solid), [M+H + :470.1.

[0647] 1 H NMR (400MHz, DMSO) δ10.94(s,1H),7.83(s,1H),7.75(d,J=1.6Hz,1H),7.48(d,J=8.5Hz,1H),7.39( dd,J=7.7,4.7Hz,3H),7.33(dd,J=7.0,2.1Hz,1H),4.35(dd,J=12.2,5.0Hz,1H),4.23–4.18(m,1H) ,4.14–4.08(m,1H),3.22(dd,J=8.8,5.6Hz,1H),3.15(t,J=8.1Hz,1H),2.83–2.76(m,2H),2.56(d, J=3.4Hz,1H),2.37–2.31(m,1H),2.15–2.09(m,1H),2.04(dd,J=8.8,3.9Hz,1H),1.90–1.83(m,1H).

[0648] Example 44: Preparation of 3-(2-chloro-3-(3-(((S)-1-methyl-2-oxopyrrolidone-3-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 41)

[0649] first step:

[0650] Triphenylphosphine (683.99 mg, 2.6077 mmol) and diisopropyl azodicarbonate (527.31 mg, 2.6077 mmol) were added to a tetrahydrofuran (20 mL) solution of 6-bromo-3H-1,3-benzothiazol-2-one (400 mg, 1.7385 mmol) and 3-(hydroxymethyl)-1-methylpyrrolidone-2-one (224.54 mg, 1.7385 mmol). The mixture was stirred at 25 °C for 16 hours under nitrogen protection. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–75%) to obtain 310 mg of crude product (a mixture of the product and triphenylphosphine oxide). The crude product was separated and purified by chiral preparative chromatography. The first peak was (S)-6-bromo-3-((1-methyl-2-oxopyrrolidone-3-yl)methyl)benzo[d]thiazol-2(3H)-one (compound 41-1, 82 mg, yield 13.49%, white solid), and the second peak was (R)-6-bromo-3-((1-methyl-2-oxopyrrolidone-3-yl)methyl)benzo[d]thiazol-2(3H)-one (compound 41-2, 80 mg, yield 13.64%, white solid).

[0651] Step Two:

[0652] To a mixed solution of compound 41-1 (60 mg, 0.1758 mmol) and INT3 (61.46 mg, 0.1758 mmol) in N,N-dimethylformamide (4 mL) and water (1 mL), potassium phosphate (111.95 mg, 0.5274 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (15.13 mg, 0.0175 mmol) were added, and the mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (30 mL x 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(3-(((S)-1-methyl-2-oxopyrrolidone-3-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidin-2,6-dione (compound 41, 44.21 mg, yield 51.76%, white solid), [M+H] + :483.1.

[0653] 1H NMR (400MHz, DMSO) δ10.92(s,1H),7.94(d,J=1.7Hz,1H),7.74(d,J=8.3Hz,1H),7.43–7.34(m,4H ),4.78(dd,J=10.4,3.7Hz,1H),4.66(dd,J=10.4,5.8Hz,1H),4.35(dd,J=12.1,5.0Hz,1H),3.37– 3.32(m,2H),2.98–2.92(m,1H),2.82(dd,J=12.7,5.2Hz,1H),2.77(s,3H),2.56(d,J=3.5Hz,1H) ,2.34(dd,J=12.5,3.6Hz,1H),2.25–2.18(m,1H),2.06(dd,J=9.0,4.0Hz,1H),2.00–1.91(m,1H).

[0654] Example 45: Preparation of 3-(2-chloro-3-(3-(((R)-1-methyl-2-oxopyrrolidone-3-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 42)

[0655] To a mixed solution of compound 41-2 (60 mg, 0.1758 mmol) and INT3 (61.46 mg, 0.1758 mmol) in N,N-dimethylformamide (4 mL) and water (1 mL), potassium phosphate (111.95 mg, 0.5274 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (15.13 mg, 0.0175 mmol) were added, and the mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (30 mL * 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(3-(((R)-1-methyl-2-oxopyrrolidone-3-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidin-2,6-dione (compound 42, 43.40 mg, yield 50.97%, white solid), [M+H + :484.1.

[0656] 1H NMR (400MHz, DMSO) δ10.92(s,1H),7.94(d,J=1.6Hz,1H),7.74(d,J=8.3Hz,1H),7.44–7.35(m,4H),4. 78(dd,J=10.4,3.7Hz,1H),4.66(dd,J=10.4,5.8Hz,1H),4.35(dd,J=12.1,5.0Hz,1H),3.37–3.32(m, 2H),2.98–2.91(m,1H),2.82(dd,J=12.7,5.0Hz,1H),2.76(d,J=6.6Hz,3H),2.56(d,J=3.5Hz,1H),2. 34(td,J=12.8,8.8Hz,1H),2.21(ddd,J=10.5,8.0,5.4Hz,1H),2.11–2.01(m,1H),1.99–1.92(m,1H).

[0657] Example 46: Preparation of 2-(6-(2-chloro-3-(2,6-dioxopiperidin-3-yl)phenyl)-2-oxobenzo[d]thiazolyl-3(2H)-yl)-N-ethyl-N-methylacetamide (compound 43)

[0658] first step:

[0659] 2-Bromoacetyl chloride (2663.28 mg, 16.920 mmol) was slowly added dropwise to a solution of N-methylethylamine (1000 mg, 16.920 mmol) in dichloromethane (10 mL), and the mixture was stirred at room temperature for 1 hour. Water (25 mL) was added, and the mixture was extracted with dichloromethane (10 mL x 3). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 2-bromo-N-ethyl-N-methylacetamide (compound 43-1, 760 mg, yield 24.95%, gray oil).

[0660] Step Two:

[0661] To a solution of 6-bromobenzo[d]thiazolyl-2(3H)-one (300 mg, 1.3039 mmol) and compound 43-1 (281.71 mg, 1.5647 mmol) in acetonitrile (5 mL), potassium carbonate (540.64 mg, 3.9117 mmol) and potassium iodide (21.63 mg, 0.1304 mmol) were added, and the mixture was stirred at 80 °C for 1 hour. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 2-(6-bromo-2-oxobenzo[d]thiazolyl-3(2H)-yl)-N-ethyl-N-methylacetamide (compound 43-2, 320 mg, yield 74.55%, white solid).

[0662] Step 3:

[0663] To a mixed solution of compound 43-2 (50 mg, 0.159 mmol) and INT3 (53.11 mg, 0.159 mmol) in N,N-dimethylformamide (2 mL) and water (0.5 mL), potassium phosphate (96.73 mg, 0.4557 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (13.07 mg, 0.016 mmol) were added, and the mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (10 mL * 3), the organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 2-(6-(2-chloro-3-(2,6-dioxopiperidin-3-yl)phenyl)-2-oxobenzo[d]thiazolyl-3(2H)-yl)-N-ethyl-N-methylacetamide (compound 43, 31.7 mg, yield 44.04%, white solid), [M+H). + :472.1.

[0664] 1 H NMR (400MHz, DMSO) δ10.63(s,1H),7.65(d,J=1.5Hz,1H),7.39–7.29(m,4H),7.21(s,1H),4.85(s,2H),4.31(dd,J=11.9,5.2Hz,1H) ,3.51–3.28(m,2H),3.08(s,3H),2.73(d,J=12.1Hz,1H),2.53(d,J=21.4Hz,1H),2.28(s,1H),2.11–2.02(m,1H),1.26–0.99(m,3H).

[0665] Example 47: Preparation of 2-(6-(2-chloro-3-(2,6-dioxopiperidin-3-yl)phenyl)-2-oxobenzo[d]thiazolyl-3(2H)-yl)-N,N-diethylacetamide (compound 44)

[0666] first step:

[0667] To a solution of 6-bromobenzo[d]thiazolyl-2(3H)-one (300 mg, 1.3039 mmol) and 2-chloro-N,N-diethylacetamide (234.11 mg, 1.5647 mmol) in acetonitrile (5 mL), potassium carbonate (540.64 mg, 3.9117 mmol) and potassium iodide (21.63 mg, 0.1304 mmol) were added, and the mixture was stirred at 80 °C for 1 hour. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 2-(6-bromo-2-oxobenzo[d]thiazolyl-3(2H)-yl)-N,N-diethylacetamide (mixture 44-1, 370 mg, yield 76.06%, white solid).

[0668] Step Two:

[0669] To a mixed solution of N,N-dimethylformamide (2 mL) and water (0.5 mL) containing mixture 44-1 (50 mg, 0.1457 mmol) and INT3 (50.94 mg, 0.1457 mmol), potassium phosphate (92.78 mg, 0.4371 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (12.54 mg, 0.015 mmol) were added. The mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (10 mL * 3), the organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 2-(6-(2-chloro-3-(2,6-dioxopiridin-3-yl)phenyl)-2-oxobenzo[d]thiazolyl-3(2H)-yl)-N,N-diethylacetamide (compound 44, 38.1 mg, yield 53.4%, white solid), [M+H). + :486.1.

[0670] 1H NMR (400MHz, DMSO) δ10.92 (s, 1H), 7.73 (d, J = 1.7Hz, 1H), 7.44–7.32 (m, 4H), 7.24 (d ,J=8.4Hz,1H),4.91(s,2H),4.35(dd,J=12.2,5.0Hz,1H),3.47(q,J=7.0Hz,2H),3. 30(q,J=7.0Hz,2H),2.78(d,J=12.3Hz,1H),2.59–2.52(m,1H),2.34(dd,J=12.7,3. 9Hz, 1H), 2.05 (dd, J = 9.1, 4.0Hz, 1H), 1.25 (t, J = 7.1Hz, 3H), 1.04 (t, J = 7.1Hz, 3H).

[0671] Example 48: Preparation of 2-(6-(2-chloro-3-(2,6-dioxopiridin-3-yl)phenyl)-2-oxobenzo[d]thiazolyl-3(2H)-yl)-N,N-diethylacetamide (compound 45)

[0672] first step:

[0673] To a solution of 6-bromobenzo[d]thiazolyl-2(3H)-one (300 mg, 1.3039 mmol) and tert-butyl 3-iodoazacyclobutane-1-carboxylate (1111.37 mg, 3.9117 mmol) in acetonitrile (5 mL), potassium carbonate (540.64 mg, 3.9117 mmol) and potassium iodide (21.63 mg, 0.1304 mmol) were added, and the mixture was stirred at 80 °C for 16 hours. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give tert-butyl 3-(6-bromo-2-oxobenzo[d]thiazolyl-3(2H)-yl)azacyclobutane-1-carboxylate (compound 45-1, 220 mg, yield 22.72%, white solid).

[0674] Step Two:

[0675] A solution of compound 45-1 (220 mg, 0.5695 mmol) in dichloromethane (4 mL) was added to trifluoroacetic acid (4 mL), and the mixture was stirred at 25 °C for 1 hour. The mixture was concentrated under reduced pressure to give 3-(azacyclobutane-3-yl)-6-bromobenzo[d]thiazol-2(3H)-one (compound 45-2, 140 mg, yield 25.00%, white solid).

[0676] Step 3:

[0677] Sodium acetate (120.79 mg, 1.473 mmol), paraformaldehyde (29.49 mg, 0.982 mmol), and sodium cyanoborohydride (61.71 mg, 0.982 mmol) were added to a methanol (5 mL) solution of compound 45-2 (140 mg, 0.491 mmol). The mixture was stirred at 25 °C for 1 hour. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 6-bromo-3-(1-methylazacyclobutane-3-yl)benzo[d]thiazol-2(3H)-one (compound 45-3, 90 mg, yield 61.26%, white solid).

[0678] Step 4:

[0679] To a mixed solution of compound 45-3 (50 mg, 0.1671 mmol) and INT3 (58.42 mg, 0.1671 mmol) in N,N-dimethylformamide (2 mL) and water (0.5 mL), potassium phosphate (106.41 mg, 0.5013 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (14.38 mg, 0.017 mmol) were added, and the mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (10 mL * 3), the organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 2-(6-(2-chloro-3-(2,6-dioxoperidin-3-yl)phenyl)-2-oxobenzo[d]thiazolyl-3(2H)-yl)-N,N-diethylacetamide (compound 45, 12.6 mg, yield 17.05%, white solid), [M+H). + :442.0.

[0680] 1 H NMR (400MHz, DMSO) δ10.92(s,1H),8.16(s,0.4H),7.72(dd,J=14.3,5.1Hz,2H),7.44–7.31(m,4H),4.93(p,J=7.2Hz,1H),4.35(dd,J=1 2.1,5.0Hz,1H),3.85(s,2H),3.53(s,2H),2.86–2.75(m,1H),2.56(d,J=3.8Hz,1H),2.35(s,3H),2.34–2.29(m,1H),2.09–2.01(m,1H).

[0681] Example 49: Preparation of 3-(2-chloro-3-(2-oxo-3-(((S)-5-oxopyrrolidone-2-yl)methyl)-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 46)

[0682] first step:

[0683] Methylsulfonyl chloride (2458.5 mg, 10.345 mmol) was added to a solution of (S)-5-(hydroxymethyl)pyrrolidone-2-one (800 mg, 6.896 mmol) and triethylamine (4187.17 mg, 41.37 mmol) in dichloromethane (20 mL). The mixture was stirred at 30 °C for 2 hours. The solution was concentrated under reduced pressure to give (S)-(5-oxopyrrolidone-2-yl)methylmethanesulfonate (compound 46-1, 910 mg, 50% purity, white solid).

[0684] Step Two:

[0685] To a solution of compound 46-1 (500 mg, 2.716 mmol) and 6-bromobenzo[d]thiazol-2(3H)-one (250 mg, 1.087 mmol) in acetonitrile (50 mL), potassium carbonate (450.05 mg, 3.259 mmol) and potassium iodide (36.07 mg, 0.2173 mmol) were added, and the mixture was stirred at 80 °C for 3 hours. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (DCM / MeOH, 0–10%) to give (S)-6-bromo-3-((5-oxopyrrolidone-2-yl)methyl)benzo[d]thiazol-2(3H)-one (compound 46-2, 150 mg, 30% yield, white solid).

[0686] Step 3:

[0687] To a mixed solution of compound 46-2 (150 mg, 0.4584 mmol) and INT3 (192.32 mg, 0.550 mmol) in N,N-dimethylformamide (20 mL) and water (4 mL), potassium phosphate (194.6 mg, 0.9168 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (39.45 mg, 0.0458 mmol) were added, and the mixture was stirred at 50 °C for 2 hours. The residue was concentrated under reduced pressure and purified by silica gel column chromatography (DCM / MeOH, 0–10%) to give 3-(2-chloro-3-(2-oxo-3-(((S)-5-oxopyrrolidone-2-yl)methyl)-2,3-dihydrobenzo[d]thiazolyl)phenyl)piperidin-2,6-dione (compound 46, 66 mg, yield 44%, white solid), [M+H]+: 469.9.

[0688] 1 H NMR (400MHz, DMSO) δ10.92(s,1H),8.73–7.61(m,2H),7.50(d,J=8.5Hz,1H),7.46–7.30(m,4H),4.35(dd,J=12.1,4.9Hz,1H),4.1 3–3.93(m,3H),2.78(ddd,J=45.7,25.6,19.2Hz,1H),2.64–2.54(m,1H),2.43–2.25(m,2H),2.24–1.99(m,3H),1.95–1.75(m,1H).

[0689] Example 50: Preparation of 3-(2-chloro-3-(3-((((S)-1-methyl-5-oxopyrrolidone-2-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 47)

[0690] first step:

[0691] Methylsulfonyl chloride (2458.5 mg, 10.345 mmol) was added to a solution of (S)-5-(hydroxymethyl)pyrrolidone-2-one (800 mg, 6.896 mmol) and triethylamine (4187.17 mg, 41.37 mmol) in dichloromethane (20 mL). The mixture was stirred at 30 °C for 2 hours. The solution was concentrated under reduced pressure to give (S)-(1-methyl-5-oxopyrrolidone-2-yl)methylmethanesulfonate (compound 47-1, 1000 mg, 75% yield, white solid).

[0692] Step Two:

[0693] To a solution of compound 47-1 (450.36 mg, 2.1731 mmol) and 6-bromobenzo[d]thiazol-2(3H)-one (200 mg, 0.8692 mmol) in acetonitrile (30 mL), potassium carbonate (360.396 mg, 2.6076 mmol) and potassium iodide (28.86 mg, 0.1738 mmol) were added, and the mixture was stirred at 80 °C for 3 hours. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (DCM / MeOH, 0–10%) to give (S)-6-bromo-3-((1-methyl-5-oxopyrrolidone-2-yl)methyl)benzo[d]thiazol-2(3H)-one (compound 47-2, 300 mg, yield 66.67%, white solid).

[0694] Step 3:

[0695] To a mixed solution of compound 47-2 (150 mg, 0.4395 mmol) and INT3 (184.35 mg, 0.5273 mmol) in N,N-dimethylformamide (20 mL) and water (4 mL), potassium phosphate (186.6 mg, 0.8791 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (45 mg, 0.05229 mmol) were added, and the mixture was stirred at 50 °C for 1 hour. The residue was concentrated under reduced pressure, and purified by silica gel column chromatography (DCM / MeOH, 0–10%) to give 3-(2-chloro-3-(3-(((S)-1-methyl-5-oxopyrrolidone-2-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 47, 23.33 mg, yield 15.5%, white solid), [M+H). + :483.9.

[0696] 1 H NMR (400MHz, DMSO) δ10.94(s,1H),7.78(d,J=1.7Hz,1H),7.57(d,J=8.4Hz,1H),7.59–7.28(m,4H),4.35(dd,J=12.2,5.0Hz,1H),4.34–4.15( m,1H),4.18–4.03(m,1H),3.97(d,J=5.5Hz,1H),2.80(s,1H),2.76(d, J=8.0Hz,3H),2.47–2.30(m,2H),2.24–1.97(m,4H),1.90–1.74(m,1H).

[0697] Example 51: Preparation of 3-(2-chloro-3-(2-oxo-3-(2-oxo-1,2-dihydropyridin-3-yl)-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 48)

[0698] first step:

[0699] Potassium carbonate (1.78 g, 12.9 mmol) and potassium iodide (0.14 g, 0.86 mmol) were added to a 20 mL solution of 6-bromobenzo[d]thiazol-2(3H)-one (1 g, 4.3 mmol), 3-fluoro-2-nitropyridine (0.73 g, 5.16 mmol), in acetonitrile. The mixture was stirred at 50 °C for 16 hours. The reaction mixture was filtered, and the filtrate was collected and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 6-bromo-3-(2-nitropyridine-3-yl)benzo[d]thiazol-2(3H)-one (compound 48-1, 1.2 g, yield 72.09%, yellow solid).

[0700] Step Two:

[0701] Iron powder (381.65 mg, 6.82 mmol) and ammonium chloride (368.02 mg, 6.82 mmol) were added to an ethanol / water (10 mL / 10 mL) solution of compound 48-1 (600 mg, 1.7 mmol). The mixture was stirred at 70 °C for 16 hours. The ethanol was removed by vacuum concentration, and the mixture was extracted with ethyl acetate (10 mL * 3). The extract was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to give crude 3-(2-aminopyridin-3-yl)-6-bromobenzo[d]thiazol-2(3H)-one (compound 48-2, 500 mg, yield 81.98%, yellow oil), which was directly used for the next reaction.

[0702] Step 3:

[0703] To a solution of compound 48-2 (500 mg, 1.55 mmol) in acetonitrile (5 mL), 10% sulfuric acid (10 mL) and sodium nitrite (128.5 mg, 1.86 mmol) were added, and the mixture was stirred at room temperature for 16 hours. Water (10 mL) and a saturated sodium carbonate aqueous solution were added to adjust the pH to 7. The mixture was filtered, and the filter cake was collected and dried to give 6-bromo-3-(2-oxo-1,2-dihydropyridin-3-yl)benzo[d]thiazolyl-2(3H)-one (compound 48-3, 190 mg, yield 34.09%, yellow solid).

[0704] Step 4:

[0705] Under nitrogen protection, potassium phosphate (84.99 mg, 0.40 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (25.84 mg, 0.03 mmol) were added to a solution of compound 48-3 (70 mg, 0.20 mmol) and INT3 (77.64 mg, 0.24 mmol) in N,N-dimethylformamide / water (10 mL / 1 mL). The mixture was stirred at 80 °C for 1 hour. Extracted with water (10 mL) and ethyl acetate (10 mL * 3), the organic phase was concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(2-oxo-3-(2-oxo-1,2-dihydropyridin-3-yl)-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 48, 7.53 mg, yield 7.99%, white solid), [M+H + :465.9.

[0706] 1 H NMR (400MHz, DMSO) δ12.34(s,1H),10.92(s,1H),7.90(dd,J=7.1,2.0Hz,1H),7.77(d,J=1.6Hz,1H),7.66(dd,J=6.4,1.9Hz,1H),7.45–7.28(m,4H ),6.83(d,J=8.3Hz,1H),6.41(t,J=6.8Hz,1H),4.35(dd,J=12.1,5.0Hz, 1H), 2.84–2.67 (m, 2H), 2.34 (dt, J=21.3, 10.5Hz, 1H), 2.12–1.99 (m, 1H).

[0707] Example 52: Preparation of 3-(2-chloro-3-(2-oxo-3-(((S)-5-oxopyrrolidone-3-yl)methyl)-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 49)

[0708] first step:

[0709] Triphenylphosphine (1.2 g, 4.8 mmol) and diethyl azodicarbonate (835 mg, 4.8 mmol) were added to a tetrahydrofuran (10 mL) solution of 6-bromobenzo[d]thiazolidin-2(3H)-one (1 g, 4 mmol) and 4-(hydroxymethyl)pyrrolidone-2-one (500 mg, 4 mmol) at 0 °C. The mixture was stirred at room temperature for 3 hours. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to obtain a mixture (700 mg). Then, after chiral preparation and purification, the first peak obtained was (S)-6-bromo-3-((5-oxopyrrolidone-3-yl)methyl)benzo[d]thiazol-2(3H)-one (compound 49-1, 300 mg, yield 43%, white solid), and the second peak was (R)-6-bromo-3-((5-oxopyrrolidone-3-yl)methyl)benzo[d]thiazol-2(3H)-one (compound 49-2, 300 mg, yield 43%, white solid).

[0710] Step Two:

[0711] Potassium phosphate (60 mg, 0.286 mmol) and methanesulfonic acid (2-dimethylformamide (2',4',6'-tri-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (12.3 mg, 0.014 mmol) were added to a mixed solution of N,N-dimethylformamide (2 mL) and water (0.5 mL) of compound 49-1 (42 mg, 0.13 mmol) and INT3 (50 mg, 0.143 mmol). The mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (30 mL * 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(2-oxo-3-(((S)-5-oxopyrrolidone-3-yl)methyl)-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 49, 22.7 mg, yield 34%, white solid), [M+H + :469.9.

[0712] 1H NMR (400MHz, DMSO) δ10.92(s,1H),7.75(d,J=1.7Hz,1H),7.61–7.50(m,2H),7.46–7.30(m,4H),4.35(dd,J=12.2,5.0Hz,1H),4.14–3.97(m,2 H),3.33(dd,J=9.5,7.9Hz,1H),3.07(dd,J=9.8,5.3Hz,1H),2.97–2.74(m,2H),2.56(d,J=3.6Hz,1H),2.38–2.24(m,2H),2.11–1.98(m,2H).

[0713] Example 53: Preparation of 3-(2-chloro-3-(3-((((S)-1-methyl-5-oxopyrrolidone-3-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 50)

[0714] first step:

[0715] Sodium hydride (24 mg, 0.612 mmol) was added to a tetrahydrofuran (10 mL) solution of compound 49-1 (100 mg, 0.306 mmol) at 0 °C, and the mixture was stirred at 0 °C for 0.5 h. Then iodomethane (87 mg, 0.612 mmol) was added, and the mixture was stirred at 0 °C for 1 h, then stirred at room temperature for 2 h. Extraction was performed with ethyl acetate (30 mL * 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give (S)-6-bromo-3-((1-methyl-5-oxopyrrolidone-3-yl)methyl)benzo[d]thiazol-2(3H)-one (compound 50-1, 60 mg, yield 57%, white solid).

[0716] Step Two:

[0717] To a mixed solution of compound 50-1 (44 mg, 0.13 mmol) and INT3 (50 mg, 0.143 mmol) in N,N-dimethylformamide (2 mL) and water (0.5 mL), potassium phosphate (60 mg, 0.286 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (12.3 mg, 0.014 mmol) were added, and the mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (30 mL * 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(3-(((S)-1-methyl-5-oxopyrrolidone-3-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidin-2,6-dione (compound 50, 17.5 mg, yield 25%, white solid), [M+H] + :483.9.

[0718] 1 H NMR(400MHz,DMSO)δ10.93(s,1H),7.76(d,J=1.7Hz,1H),7.56(d,J=8.4Hz,1H), 7.44–7.37(m,3H),7.36–7.32(m,1H),4.35(dd,J=12.2,5.1Hz,1H),4.12–3.99( m,2H),3.41(s,1H),3.17(dd,J=9.8,5.4Hz,1H),2.82(ddd,J=17.4,13.6,7.1Hz ,2H),2.71(s,3H),2.56(d,J=3.7Hz,1H),2.44–2.31(m,2H),2.18–1.99(m,2H).

[0719] Example 54: Preparation of 3-(2-chloro-3-(2-oxo-3-(((R)-5-oxopyrrolidone-3-yl)methyl)-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 51)

[0720] Potassium phosphate (60 mg, 0.286 mmol) and methanesulfonic acid (2-dimethylformamide (2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (12.3 mg, 0.014 mmol) were added to a mixed solution of N,N-dimethylformamide (2 mL) and water (0.5 mL) of compound 49-2 (42 mg, 0.13 mmol) and INT3 (50 mg, 0.143 mmol). The mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (30 mL * 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(2-oxo-3-(((R)-5-oxopyrrolidone-3-yl)methyl)-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 51, 21.2 mg, yield 33%, white solid), [M+H + :470.0.

[0721] 1 H NMR (400MHz, DMSO) δ10.92(s,1H),7.75(d,J=1.7Hz,1H),7.63–7.50(m,2H),7.38(dddd,J=14.9,9.2,6.4,3.1Hz,4H),4.35(dd,J=12.2,5.0Hz,1H),4.1 1–4.00(m,2H),3.33(dd,J=9.4,7.9Hz,1H),3.07(dd,J=9.7,5.4Hz,1H),2.9 9–2.75(m,2H),2.56(d,J=3.7Hz,1H),2.39–2.24(m,2H),2.10–1.98(m,2H).

[0722] Example 55: Preparation of 3-(2-chloro-3-(3-(((R)-1-methyl-5-oxopyrrolidone-3-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 52)

[0723] first step:

[0724] Sodium hydride (24 mg, 0.612 mmol) was added to a tetrahydrofuran (10 mL) solution of compound 49-2 (100 mg, 0.306 mmol) at 0 °C, and the mixture was stirred at 0 °C for 0.5 h. Then iodomethane (87 mg, 0.612 mmol) was added, and the mixture was stirred at 0 °C for 1 hour, then stirred at room temperature for 2 hours. Extraction was performed with ethyl acetate (30 mL * 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give (R)-6-bromo-3-((1-methyl-5-oxopyrrolidone-3-yl)methyl)benzo[d]thiazol-2(3H)-one (compound 52-1, 60 mg, 57% yield, white solid).

[0725] Step Two:

[0726] To a mixed solution of compound 52-1 (44 mg, 0.13 mmol) and INT3 (50 mg, 0.143 mmol) in N,N-dimethylformamide (2 mL) and water (0.5 mL), potassium phosphate (60 mg, 0.286 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (12.3 mg, 0.014 mmol) were added, and the mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (30 mL * 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 3-(2-chloro-3-(3-(((R)-1-methyl-5-oxopyrrolidone-3-yl)methyl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidin-2,6-dione (compound 52, 22.4 mg, yield 32%, white solid), [M+H] + :483.9.

[0727] 1H NMR (400MHz, DMSO) δ10.93(s,1H),7.76(d,J=1.7Hz,1H),7.56(d,J=8.4Hz,1H),7.45–7.31(m,4H),4.35(dd,J=12.2,4.9Hz,1H),4.14–3.99(m,2H),3 .44(dd,J=9.7,7.9Hz,1H),3.17(dd,J=9.8,5.4Hz,1H),2.92–2.76(m,2H) ,2.71(s,3H),2.56(d,J=3.6Hz,1H),2.45–2.30(m,2H),2.18–1.94(m,2H).

[0728] Example 56: Preparation of 2-(6-(2-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)yl)phenyl)-2-oxobenzo[d]thiazolyl-3(2H)-yl)-N,N-dimethylacetamide (compound 53)

[0729] first step:

[0730] A mixed solution of compound 15-1 (520 mg, 0.152 mmol), bis(boron) (4190 mg, 16.5 mmol), 1,1'-bis(diphenylphosphine)ferrocene]palladium(II) dichloride (118 mg, 0.165 mmol) and potassium acetate (486 mg, 4.95 mmol) in 1,4-dioxane (20 mL) was stirred for 3 hours under nitrogen protection at 95 °C. Extracted with ethyl acetate (30 mL * 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to obtain N,N-dimethyl-2-(2-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborane-2-yl)benzo[d]thiazo-3(2H)-yl)acetamide (compound 53-1, 350 mg, yield 75.74%, white solid).

[0731] Step Two:

[0732] 3-Bromo-2-chloroaniline (2 g, 9.7 mmol) was dissolved in toluene (30 mL), and acrylic acid (3.5 g, 48.5 mmol) was added. The mixture was stirred at 110 °C for 16 hours. After cooling to room temperature, the solution was concentrated under reduced pressure to give crude 3-((3-bromo-2-chlorophenyl)amino)propionic acid (compound 53-2, 1.7 g, yield 63.3%, brown oil), which was used directly in the next reaction.

[0733] Step 3:

[0734] Compound 53-2 (1.7 g, 6.1 mmol) was dissolved in acetic acid (30 mL), and urea (3.66 g, 61 mmol) was added. The mixture was stirred at 120 °C for 16 hours. The mixture was extracted with ethyl acetate (30 mL x 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 1-(3-bromo-2-chlorophenyl)dihydropyrimidine-2,4(1H,3H)-dione (compound 53-3, 1.1 g, yield 59.02%, yellow solid).

[0735] Step 4:

[0736] Potassium phosphate (168 mg, 0.791 mmol) and methanesulfonic acid (2-dimethylformamide (2'-methylamino-1,1'-biphenyl) (2'-biphenyl-2-yl)palladium(II) (23 mg, 0.026 mmol) were added to a mixed solution of compound 53-3 (80 mg, 0.264 mmol) and compound 53-1 (96 mg, 0.264 mmol) in N,N-dimethylformamide (2 mL) and water (0.5 mL). The mixture was stirred at 50 °C for 1 hour under nitrogen protection. Extracted with ethyl acetate (30 mL x 3), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to obtain 2-(6-(2-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)yl)phenyl)-2-oxobenzo[d]thiazolyl-3(2H)-yl)-N,N-dimethylacetamide (compound 53, 46.6 mg, yield 37.67%, white solid), [M+H). + :459.0.

[0737] 1 H NMR (400MHz, DMSO) δ10.49(s,1H),7.77(d,J=1.7Hz,1H),7.55–7.48(m,2H),7.42(ddd,J=15.8,7.9,1.9Hz,2H),7.32(d,J= 8.4Hz,1H),4.94(s,2H),3.81–3.74(m,1H),3.67(d,J=6.3Hz,1H),3.13(s,3H),2.88(s,3H),2.76(dd,J=10.4,4.2Hz,2H).

[0738] Example 57: Preparation of 3-(2-chloro-3-(2-oxo-3-(6-oxo-1,6-dihydropyridin-2-yl)-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidine-2,6-dione (compound 54)

[0739] first step:

[0740] To a solution of 6-bromobenzo[d]thiazol-2(3H)-one (1500 mg, 6.52 mmol) in N,N-dimethylformamide (15 mL), 2,6-difluoro-3-nitropyridine (1145 mg, 7.17 mmol) and cesium carbonate (4251 mg, 13.03 mmol) were added, and the reaction mixture was stirred at 80 °C for 3 hours. The mixture was diluted with water (50 mL), extracted with ethyl acetate (50 mL x 3), and the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain crude 6-bromo-3-(6-fluoro-5-nitropyridine-2-yl)benzo[d]thiazol-2(3H)-one (compound 54-1, 2.5 g, yellow solid), which was used directly in the next step.

[0741] Step Two:

[0742] Potassium carbonate (1118 mg, 8.10 mmol) was added to a tetrahydrofuran / water (15 mL / 15 mL) solution of compound 54-1 (2500 mg, 4.05 mmol), and the mixture was stirred at room temperature for 12 hours. The solution was diluted with water (20 mL), extracted with ethyl acetate (20 mL x 2), and the organic phases were combined, dried over anhydrous sodium sulfate, and the organic phase was concentrated. The crude product was purified by a reverse-phase system to give 6-bromo-3-(6-hydroxy-5-nitropyridin-2-yl)benzo[d]thiazolyl-2(3H)-one (compound 54-2, 500 mg, yellow solid).

[0743] Step 3:

[0744] Reduced iron powder (303 mg, 5.43 mmol) and ammonium chloride (291 mg, 5.44 mmol) were added to an ethanol / water (8 mL / 2 mL) solution of compound 54-2 (500 mg, 1.36 mmol). The reaction solution was stirred at 75 °C for 4 hours. The solution was diluted with water (50 mL), extracted with ethyl acetate (50 mL * 3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc, 0–50%) to give 3-(5-amino-6-oxo-1,6-dihydropyridin-2-yl)-6-bromobenzo[d]thiazol-2(3H)-one (compound 54-3, 320 mg, yield 69.67%, off-white solid).

[0745] Step 4:

[0746] Compound 54-3 (240 mg, 0.710 mmol) was dissolved in acetonitrile (1 mL). The reaction system was cooled to 0 °C, and sulfuric acid (1 mL, 25% w / w, aq.) and sodium nitrite (98 mg, 1.42 mmol, dissolved in 0.5 mL of water) were added dropwise to the reaction system. The mixture was stirred at room temperature for 4 hours. The solution was diluted with water (10 mL), and the aqueous phase was purified by extraction with methyl tert-butyl ether (10 mL * 3). After removing residual organic solvents by concentration under reduced pressure, the pH of the system was adjusted to 10 by adding saturated sodium carbonate aqueous solution, and then extracted with ethyl acetate (10 mL * 3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was dissolved in methanol (5 mL), and saturated sodium carbonate aqueous solution (5 mL) was added dropwise. The mixture was stirred at room temperature for 1 hour. Dilute with water (50 mL), extract with ethyl acetate (50 mL * 3), combine the organic phases, dry with anhydrous sodium sulfate, concentrate under reduced pressure, and purify the residue by silica gel column chromatography (PE / EtOAc, 0–50%) to give 6-bromo-3-(6-oxo-1,6-dihydropyridin-2-yl)benzo[d]thiazol-2(3H)-one (compound 54-4, 50 mg, yield 21.8%, off-white solid).

[0747] Step 5:

[0748] To a solution of compounds 54-4 (50 mg, 0.155 mmol) and INT3 (65 mg, 0.186 mmol) in N,N-dimethylformamide / water (5 mL / 0.2 mL), methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (13.3 mg, 3.1 μmol) and tripotassium phosphate (19.5 mg, 0.0155 mmol) was added, and the mixture was stirred at 80 °C for 30 minutes under nitrogen protection. Dilute with water (10 mL), extract with ethyl acetate (10 mL * 3), combine the organic phases, dry to anhydrous sodium sulfate, concentrate under reduced pressure, and preparatively chromatographically analyze the residue by high performance liquid chromatography to obtain 3-(2-chloro-3-(2-oxo-3-(6-oxo-1,6-dihydropyridin-2-yl)-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 54, 10.7 mg, yield 14.84%, white solid), [M+H] + :466.0.

[0749] 1H NMR (400MHz, DMSO-d6) δ10.93(s,1H),7.93(t,J=7.9Hz,1H),7.80(d,J=1.6Hz,1H),7.44–7.31(m,4H),7.12(d,J=7.2Hz,1H),7.07(d,J=8. 4Hz,1H),6.82(d,J=8.0Hz,1H),4.35(dd,J=12.2,5.0Hz,1H),2.85–2.74(m,1H),2.68–2.54(m,1H),2.40–2.89(m,1H),2.10–2.00(m,1H).

[0750] Example 58: Preparation of 3-(2-chloro-3-(2-oxo-3-((S)-5-oxopyrrolidone-3-yl)-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidine-2,6-dione (compound 55)

[0751] first step:

[0752] Under nitrogen protection, diisopropyl azodicarbonate (5.82 g, 28.8 mmol) was added dropwise to a tetrahydrofuran (70 mL) solution of 6-bromobenzo[d]thiazol-2(3H)-one (2.2 g, 9.6 mmol), (R)-4-hydroxypyrrolidone-2-one (2.91 g, 28.8 mmol), and triphenylphosphine (7.55 g, 28.8 mmol). The mixture was stirred at 60 °C for 12 hours. The reaction mixture was cooled, and the solvent was removed by rotary evaporation. The residue was purified by silica gel column chromatography (DCM / MeOH, 0–10%) to give (S)-6-bromo-3-(5-oxopyrrolidone-3-yl)benzo[d]thiazol-2(3H)-one (compound 55-1, 0.9 g, yield 19.8%, pale yellow solid).

[0753] Step Two:

[0754] To a mixed solution of compound 55-1 (120 mg, 0.38 mmol), INT3 (201 mg, 0.57 mmol), N,N-dimethylformamide (10 mL), and water (2.5 mL), potassium phosphate (163 mg, 0.77 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (33 mg, 0.038 mmol) were added, and the mixture was stirred at 50 °C for 1 hour under nitrogen protection. Dilute with water (30 mL), extract with ethyl acetate (10 mL * 3), combine the organic phases and wash with saturated brine (30 mL), dry with anhydrous sodium sulfate, filter, concentrate under reduced pressure, and purify the residue by high-performance liquid chromatography to obtain 3-(2-chloro-3-(2-oxo-3-((S)-5-oxopyrrolidine-3-yl)-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 55, 2.1 mg, yield 1.17%, white solid), [M+H] + :456.0.

[0755] 1 H NMR (400MHz, DMSO) δ10.94(s,1H),7.96(s,1H),7.77(s,1H),7.42(d,J=5.7Hz,2H),7.39(dd,J=6.4,4.2Hz,1H),7.33(dd,J=7.0,2.2Hz,1H ), 5.50 (s, 1H), 4.37–4.32 (m, 1H), 3.72 (t, J = 9.8Hz, 2H), 3.58 (dd, J = 10.2, 5.7Hz, 2H), 2.73 (dd, J = 17.2, 6.8Hz, 2H), 2.07 (d, J = 8.4Hz, 2H).

[0756] Example 59: Preparation of 3-(2-chloro-3-(2-oxo-3-((R)-5-oxopyrrolidine-3-yl)-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 56)

[0757] first step:

[0758] Under nitrogen protection, diisopropyl azodicarbonate (7.71 g, 38.15 mmol) was added dropwise to a tetrahydrofuran (30 mL) solution of 6-bromobenzo[d]thiazol-2(3H)-one (2.5 g, 10.91 mmol), (S)-4-hydroxypyrrolidone-2-one (2.91 g, 28.8 mmol), and triphenylphosphine (5.33 g, 32.7 mmol). The mixture was stirred at 60 °C for 12 hours. The reaction mixture was cooled, and the solvent was removed by rotary evaporation. The residue was purified by C18 reversed-phase column chromatography to give (R)-6-bromo-3-(5-oxopyrrolidone-3-yl)benzo[d]thiazol-2(3H)-one (compound 56-1, 0.15 g, yield 4.59%, yellow solid).

[0759] Step Two:

[0760] To a mixed solution of compound 56-1 (50 mg, 0.15 mmol), INT3 (111.5 mg, 0.30 mmol), N,N-dimethylformamide (4 mL), and water (1 mL), potassium phosphate (67.73 mg, 0.30 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (13.73 mg, 0.015 mmol) were added, and the mixture was stirred at 50 °C for 1 hour under nitrogen protection. Dilute with water (30 mL), extract with ethyl acetate (10 mL * 3), combine the organic phases and wash with saturated brine (30 mL), dry to anhydrous sodium sulfate, filter, concentrate under reduced pressure, and purify the residue by high-performance liquid chromatography to obtain 3-(2-chloro-3-(2-oxo-3-((R)-5-oxopyrrolidine-3-yl)-2,3-dihydrobenzo[d]thiazo-6-yl)phenyl)piperidin-2,6-dione (compound 56, 2.1 mg, yield 17.17%, white solid), [M+H] + :456.0.

[0761] 1H NMR (400MHz, DMSO) δ10.94(s,1H),7.96(s,1H),7.77(s,1H),7.42(d,J=5.4H z,2H),7.40–7.36(m,1H),7.33(dd,J=7.0,2.1Hz,1H),5.50(dd,J=15.9,9.9 ,6.4Hz,1H),4.35(dd,J=12.2,5.0Hz,1H),3.72(t,J=9.7Hz,1H),3.58(dd,J =10.2,5.6Hz,1H),2.83–2.59(m,4H),2.38–2.26(m,1H),2.09–2.01(m,1H).

[0762] Example 60: Preparation of 3-(2-chloro-3-(3-((S)-1-methyl-5-oxopyrrolidone-3-yl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 57)

[0763] first step:

[0764] Iodomethane (634 mg, 4.47 mmol) was added to a solution of compound 55-1 (140 mg, 0.45 mmol) and cesium carbonate (728 mg, 2.24 mmol) in N,N-dimethylformamide (10 mL) at room temperature, and the mixture was stirred at 50 °C for 12 hours. The mixture was concentrated under reduced pressure, and the residue was purified by C18 reverse-phase column chromatography to give (S)-6-bromo-3-(1-methyl-5-oxopyrrolidone-3-yl)benzo[d]thiazolyl-2(3H)-one (compound 57-1, 33 mg, yield 22.33%, white solid).

[0765] Step Two:

[0766] Under nitrogen protection, potassium phosphate (36 mg, 0.17 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (7 mg, 0.009 mmol) were added to a mixed solution of N,N-dimethylformamide (4 mL) and water (1 mL) of compound 57-1 (28 mg, 0.09 mmol) and INT3 (90 mg, 0.26 mmol). The mixture was stirred at 50 °C for 1 hour under nitrogen protection. Dilute with water (20 mL), extract with ethyl acetate (10 mL * 3), combine the organic phases and wash with saturated brine (30 mL), dry to anhydrous sodium sulfate, filter, concentrate under reduced pressure, and purify the residue by high-performance liquid chromatography to obtain 3-(2-chloro-3-(3-((S)-1-methyl-5-oxopyrrolidine-3-yl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidin-2,6-dione (compound 57, 6.5 mg, yield 16.0%, white solid), [M+H + :470.0.

[0767] 1 H NMR (400MHz, DMSO) δ10.93(s,1H),7.77(d,J=1.7Hz,1H),7.37(tdd,J=9.2,8.5,2.0Hz,5H),5.49–5.36(m,1H),4.35(dd,J=12.2,5.0Hz, 1H),3.81(t,J=9.9Hz,1H),3.68(dd,J=10.5,5.1Hz,1H),2.87–2.72(m,6H),2.56(d,J=3.7Hz,1H),2.37–2.30(m,1H),2.10–1.99(m,1H).

[0768] Example 61: Preparation of 3-(2-chloro-3-(3-((R)-1-methyl-5-oxopyrrolidone-3-yl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidine-2,6-dione (compound 58)

[0769] first step:

[0770] Iodomethane (453.41 mg, 3.19 mmol) was added to a solution of compound 56-1 (100 mg, 0.32 mmol) and cesium carbonate (520.46 mg, 1.59 mmol) in N,N-dimethylformamide (5 mL) at room temperature. The mixture was stirred at 50 °C for 12 hours. The mixture was concentrated under reduced pressure, and the residue was purified by C18 reverse-phase column chromatography to give (R)-6-bromo-3-(1-methyl-5-oxopyrrolidone-3-yl)benzo[d]thiazol-2(3H)-one (compound 58-1, 20 mg, yield 19.14%, white solid).

[0771] Step Two:

[0772] Under nitrogen protection, potassium phosphate (25.91 mg, 0.12 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tris-isopropyl-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (5.25 mg, 0.0061 mmol) were added to a mixed solution of N,N-dimethylformamide (4 mL) and water (1 mL) of compound 58-1 (20 mg, 0.061 mmol) and INT3 (53.4 mg, 0.15 mmol). The mixture was stirred at 50 °C for 1 hour under nitrogen protection. Dilute with water (20 mL), extract with ethyl acetate (10 mL * 3), combine the organic phases and wash with saturated brine (30 mL), dry with anhydrous sodium sulfate, filter, concentrate under reduced pressure, and purify the residue by high-performance liquid chromatography to obtain 3-(2-chloro-3-(3-((R)-1-methyl-5-oxopyrrolidine-3-yl)-2-oxo-2,3-dihydrobenzo[d]thiazolyl-6-yl)phenyl)piperidin-2,6-dione (compound 58, 5.64 mg, yield 19.48%, white solid), [M+H] + :470.0.

[0773] 1 H NMR (400MHz, DMSO) δ10.94(s,1H),7.77(d,J=1.7Hz,1H),7.47–7.25(m,5H),5.43(dt,J=14.1,8.8Hz,1H),4.35(dd,J=12.2,5.0Hz,1 H),3.81(t,J=9.9Hz,1H),3.68(dd,J=10.5,5.1Hz,1H),2.84–2.74(m,6H),2.59–2.54(m,1H),2.37–2.27(m,1H),2.08–2.00(m,1H).

[0774] Example 1: Detection of the degradation ability of the compound on VAV1-HiBiT in Jurkat_KI_VAV1-HiBiT cells

[0775] This embodiment aims to establish an in vitro detection method based on endogenous marker cell lines to evaluate the degradation ability of compounds on VAV1-HiBiT fusion protein in Jurkat_KI_VAV1-HiBiT cells, and to provide a standardized scheme for screening degrading agents targeting VAV1 protein.

[0776] Cell Culture and Inoculation

[0777] The Jurkat_KI_VAV1-HiBiT_sc cell line, containing an endogenous VAV1 gene C-terminus fused with a HiBiT tag, was retrieved from the cell bank. It was cultured in RPMI 1640 complete medium supplemented with 10% fetal bovine serum (FBS, Gibco) and 1% penicillin-streptomycin (pH 7.4). When the cells were in the logarithmic growth phase, the cell density was adjusted to 5 × 10⁶ cells / year using this medium. 5 cells / mL. Using a multichannel pipette (Eppendorf), cells were seeded at a rate of 45 μL / well into 384-well white clear-bottom cell culture plates (Greiner, catalog number 781090), approximately 2500 cells per well. The culture plates were incubated overnight at 37°C with 5% CO2 to allow the cells to adhere.

[0778] Compound treatment

[0779] Concentration gradient preparation: A 10 mM stock solution of the analyte in DMSO was prepared and removed from a -20°C freezer. The 10 mM stock solution was then serially diluted 3-fold using dimethyl sulfoxide (DMSO, Sigma) to generate 10 concentration gradients starting from 10 μL. The final concentration of DMSO in subsequent experiments was less than or equal to 0.25% (v / v). Two replicates were set up for each concentration.

[0780] Sample addition and incubation: Carefully discard the culture medium from the wells using a pipette. Then, using a multichannel pipette (Eppendorf), add 45 μL of RPMI 1640 complete medium containing different concentrations of compounds to each well. This medium is 0.25% DMSO. An equal volume of RPMI 1640 complete medium containing 0.25% DMSO was added to the control group. After sealing the culture plates, incubate them at 37°C and 5% CO2 for 24 hours.

[0781] Detection of light emission signals

[0782] according to Following the instructions for the HiBiT luminescent assay kit (Promega, catalog number N3050), mix the HiBiT substrate and detection buffer at a ratio of 1:100. Equilibrate the mixture at room temperature for 30 minutes. Using a multichannel pipette (Eppendorf), add 45 μL of the working solution to each well and gently agitate the culture plate to mix. After incubating at room temperature for 10 minutes, measure the luminescence intensity (RLU, relative emission unit) using a microplate reader (Envision, PerkinElmer, detection wavelength >400 nm). Record the emission signal at an excitation wavelength of 365 nm.

[0783] Data processing and analysis

[0784] Signal values ​​from blank wells (wells in 384-well plates containing cell-free RPMI 1640 complete medium) and negative control wells (wells treated with 0.25% DMSO) were subtracted, and the corrected RLU value was calculated using the formula "Corrected RLU = Experimental Group RLU - Blank Well RLU". Wells treated with PBS (Gibco) were used as the control group, and the degradation rate was calculated using the formula "Degradation Rate (%) = (1 - Corrected Experimental Group RLU / Corrected Control Group RLU) × 100%". A four-parameter logistic regression was performed on the concentration-degradation rate data using GraphPad Prism software to calculate the half-maximum degradation concentration (DC). 50 (Unit: nM)

[0785] The degradation results of VAV1-HiBiT protein in HiBiT cells are described below.

[0786] Table 1. Degradation results of VAV1-HiBiT protein by some exemplary compounds of this application.

[0787] It should be understood that the above embodiments are exemplary and are not intended to encompass all possible implementations included in the claims. Various modifications and changes can be made to the above embodiments without departing from the scope of this disclosure. Similarly, the various technical features of the above embodiments can be arbitrarily combined to form other embodiments of the present invention that may not be explicitly described. Therefore, the above embodiments only illustrate several implementations of the present invention and do not limit the scope of protection of this patent.

Claims

1. A compound of formula (I) or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives, and pharmaceutically acceptable salts thereof. in, X 1 X 2 X 3 X 4 X 5 Each is independently selected from C(R) s 2. NR s , C(=O), S, O, SO and SO2; Each time it appears, R s Each is independently selected from hydrogen, deuterium, and C. 1-6 Alkyl, C 1-6 Halogenated alkyl and C 1-6 Alkoxy; X 6 Selected from C, N, and S; R 1 Selected from non-existent, hydrogen, deuterium, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl and C 1-6 Alkoxy; Ring A is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 heteroaryl groups; Each time it appears, R A Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. u Replaced; Ring B is selected from bond, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 heteroaryl groups; Each time it appears, R B Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. B-1 Replaced; Or, each time it occurs, two Rs B And the atoms bonded to them together form C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 membered heteroaryl, the C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 The aryl and 5-16 heteroaryl groups are each independently bounded by one or more R groups. B-1 Replaced; Each time it appears, R B-1 Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. u Replaced; L 1 Selected from key, -(C=O)-, -S-, -S(=O)-, -S(=O)2-, -S(O)(NR)-, -SC 1-4 alkylene-, -C 1-4 Alkylenes -S-, -O-, -OC 1-4 alkylene-, -C 1-4 Alkylenes -O-, -NR'-, -NR'(C=O)-, -NR'-C 1-4 alkylene-, -C 1-4 Alkylene-NR'-, -C 1-4 Alkylene -C(=O)-, -C(=O)-C 1-4 Alkylene-, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1a Replaced; at the same time, the -SC 1-4 alkylene-, -C 1-4 Alkylene-S-, -OC 1-4 alkylene-, -C 1-4 Alkylene-O-, -NR'-C 1-4 alkylene-, -C 1-4 Alkylene-NR'-, -C 1-4 Alkylene -C(=O)-, -C(=O)-C 1-4 Alkylene-, C 1-6 Alkylene, C 2-6 imide and C 2-6 One or more methylene, vinylene, or ethynyl groups in the ethynyl group are each independently separated by -Cy x -, -O-, -C(O)-, -C(S)-, -CR2-, -CF2, -CRF-, -CR(OR)-, -NR-, -C(NR)-, -S-, -S(O), -S(O)2, -S(O)(NR)- and -CR=CR- substitutions; Each time -Cy appears x - Each is independently selected from C 6-16 Aryl, 5-16 heteroaryl, C 3-12 cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. u replace; Each time it appears, R is independently selected from hydrogen, C, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 membered heteroaryl, the C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 heteroaryl groups are affected by one or more R groups. u replace; Alternatively, two R atoms and the atoms bonded to them together form C. 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 membered heteroaryl, the C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 heteroaryl groups are affected by one or more R groups. u replace; Each time L appears 1a Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, P(=O)R c R d -S(=O)(=NR) c )R b -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1b Replaced; Or, each time it appears, two or more L 1a Together with the atoms bonded to them, they form C. 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1b Replaced; Each time L appears 1b Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1c Replaced; Each time L appears 1c Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1d Replaced; Each time L appears 1d Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d ; L 2 Selected from bonds, hydrogen, C 1-6 Alkyl, -C(=O)NR c R d C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein -C(=O)NR c R d C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2a Replaced; Each time L appears 2a Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2b Replaced; Or, each time it appears, two or more L 2a Together with the atoms bonded to them, they form C. 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2b Replaced; Each time L appears 2b Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2c Replaced; Each time L appears 2c Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2d Replaced; Each time L appears 2d Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d ; Each time it appears, R' is independently selected from hydrogen, deuterium, and C. 1-6 alkyl; Each time it appears, R u Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -C 1-6 Alkyl-(6-10)aryl, -C 1-6 Alkyl-(5-14 quinary)heteroaryl, -C 1-6 Alkyl-C 3-12 cycloalkyl, -C 1-6 Alkyl-(3-12-membered) heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. x replace; Or, each time it occurs, two or more R u And the atoms bonded to them form C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl groups and 3-12 membered heterocyclic groups are separated by one or more R groups x replace; Each time it appears, R x Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -SR b -SC(=O)R a -C(=O)SR a -OC(=O)OR b -OC(=O)R a -C(=O)OR b -S(=O)R a -S(=O)2R a -S(=O)2OR b -S(=O)2NR c R d -NR c R d -NR c S(=O)2R a -NR c S(=O)R a -NR c S(=O)2OR b -NR c S(=O)2NR c R d -NR c C(=O)NR c R d -NR c C(=O)R a -NR c C(=O)OR b -OR b -OS(=O)2R a -OS(=O)2OR b -OS(=O)2NR c R d -OC(=O)NR c R d -OC(=O)NR c R d -C(=O)R a -C(=O)OR b and -C(=O)NR c R d The amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. y replace; Each time it appears, R a Each is independently selected from hydrogen and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. y replace; Each time it appears, R b Each is independently selected from hydrogen and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. y replace; Each time it appears, R c R d Each is independently selected from hydrogen and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. y replace; Or, each time it appears, R c and R d And the atoms attached to them form (3-12) heterocyclic groups or (5-12) heteroaryl groups, said heterocyclic groups and heteroaryl groups being bonded by one or more R y replace; Each time it appears, R y Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. z replace; Each time it appears, R z Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-10 Aryl, 5-14 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups; m is selected from 0, 1, 2, 3, 4, 5, and 6; n is selected from 0, 1, 2, 3, 4, 5, and 6.

2. The compound of formula (I) according to claim 1, or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives, and pharmaceutically acceptable salts, characterized in that, The X 1 and X 3 Each is independently selected from C (=O), S, O, SO and SO2; Preferably, the X 1 and X 3 Each is independently selected from C (=O).

3. The compound of formula (I) according to claim 1 or 2, or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives, and pharmaceutically acceptable salts, characterized in that, The X 2 Selected from NR s , C(=O), S, O, SO and SO2; Preferably, the X 2 Selected from NR s ; More preferably, the X 2 Selected from NH.

4. The compound of formula (I) according to any one of claims 1-3, or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives, and pharmaceutically acceptable salts, characterized in that, The X 4 and X 5 Each is independently selected from C(R) s )2, C(=O), S, O, SO and SO2; Preferably, the X 4 and X 5 Each is independently selected from C(R) s )2; More preferably, the X 4 and X 5 Each is independently selected from CH2.

5. The compound of formula (I) according to any one of claims 1-4, or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives, and pharmaceutically acceptable salts, characterized in that, The X 6 Selected from C.

6. The compound of formula (I) according to any one of claims 1-5, or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives, and pharmaceutically acceptable salts, characterized in that, The R 1 Selected from non-existent, H, D, halogen, amino, hydroxyl and C 1-6 alkyl; Preferably, the R 1 Selected from non-existent, H, D, halogen, hydroxyl, and amino groups; More preferably, the R 1 Selected from non-existent, H, D and halogens; Most preferably, the R 1 Selected from non-existent and H.

7. The compound of formula (I) according to any one of claims 1-6, or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives, and pharmaceutically acceptable salts, characterized in that, The compound has a structure as shown in formula (II): Among them, ring A, ring B, and R A R B L 1 L 2 m and n are as defined in any one of claims 1-5.

8. The compound of formula (I) according to any one of claims 1-7, or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives, and pharmaceutically acceptable salts, characterized in that, Ring A is selected from C. 6-16 Aryl and 5-16 heteroaryl groups; Preferably, ring A is selected from C. 6-14 Aryl and 6-10 heteroaryl groups; More preferably, the ring A is selected from...

9. The compound of formula (I) according to any one of claims 1-8, or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives, and pharmaceutically acceptable salts, characterized in that, Each time it occurs, the R A Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups; Preferably, each time R occurs, A Each is independently selected from hydrogen, oxo group, halogen, and C. 1-6 Halogenated alkoxy groups; More preferably, each time it occurs, the R A Each is independently selected from hydrogen, oxo group, halogen, and C. 1-3 Halogenated alkoxy groups; Most preferably, each time R occurs, A Each is independently selected from hydrogen, oxo group, Cl and difluoromethoxy group.

10. The compound of formula (I) according to any one of claims 1-9, or a stereoisomer, tautomer, solvate, hydrate, prodrug, stable isotopic derivative, or pharmaceutically acceptable salt thereof, characterized in that, The ring B is selected from bonds, C 3-8 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-16 Aryl and 5-16 heteroaryl groups; Preferably, the ring B is selected from bonds, C 5-8 cycloalkyl, C 6-10 Aryl, 5-10-membered heteroaryl and 5-10-membered heterocyclic group, wherein the 5-10-membered heteroaryl and 5-10-membered heterocyclic group contain 1-4 heteroatoms, wherein the heteroatoms are selected from N, O and S; More preferably, the ring B is selected from bonds, 11. The compound of formula (I) according to any one of claims 1-10, or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives, and pharmaceutically acceptable salts, characterized in that, Each time it occurs, the R B Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the amino group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more R groups. B-1 Replaced; Preferably, each time R occurs, B Each is independently selected from hydrogen, oxo group, amino group, and C. 1-6 Alkyl groups, wherein the amino group and C 1-6 Alkyl groups are each independently bound by one or more R B-1 Replaced; More preferably, each time it occurs, the R B Each is independently selected from hydrogen, oxo group, amino group, and C. 1-3 Alkyl groups, wherein the amino group and C 1-3 Alkyl groups are each independently bound by one or more R B-1 Replaced; Most preferably, each time R occurs, B Each group is independently selected from hydrogen, oxo, amino, and methyl, wherein each amino and methyl group is independently converted by one or more R groups. B-1 What it replaced.

12. The compound of formula (I) according to any one of claims 1-11, or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives, and pharmaceutically acceptable salts, characterized in that, Each time it occurs, the R B-1 Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups; Preferably, each time R occurs, B-1 Each group is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, and amino groups; More preferably, each time it occurs, the R B-1 Each is independently selected from hydrogen.

13. The compound of formula (I) according to any one of claims 1-12, or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives, and pharmaceutically acceptable salts, characterized in that, The L 1 Selected from key, -(C=O)-, -S-, -S(=O)-, -S(=O)2-, -S(O)(NR)-, -SC 1-4 alkylene-, -C 1-4 Alkylenes -S-, -O-, -OC 1-4 alkylene-, -C 1-4 Alkylenes -O-, -NR'-, -NR'(C=O)-, -NR'-C 1-4 alkylene-, -C 1-4 Alkylene-NR'-, -C 1-4 Alkylene -C(=O)-, -C(=O)-C 1-4 Alkylene-, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 1a Replaced; Preferably, the L 1 Selected from key, -O-, -OC 1-4 Alkylene-, -NR'-, -C 1-6 alkylene-NH- and C 1-6 Alkylene, the C 1-6 Each alkylene group is independently bounded by one or more L 1a Replaced; More preferably, the L 1 Selected from key, -O-, -OC 1-3 Alkylene-, -NR'-, -C 1-3 alkylene-NH- and C 1-3 Alkylene, the C 1-3 Each alkylene group is independently bounded by one or more L 1a Replaced; Most preferably, the L 1 Selected from the group consisting of -O-, -O-CH2-, -NH-, -CH2-NH-, methylene, ethylene, and propylene, wherein each of the methylene, ethylene, and propylene groups is independently bound by one or more L- groups. 1a What it replaced.

14. The compound of formula (I) according to any one of claims 1-13, or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives, and pharmaceutically acceptable salts, characterized in that, Each time L appears, 1a Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, -NR c R d -SR b -S(=O)R a -S(=O)2R a -P(=O)R c R d -OS(=O)2R a -NR c C(=O)R a -NR c C(=O)OR b -S(=O)(=NR) c )R b and -OC(=O)NR c R d ; Preferably, each time L occurs, 1a Each is independently selected from hydrogen, hydroxyl, amino, oxo group, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, -NR c R d -SR b -S(=O)R a -S(=O)2R a -P(=O)R c R d -OS(=O)2R a -NR c C(=O)R a -NR c C(=O)OR b -S(=O)(=NR) c )R b and -OC(=O)NR c R d ; More preferably, each time L occurs, 1a Each is independently selected from hydrogen, hydroxyl, amino, oxo group, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, -NR c R d -SR b -S(=O)R a -S(=O)2R a -P(=O)R c R d -OS(=O)2R a -NR c C(=O)R a -NR c C(=O)OR b -S(=O)(=NR) c )R b and -OC(=O)NR c R d ; Most preferably, each time L occurs, 1a Each is independently selected from hydrogen, hydroxyl, amino, oxo, methyl, trifluoromethyl, methoxy, N(CH3)2, NH(CH3), SH, SCH3, S(O)CH3, S(=O)2CH3, S(=O)2OCH3, P(=O)(CH3)2, P(=O)(OH)2, P(=O)(OCH3)2, -OS(=O)2CH3, -NHC(=O)CH3, -N(CH3)C(=O)CH3, -NHC(=O)OCH3, -S(=O)(=NH)CH3, -S(=O)(=NCH3)CH3 and -OC(=O)NH(CH3).

15. The compound of formula (I) according to any one of claims 1-14, or a stereoisomer, tautomer, solvate, hydrate, prodrug, stable isotopic derivative, or pharmaceutically acceptable salt thereof, characterized in that, The L 2 Selected from bonds, hydrogen, C 1-6 Alkyl, -C(=O)NR c R d C 6-14 Aryl, C 3-8 Cycloalkyl, 5-12-membered heteroaryl and 3-12-membered heterocyclic groups, wherein -C(=O)NR c R d C 6-14 Aryl, C 3-8 Cycloalkyl, 5-12-membered heteroaryl, and 3-12-membered heterocyclic groups are each independently bound by one or more L... 2a Replaced; Preferably, the L 2 Selected from bonds, hydrogen, C 1-6 Alkyl, -C(=O)NR c R d C 6-10 Aryl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic and 5-7 membered heteroaryl, wherein -C(=O)NR c R d C 6-10 Aryl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic and 5-7 membered heteroaryl groups are bound by one or more L 2a Replaced; More preferably, the L 2 Selected from bonds, hydrogen, C 1-3 Alkyl, -C(=O)NR c R d C 6-10 Aryl, C 3-8 Cycloalkyl, 4-7-membered heterocyclic and 5-7-membered heteroaryl groups, wherein the 4-7-membered heterocyclic and 5-7-membered heteroaryl groups contain 1-4 heteroatoms selected from N, O and S, and the C 6-10 Aryl, C 3-8 Cycloalkyl, 4-7 membered heterocyclic and 5-7 membered heteroaryl groups are bound by one or more L 2a Replaced; Most preferably, the L 2 Selected from the following groups: bond, hydrogen, methyl, -C(=O)NH2, -C(=O)N(H)CH3, -C(=O)N(H)CH2CH3, -C(=O)N(CH3)2, -C(=O)N(CH3)CH2CH3, -C(=O)N(CH2CH3)2, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyridinyl, furanyl, thiophene, pyrrole, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, 1, 2,4-Thiadiazolyl, 1,2,3-Triazolyl, 1,2,4-Triazolyl, Pyridazinyl, Pyrazinyl, 2,3-Dihydro-1H-pyrazolyl, Oxalbidinyl, Tetrahydrofuranyl, Tetrahydropyranyl, Thiobutyl, Tetrahydrothiophenyl, Tetrahydrothiaranyl, Isothiazolyl, 1,3-Thiohexacyclic butyl, 1,2-Thiazinyl, 1,3-Thiazinyl, Thiazolyl, 1,3-Dazathidinyl, Imidazolyl, Pyrazolyl, Pyrrolidinyl, Piperidinyl, 1,3-Oxazinyl, 1,2-Dihydropyridinyl, Morpholinyl, Pyrimidinyl, Piperazinyl, Acetidinyl, Oxazolyl, Hexahydropyrimidinyl, Oxazolyl, Imidazolyl and The cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyridyl, furanyl, thiophene, pyrrolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, pyrazinyl, pyrazinyl, and 2,3-dihydro-1H-pyrazole are mentioned. alkyl, oxadiazinyl, tetrahydrofuranyl, tetrahydropyranyl, thiobutyl, tetrahydrothiophenyl, tetrahydrothiaranyl, isothiazolyl, 1,3-thiazolebutyl, 1,2-thiazinyl, 1,3-thiazinyl, thiazolyl, 1,3-diazhidinyl, imidazolyl, pyrazolyl, pyrrolidinyl, piperidinyl, 1,3-oxazinyl, 1,2-dihydropyridinyl, morpholinyl, pyrimidinyl, piperazinyl, acridinel, oxazolyl, hexahydropyrimidinyl, oxazolyl, imidazolyl and by one or more L 2a What it replaced.

16. The compound of formula (I) according to any one of claims 1-15, or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives, and pharmaceutically acceptable salts, characterized in that, Each time L appears, 2a Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the amino group, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2b Replaced; Preferably, each time L occurs, 2a Each is independently selected from hydrogen, halogen, cyano, hydroxyl, amino, oxo, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy groups, 4-5 membered heterocyclic groups and C 3-5 cycloalkyl, said amino, C 1-3 Alkyl, C 1-3 Alkoxy groups, 4-5 membered heterocyclic groups and C 3-5 Each cycloalkyl group is independently bound by one or more L 2b Replaced; More preferably, each time L occurs, 2a Each is independently selected from hydrogen, halogen, cyano, hydroxyl, amino, oxo, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy groups, 4-5 membered heterocyclic groups and C 3-5 Cycloalkyl groups, wherein the 4-5 membered heterocyclic group contains 1-4 heteroatoms selected from N, O, and S, and the amino group, C 1-3 Alkyl, C 1-3 Alkoxy groups, 4-5 membered heterocyclic groups and C 3-5 Each cycloalkyl group is independently bound by one or more L 2b Replaced; Most preferably, each time L occurs, 2a Each group is independently selected from hydrogen, F, cyano, hydroxyl, amino, oxo, methyl, trifluoroethyl, difluoroethyl, trifluoromethyl, difluoromethyl, methoxy, oxadiazine, and cyclopropyl, wherein each amino, methyl, methoxy, oxadiazine, and cyclopropyl group is independently separated by one or more L groups. 2b Replaced; Or, each time it appears, two or more L 2a Together with the atoms bonded to them, they form C. 6-10 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups, wherein the C 6-10 Aryl, 5-16 heteroaryl, C 3-12 The cycloalkyl group and the 3-12 membered heterocyclic group are each independently bound by one or more L... 2b Replaced; Preferably, each time it occurs, two or more L 2a Together with the atoms bonded to them, they form C. 6-10 Aryl, C 3-5 Cycloalkyl, 4-6 membered heterocyclic and 5-7 membered heteroaryl, wherein C 6-10 Aryl, C 3-5 Cycloalkyl, 4-6 membered heterocyclic and 5-7 membered heteroaryl groups are each independently bound by one or more L groups. 2b Replaced; More preferably, each time it appears, two or more L 2a Together with the atoms bonded to them, they form C. 6-10 Aryl, C 3-5 Cycloalkyl, 4-6-membered heterocyclic and 5-7-membered heteroaryl groups, wherein the 4-6-membered heterocyclic and 5-7-membered heteroaryl groups contain 1-4 heteroatoms selected from N, O and S, and the C 6-10 Aryl, C 3-5 Cycloalkyl, 4-6 membered heterocyclic and 5-7 membered heteroaryl groups are each independently bound by one or more L groups. 2b Replaced; Most preferably, each time it occurs, two or more L 2a Together with the atoms bonded to them, they form cyclopropyl, cyclobutyl, cyclopentyl, pyrrolyl, oxadiazyl, tetrahydropyranyl, tetrahydrofuranyl, pyrazolyl, imidazolyl, pyrazolyl, phenyl, furanyl, thiophenyl, pyrrolyl, oxadiazolyl, and pyridyl, wherein each of the cyclopropyl, cyclobutyl, cyclopentyl, pyrrolyl, oxadiazolyl, tetrahydropyranyl, tetrahydrofuranyl, pyrazolyl, imidazolyl, pyrazolyl, phenyl, furanyl, thiophenyl, pyrrolyl, oxadiazolyl, and pyridyl groups is independently bounded by one or more L... 2b What it replaced.

17. The compound of formula (I) according to any one of claims 1-16, or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives, and pharmaceutically acceptable salts, characterized in that, Each time L appears, 2b Each is independently selected from hydrogen, deuterium, oxo group, thio group, halogen, cyano, nitro, hydroxyl, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Alkylamino, C 2-6 alkenyl, C 2-6 alkynyl group, C 6-16 Aryl, 5-16 heteroaryl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic groups; Preferably, each time L occurs, 2b Each is independently selected from hydrogen, oxo group, C 1-6 Alkoxy and C 1-6 alkyl; More preferably, each time L occurs, 2b Each is independently selected from hydrogen, oxo group, C 1-3 Alkoxy and C 1-3 alkyl; Most preferably, each time L occurs, 2b Each is independently selected from hydrogen, oxo, methoxy, and methyl.

18. The compound of formula (I) according to any one of claims 1-17, or a stereoisomer, tautomer, solvate, hydrate, prodrug, stable isotopic derivative, or pharmaceutically acceptable salt thereof, characterized in that, -L1-L2 are selected from bonds, methyl, amino, -CH2CF3、 19. A compound or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives, and pharmaceutically acceptable salts, characterized in that, The compound is selected from:

20. A compound or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives, and pharmaceutically acceptable salts, characterized in that, The compound is selected from:

21. A pharmaceutical composition comprising the compound of any one of claims 1-20 or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives and pharmaceutically acceptable salts, and one or more pharmaceutically acceptable carriers, diluents or excipients.

22. The compound of any one of claims 1-20 or its stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives and pharmaceutically acceptable salts, or the pharmaceutical composition of claim 21, used for prevention and / or treatment of symptoms, diseases or conditions associated with abnormal expression or dysfunction of VAV1. Preferably, the conditions, diseases, or illnesses associated with abnormal VAV1 expression or dysfunction include autoimmune diseases, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, tumors, rhinitis, conjunctivitis, allergic contact dermatitis, inflammatory diseases, inflammatory bowel disease, Crohn's disease, ulcerative colitis, internal asthma, inflammatory lung injury, inflammatory liver injury, eczematous dermatitis, lipoid dermatitis, inflammatory eye disease, keratitis, myocarditis, hepatitis, pleurisy, type I or type II diabetes, anemia, uveitis, psoriasis, ulcerative colitis, atherosclerosis, myocarditis, pulmonary fibrosis, systemic sclerosis, host diseases, myasthenia gravis, allergic diseases, Sjogren's syndrome, autoimmune liver disease, chronic inflammatory demyelinating polyneuropathy, and macular degeneration. Amyloidosis, inflammatory eye diseases, chronic transplant-host disease, pulmonary hypertension or vascular inflammation, asthma, thyroiditis, atopic dermatitis, osteoarthritis, irritant contact dermatitis, inflammatory eye diseases, graft-versus-host disease, chronic transplant rejection, acute transplant rejection, transplant vascular disease, transplant atherosclerosis, transplant coronary artery disease, B-cell lymphoma, B-cell leukemia, T-cell leukemia, acute myeloid leukemia, axial spondyloarthritis, cancer, malignant tumors, hematological malignancies, lymphoma, lymphocytosis, T-cell lymphoma, intestinal T-cell lymphoma, lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, lens keratinocyte lymphoma, kidney disease, lupus nephritis, inflammatory glomerular injury.

23. The use of the compound or stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotope derivatives and pharmaceutically acceptable salts thereof, or the pharmaceutical composition according to claim 21, for the prevention and / or treatment of symptoms, diseases or conditions related to abnormal expression or dysfunction of VAV1; Preferably, the conditions, diseases, or illnesses associated with abnormal VAV1 expression or dysfunction include autoimmune diseases, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, tumors, rhinitis, conjunctivitis, allergic contact dermatitis, inflammatory diseases, inflammatory bowel disease, Crohn's disease, ulcerative colitis, internal asthma, inflammatory lung injury, inflammatory liver injury, eczematous dermatitis, lipoid dermatitis, inflammatory eye disease, keratitis, myocarditis, hepatitis, pleurisy, type I or type II diabetes, anemia, uveitis, psoriasis, ulcerative colitis, atherosclerosis, myocarditis, pulmonary fibrosis, systemic sclerosis, host diseases, myasthenia gravis, allergic diseases, Sjogren's syndrome, autoimmune liver disease, chronic inflammatory demyelinating polyneuropathy, and macular degeneration. Amyloidosis, inflammatory eye diseases, chronic transplant-host disease, pulmonary hypertension or vascular inflammation, asthma, thyroiditis, atopic dermatitis, osteoarthritis, irritant contact dermatitis, inflammatory eye diseases, graft-versus-host disease, chronic transplant rejection, acute transplant rejection, transplant vascular disease, transplant atherosclerosis, transplant coronary artery disease, B-cell lymphoma, B-cell leukemia, T-cell leukemia, acute myeloid leukemia, axial spondyloarthritis, cancer, malignant tumors, hematological malignancies, lymphoma, lymphocytosis, T-cell lymphoma, intestinal T-cell lymphoma, lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, lens keratinocyte lymphoma, kidney disease, lupus nephritis, inflammatory glomerular injury.

24. Use of the compound or stereoisomers, tautomers, solvates, hydrates, prodrugs, stable isotopic derivatives and pharmaceutically acceptable salts thereof, or the pharmaceutical composition of claim 21, in the manufacture of a medicament for the prevention and / or treatment of symptoms, diseases or conditions associated with abnormal expression or dysfunction of VAV1. Preferably, the conditions, diseases, or illnesses associated with abnormal VAV1 expression or dysfunction include autoimmune diseases, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, tumors, rhinitis, conjunctivitis, allergic contact dermatitis, inflammatory diseases, inflammatory bowel disease, Crohn's disease, ulcerative colitis, internal asthma, inflammatory lung injury, inflammatory liver injury, eczematous dermatitis, lipoid dermatitis, inflammatory eye disease, keratitis, myocarditis, hepatitis, pleurisy, type I or type II diabetes, anemia, uveitis, psoriasis, ulcerative colitis, atherosclerosis, myocarditis, pulmonary fibrosis, systemic sclerosis, host diseases, myasthenia gravis, allergic diseases, Sjogren's syndrome, autoimmune liver disease, chronic inflammatory demyelinating polyneuropathy, and macular degeneration. Amyloidosis, inflammatory eye diseases, chronic transplant-host disease, pulmonary hypertension or vascular inflammation, asthma, thyroiditis, atopic dermatitis, osteoarthritis, irritant contact dermatitis, inflammatory eye diseases, graft-versus-host disease, chronic transplant rejection, acute transplant rejection, transplant vascular disease, transplant atherosclerosis, transplant coronary artery disease, B-cell lymphoma, B-cell leukemia, T-cell leukemia, acute myeloid leukemia, axial spondyloarthritis, cancer, malignant tumors, hematological malignancies, lymphoma, lymphocytosis, T-cell lymphoma, intestinal T-cell lymphoma, lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, lens keratinocyte lymphoma, kidney disease, lupus nephritis, inflammatory glomerular injury.